Official Transcript of Proceedings ACRST-3187

NUCLEAR REGULATORY COMMISSION

ORIGINAL

Title:

Advisory Committee on Reactor Safeguards Reliability and Probabalistic Risk Assessment

Subcommittee

PROCESS USING ADAMS TEMPLATE: ACRS/ACNW-005

Docket Number:

(not applicable)

Location:

Rockville, Maryland

Date:

Friday, February 22, 2002

Work Order No.:

NRC-253

Pages 1-209

NEAL R. GROSS AND CO., INC. Court Reporters and Transcribers 1323 Rhode Island Avenue, N.W. Washington, D.C. 20005

ACRS Office Copy - Retain for the Life of the Committee

1	UNITED STATES OF AMERICA
2	NUCLEAR REGULATORY COMMISSION
3	+ + + +
4	ADVISORY COMMITTEE ON REACTOR SAFEGUARDS
5	(ACRS)
6	+ + + +
7	MEETING OF THE SUBCOMMITTEE ON RELIABILITY AND
8	PROBABALISTIC RISK ASSESSMENT
9	+ + + +
10	FRIDAY,
11	FEBRUARY 22, 2002
12	+ + + +
13	ROCKVILLE, MARYLAND
14	The Subcommittee met at the Nuclear Regulatory
15	Commission, Two White Flint North, T2B3, 11545
16	Rockville Pike, at 8:30 a.m., George Apostolakis,
17	Chairman, presiding.
18	COMMITTEE MEMBERS:
19	GEORGE APOSTOLAKIS, Chairman
20	THOMAS S. KRESS
21	F. PETER FORD
22	DANA A. POWERS
23	WILLIAM J. SHACK
24	STEPHEN L. ROSEN
25	

		2
1	ACRS STAFF PRESENT:	
2	MICHAEL T. MARKLEY	
3		
4	ALSO PRESENT:	
5	ADRIAN HEYMER	
6	BIFF BRADLEY	
7	TOM HOOK	
8	DOUG TRUE	
9	BILL BURCHILL	
10	GARETH PARRY	
11	MIKE CHEOK	
12	TIM REED	
13	PARVIS MOIENI	
14	BOB LUTZ	
15	LOUIS CHU	
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		

	3
1	A-G-E-N-D-A
2	Introduction
3	Chairman Apostolakis 5
4	Industry Presentation
5	Mr. Heymer, NEI 6
6	Mr. True
7	Response to ACRS questions on NEI 00-04 60
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

P-R-O-C-E-E-D-I-N-G-S

2

1

8:34 a.m.

3 4

5

6

7

8 9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

CHAIRMAN APOSTOLAKIS: The meeting will now come to order. This is a meeting of the Advisory Committee on Reactor Safeguards, Subcommittee on Reliability and Probabalistic Risk Assessment.

I am George Apostolakis, Chairman of the Subcommittee.

Subcommittee members in attendance are Peter Ford, Tom Kress, Dana Powers, Steve Rosen and William Shack.

The purpose of this meeting is to continue discussion the Subcommittee's of risk-informed revisions to the special treatment requirements of 10 CFR Part 50. The Subcommittee will review the proposed industry guidance in NEI 00-04, Revision B, "Option 2 Implementation guideline." The Subcommittee will gather information, analyze relevant issues and facts, and formulate proposed positions and actions, deliberation appropriate, for by the full as Committee.

Mr. Michael T. Markley is the Cognizant ACRS Staff Engineer for this meeting.

The rules for participation in today's meeting have been announced as part of the notice of

first

this meeting previously published in the Federal 1 Register on January 30, 2002. 2 A transcript of this meeting is being kept 3 and will be made available as stated in the Federal 4 5 Register notice. speakers Ιt is requested that 6 7 identify themselves and speak with sufficient clarity and volume so that they can be readily heard. 8 We have received no written comments or 9 10 requests for time to make oral statements from members 11 of the public regarding today's meeting. This Subcommittee last met on December 4, 12 13 2001, to discuss 10 CFR 50.69 and NEI 00-04 Revision 14 In a memorandum dated January 24, 2002, the ACRS staff forwarded a list of individual ACRS member 15 16 questions on NEI 00-04 Revision B to the staff and NEI 17 for use in preparing for this meeting. We would like to spend most of our time today addressing those 18 questions and, of course, any other issues that our 19 visitors would like to raise. 20 21 On February 11, 2002, the staff also provided a list of questions on NEI 00-04. Both lists 22 of questions are publicly available and will be 23 furnished upon request. 24

We will now proceed with the meeting and

I call upon Mr. Adrian Heymer of NEI and his colleagues to begin.

MR. HEYMER: Thank you, George.

My name is Adrian Heymer, I'm the project manager with NEI responsible for risk-informed activities covering Option 2 and Option 3.

We've got here today at the table some utility people and Doug True, whose been helping us with the guideline, especially in the area of categorization.

On my left I've got Tom Hook from Dominion and Surrey is a pilot plant. They've just gone through the IDP. And he's here to give some insights into the categorization and the IDP process that went on at Surrey and what they learned from it; some of the strengths, some of the weaknesses.

And I think it's worthwhile saying that as we've gone through this process, this is the third pilot activity that was done a few weeks ago at Surrey. The first one we learned a lot; we tried to incorporate the lessons learned into the second. The second we learned a little bit more and refined the process. And so when we got to Surrey I think it was a reflection of just a general learning experience. And that's the whole idea of the pilot activity.

I think it's true, as with all things, that we drafted a guideline and the staff said they thought it was of sufficient level to allow the pilots to proceed. And we proceeded down that path recognizing that we would learn things as we went through the pilot activities to strengthen; have to go back and strengthen the guidance.

Doug True is here on my right from ERIN Engineering, and he's been helping us with specifically on PRA issues and categorization as a general advisor on the Option 2 activities to NEI and the industry.

On my far right is Bill Burchill from Exelon. And Bill has been with the Option 2 activity and risk-informed regulation since really the start. He represents Exelon, who was a pilot plant at the Quad Cities that was done last year as the first one and that really identified that we had a little bit more work to do. And Bill will assist us in responding to some of the specific questions.

Also in the audience we have Parvis Moieni from Southern California Edison, Jason Brown and Bob Lutz from the Westinghouse Owners Group. They're here representing Wolf Creek whose the fourth pilot. And also the Westinghouse Owners Group who have been very

active in this Option 2 activity.

And we have a few other members of the industry from NEI in the audience.

What we would like to do today is to go through just an overview of what we're going to cover fundamentally. We're going to just go back and do a very brief overview of NEI 00-04, go through that in about 30 minutes and then get to the interactions on those specific questions.

And then also as we go through the process, either at the end or as we're going through the process, we'll invite the pilots to provide some insights into some of the pilot activities and what they learned both from the PRA perspective, form the PRA quality and from the categorization.

So, that's what we want to try.

The first couple of slides are really principles, and it was just to give a sort of a general introduction as regards what the principles of risk-informed regulation, and it's really focusing on the right stuff.

And we've got smart as years have gone by, and so it's the application of NRC requirements based on the safety significance of the equipment and the activities. I have taken into account what we've

NEAL R. GROSS

learned through operating experience, the design and engineering techniques and insights from PRA and also taken advantage of advances in technology.

And the real thrust of this is that the real focus of the regulatory requirements should be on those matters that are safety significant, necessarily at low safety-significant. And that was really the purpose of Option 2 as we see it, and I think it's really important if we're going to be successful in this enterprise and this activity to look at what really is Option 2. And it's the application of NRC's special treatment requirements such as QA, EQ, 50.55(a), the maintenance rule, Appendix B, which is QΑ based the safety on significance of the equipment. And it's fundamentally a two step process.

The first step, which we're really focusing on here and which the guideline will focus on, is the categorization. The second step is the application of treatment.

There are some ground rules that have been established as we go through this, and one of those ground rules is right up front, which was the design basis are not changed. And I think when the industry started off on Option 2 we had a view that perhaps we

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

2 and we would have two categories. As we started interactions with the staff 3 4 it became clear, especially since we were going to 5 maintain the design basis and this was going to be an 6 optional activity, that in fact perhaps we should have 7 a slightly different structure. And the NRC staff 8 proposed the full box, the quadrant structure. 9 took a look at that, we assessed it and we felt that 10 we could probably work with it. And that's we've been 11 trying to do. But the real thrust of this discussion 12 here is on the NEI 00-04, the categorization process 13 and that's what we're here to talk about today. 14 I'll now hand over to Doug True, whose 15 going to give a very brief overview. And we probably 16 won't go through all these slides as a matter of time, 17 but we will just give you a very rough overview of 18 what NEI 00-04 talks to as regards to categorization. 19 MR. TRUE: Do they have this? 20 MR. HEYMER: Yes. You should have the handout. 21 22 CHAIRMAN APOSTOLAKIS: We don't. We have 23 yours. 24 MR. HEYMER: It's the same thing --No. 25 CHAIRMAN APOSTOLAKIS: It's the same

were going to change the definition of safety related

1	thing?
2	MR. HEYMER: No.
3	CHAIRMAN APOSTOLAKIS: No, it can't be the
4	same thing.
5	MR. HEYMER: There were two sets in the
6	package I just gave you. One was the
7	CHAIRMAN APOSTOLAKIS: Oh, there were?
8	You guys got it? Yes, we didn't get it. All right.
9	Let's go on.
10	MR. HEYMER: Well, it's early in the
11	morning. I sort of lost a few marbles last night or
12	something.
13	CHAIRMAN APOSTOLAKIS: Okay. Doug?
14	MR. TRUE: Okay. As Adrian said, we have
15	a lot of material here. I'll just kind of slip
16	through these quickly and kind of hit on a few high
17	points in order to get through this quickly and get on
18	to the questions.
19	I'm going to skip through to I think it's
20	the fifth slide, safety-significant attributes. I
21	just want to make a couple of quick points on that
22	subject.
23	One of the things that we started with,
24	actually, in the Option 2 effort within the task force
25	was to look at well if we think about what PRAs have

told us, we're going to find what are the differences and where are we going to find differences in what the design basis has told us about important equipment and what PRAs have told us. And we kind of keyed in on this notion of safety-significant attributes.

So for the equipment that were identified as safety-significant through whatever categorization process we used, we wanted to keep track of that, what attributes of those components made them safety-significant.

And that comes from the fact that the performance requirements for the design basis in some cases are more limiting than for PRA or for risk assessment perspective, and in other cases the accident performance is more limiting than the design basis. So we have this kind of mix and match we have to reconcile.

And as part of the categorization process we expect the categorization team and the IDP to address those attributes which make the SSCs safety-significant. And those things include the functions, the performance attributes, the pressure flows, temperatures, environment; that kind of thing, and any actuation requirements.

And just as kind of a point of reference,

NEAL R. GROSS

we provided two hypothetical examples which are not a particular reach in this area.

First in the area of RISC-1s, those are the safety related, safety significant SSCs. For BWRs the ability to vent a containment and remove decay heat is often a safety-significant function. we realized that containment vent valves, which are part of the containment isolation system, might end up being safety-significant. And while their design basis function was close isolate the to to containment, there severe accident function or core damage in the containment failure function was to open and control -- open and close in order to control containment pressure and allow decay heat removal. So we were expecting the valves to do the opposite thing that the design basis expected them to do.

And here's some examples of the safety-significant attributes that might be tracked in this process include: What are the conditions we're expecting the valve to have to open under; what kind of capability does the PRA assume we need for being able to open that, whether it's from the control room or be able to do that locally using air bubbles or whatever. Different PRAs and different plants have different capabilities in those areas.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

But as we moved forward and we implement Option 2 and we made changes to the plant, we would want to keep track of those attributes and put that into our change control process so that we didn't lose track of the fact that those were now important functions for those components.

In the RISC-2 area, which is a non-safety related but safety-significant SSCs, an example might be a startup feedwater pump that was originally designed to help the plant go through power ascension and shutdown has no particular design basis from an accident analysis perspective, but in some plants it probably provides a risk significant function of making up to the steam generators as a backup to aux feedwater effectively in cases where all aux feedwater might be lost.

In that case, we certainly would want to keep track of the flow and head requirements, which probably are not a lot different than design basis. But in some plants also the ability to attach that startup feedwater pump to 1E Bus and power from a diesel generator so that it works in the event of a loss of offsite power is an attribute that we would want to keep track of and not lose over time as the plant changed.

1	CHAIRMAN APOSTOLAKIS: What you are
2	categorizing is a component, right? I mean, if I look
3	at the matrix, I will see components in there not
4	attributes or anything?
5	MR. TRUE: No. You categorize the
6	component.
7	CHAIRMAN APOSTOLAKIS: Yes. So this
8	discussion helps us do that, is that what you're
9	saying?
10	MR. TRUE: I think all we're saying is
11	that there's an adder when we go to the process of
12	through the process of categorizing we say this
13	startup feedwater pump is safety-significant, we want
14	to not only know that it's safety-significant, we want
15	to know why it's safety-significant so that we
16	incorporate those attributes into the change control
17	processes going forward in the plant and we don't lose
18	track of that.
19	CHAIRMAN APOSTOLAKIS: Yes. Well, and
20	that presumably
21	MR. TRUE: And that the treatment is
22	focused on those aspects.
23	CHAIRMAN APOSTOLAKIS: Presumably when you
24	declare the safety-significant, you went through this
25	process, right? You knew already. I mean, that's why

Т	you said it was safety-significant because of all
2	these things? And then you pass that along to whoever
3	makes a decision?
4	MR. TRUE: Right. Right. But, for
5	example, the startup feedwater pump, it is not safety-
6	significant in being able to function post-seismic
7	event. See, we can't paint all the components with
8	the same brush because it's not like the safety
9	related designation which automatically gets category
10	1 seismic and 1E power and all those things.
11	In this case we're going to have a little
12	bit more mixture of attributes that are important and
13	we're going to have to keep track of those.
14	CHAIRMAN APOSTOLAKIS: So that would be
15	more relevant when you decide what treatment to apply?
16	MR. TRUE: Yes. Yes.
17	CHAIRMAN APOSTOLAKIS: Which is very
18	different from the current practice of safety related
19	gets all
20	MR. TRUE: Gets everything and everything
21	else is treated in a different way.
22	CHAIRMAN APOSTOLAKIS: I believe South
23	Texas had a separate category for that in the middle
24	somewhere there where it was focused. But anyway,
25	let's go on.

1 2

MR. TRUE: The four step process, I'm going to kind of skip through that. And just talk about a little bit the structure of the categorization process. Slide 8.

As you know from reading the document, we've tried to utilize the PRAs where they're available and use importance measures as a screening tool to identify the potentially safety-significant structure systems and components. We then utilized some sensitivity studies to test the robustness of those base importance measures.

One of the things we were looking for in the categorization process was one that was relatively robust and stable and we're not going to have SSCs jumping in and out of the categories over time. And so we've tried to use the sensitivity studies as one of the ways to make sure we are assuring that that's the case.

Where PRAs aren't available, we've tried to be more conservative in the way we've applied the categorization process knowing that if utilities wanted to go off and develop a PRA in an area where they don't have one and gain some additional benefit, they could do that. But if they had a seismic margins analysis, for example, instead of a seismic PRA we

wanted them to be able to use that as part of their 1 2 categorization scheme. 3 We take all that risk information and 4 supplement it with some defense-in-depth assessment. 5 And then finally at the end we do a sensitivity study б to look at the aggregate impact of a postulated change 7 in all of the RISC SSCs simultaneously jumping to some 8 higher unreliability to make sure that that change was 9 small. 10 as I said, the objective was to 11 develop a scheme that was comprehensive, didn't just focus for example on internal events and kind of hand 12 13 away through the other hazards and operating modes, 14 and robust to the importance measures, took into 15 account the fact that there could be variations in 16 And then long term stable so that we weren't 17 having equipment jumping from one category to another 18 over the life of the plant. 19 DR. ROSEN: Doug, you would acknowledge, 20 would you not, that your next to last bullet while it 21 is bounding, it's certainly unrealistic? 22 MR. TRUE: I think it is very unrealistic. 23 That all of them would go to some upper level of 24 value. 25 DR. ROSEN: All at one time -- suddenly?

MR. TRUE: All of them.
DR. ROSEN: And all at one time?
MR. TRUE: All at one time. Without you
noticing it.
DR. ROSEN: And without anything to do
I can't imagine anything that could do that to all the
components.
MR. TRUE: In fact, we believe that likely
there will be very little change in the performance
DR. ROSEN: Well, that's totally
unrealistic.
MR. TRUE: Yes.
DR. ROSEN: But the answer that comes out
of that sensitivity study in the next to last bullet
is really very unrealistic.
MR. TRUE: I believe so. But if we need
it, or we use it because we realize that there are
shortcomings in using individual importance measures.
And if you're going to individual importance
measures are going to make any decisions about
individual components of getting insights about
individual components, we're talking about a batch of
components and the individual importance measures are
not useful for that. So a sensitivity study is a way

to address the fact that there could be synergisms

1	that we want to look for in that aggregate of
2	assessment helps us
3	DR. ROSEN: But nobody should use the
4	number that comes out of that and believe it as being
5	anything that's physically real?
6	MR. TRUE: Correct.
7	DR. KRESS: Wouldn't it be better to treat
8	that like a common-cause failure or you only change
9	the failure frequency of one of them, but use some
10	multiple Greek letter to get the probability of
11	failure of the others in order to get an importance
12	measure? What do you think, George? Rather than just
13	say the whole group has a
14	CHAIRMAN APOSTOLAKIS: To have a lower
15	yes.
16	DR. KRESS: Because they're not all going
17	to fail at the same time.
18	CHAIRMAN APOSTOLAKIS: Sure.
19	MR. TRUE: Well, they're not all we're
20	not saying when they all fail. We're saying their
21	probability of failure all goes up by a factor.
22	DR. KRESS: When you do the RAW for the
23	group, you assume that measure is all of them going.
24	MR. TRUE: Yes, the RAWs are done
25	individually as a part of the screening process.

WASHINGTON, D.C. 20005-3701

1	DR. KRESS: Oh, you're not doing
2	MR. TRUE: No. No.
3	CHAIRMAN APOSTOLAKIS: They just do
4	probability.
5	DR. ROSEN: Just going to a Delta CDF for
6	the group, but through the sensitivity study.
7	MR. TRUE: Through the sensitivity study
8	of increasing the unreliability
9	DR. KRESS: That's by increasing the
10	factor of 10. But the RAW is simply for one
11	component
12	MR. TRUE: For individual events.
13	DR. KRESS: Yes, that's what I think you
14	ought use, common-cause and get a different RAW than
15	that.
16	CHAIRMAN APOSTOLAKIS: Yes, we'll come
17	into that discussion.
18	DR. KRESS: Okay.
19	DR. POWERS: Can you give me some more
20	insight of what a defense-in-depth assessment looks
21	like?
22	MR. TRUE: Yes, if you'll hold on just a
23	couple of slides, we'll get to that.
24	CHAIRMAN APOSTOLAKIS: Now, when you say
25	your PRAs are not available, what does that mean?

1	That they are not available because nobody has ever
2	done a PRA for this particular mode or this particular
3	licensee happens not to have a PRA for something for
4	which others have done a PRA?
5	MR. TRUE: The latter. Where a plant does
6	not have a PRA currently.
7	CHAIRMAN APOSTOLAKIS: So there should be
8	a clear demonstration then that the categorization
9	process is conservative in that case, and we'll come
10	back to that during the discussion I hope?
11	MR. TRUE: We can. I actually didn't plan
12	on all those flow charts that go through every
L3	different way we look at things. We can
L4	CHAIRMAN APOSTOLAKIS: I mean, there was
L5	a question on fires which you presumably have
L6	addressed?
L7	MR. TRUE: Yes. Yes.
L8	CHAIRMAN APOSTOLAKIS: There was a
19	question. So when we come to that, we'll probably
20	raise a similar question.
21	MR. TRUE: Okay.
22	DR. SHACK: Well, since you're not
23	covering that, let me just you know, as I read the
24	seismic margins analysis, for example, it looks to me
25	like you're protecting your one shutdown path, at

1.	least that's the way I read this. You know, I look at
2	what I need for that one shutdown path and I
3	categorize to maintain that shutdown path. But in
4	fact, I couldn't in fact be upping my risk because I'm
5	not really paying attention to the other things that
6	are neglected in the margins analysis that could in
7	fact give me an assessment. So my change in risk
8	could be larger than I think it is?
9	I'm not sure how in the margins analysis
10	you assure that your categorization process is
11	conservative.
12	CHAIRMAN APOSTOLAKIS: Or the final
13	analysis.
14	MR. TRUE: Well, it's the same sort of
15	thing. Anytime you have the margins analysis
16	CHAIRMAN APOSTOLAKIS: That's right.
17	MR. TRUE: and you're protecting one or
18	a limited set of shutdown paths
19	CHAIRMAN APOSTOLAKIS: A screening.
20	Whenever you have a screening process to demonstrate
21	that something is not important, it's not clear to us
22	how you handle it and whether the results are
23	conservative.
24	MR. TRUE: Okay.
25	CHAIRMAN APOSTOLAKIS: So I don't know

1	whether you want to address it now or later.
2	MR. TRUE: We can come back.
3	CHAIRMAN APOSTOLAKIS: We'll come back to
4	it. Okay. Great.
5	DR. FORD: Can I follow up on this
6	question of the areas where there is not a PRA?
7	MR. TRUE: Yes.
8	DR. FORD: In reading through the 00-04
9	document I was looking for references to time
10	dependent degradation of passive components. And I
11	couldn't find anything at all in that document which
12	related specifically to that. And degradation of the
13	containment, for instance, or some of the passive
14	components like core shrouds or whatever.
15	If there was a component which was safety
16	related and was put into RISC-3, how would that be
17	determined when you don't have a time dependent PRA
18	for those phenomena? Could it be done by an IDP
19	process? And if so, who would be the experts on the
20	panel to address this?
21	MR. TRUE: I think the categorization
22	process in 00-04 isn't really designed to deal with
23	passive loads of components. There's a separate
24	DR. FORD: Passive components are
25	mentioned in 00-04.

MR. TRUE: Yes, I think we hand it off to
the ASME.
MR. HEYMER: Yes. The prime thrust of the
categorization that we cover is dealing with active.
When we get to passive there are ASME processes out
there that look at classification of passive
components. And what we say is that it's assumed to be
where it is today, unless you've done one of those
passive categorization schemes that is run through
ASME. And then if you've done that, then you can
start looking at things like the pressure boundary.
But that's what you've got to do.
So we hand off to, we point to another
group that's already done that work. And so we're
relying on those.
DR. FORD: So time dependent degradation
of passive components; pressure boundaries, core
shrouds which are not pressure boundaries, but things
of this nature which are safety related are not
covered in this document?
MR. HEYMER: If they're not covered by the
ASME process, they're not covered by this document.
DR. FORD: Okay.
MR. HEYMER: Tom?
MR. HOOK: Yes. I just wanted to make a

1	point that in the current draft of ASME code case that
2	categorizes passive components for the Option 2 effort
3	it makes the assumption that those passive components
4	are failed for the purpose of the categorization.
5	That the failure rate is 1.0 and only focuses on the
6	consequence of failure.
7	So, items like core shrouds and
8	containments all come up as high because of that
9	process.
10	DR. FORD: So they'd be automatically in
11	RISC-1 and RISC-2?
12	MR. HOOK: Right.
13	DR. FORD: Okay.
14	MR. TRUE: Okay. We use a variety of
15	quite specific RISC information and deterministic
16	information. I don't need to spend any time on that.
17	PRA quality, I had several questions that
L8	dealt with that which we'll get back to, but I thought
L9	it deserved a brief discussion.
20	The 00-04 allows for the use of NEI 00-02,
21	which is the peer review process or the ASME standard
22	for evaluating the quality of the internal events at-
23	power PRA. We believe out of both of those documents,
24	the peer review provides the greatest insight into the
25	strengths and limitations of the PRA. And that the

14

15

16

17

18

19

20

21

22

23

24

25

observations that come out of that peer process, whether it's one driven by the ASME standard or from 00-02 have to be dispositioned as part of this process. And those are either dispositioned by incorporating -- making a change to the PRA model to address the observation, look for a way to handle that through sensitivity studies which are then passed on and looked at as part of the categorization process, or provide some justification that the assumption or the issue that's raised in the observation doesn't effect the categorization. I think that that third one is probably the least likely to be used, but there may be cases where depending upon the comment, that might be applicable.

Then it's up to the utility or the licensee to provide a characterization of the PRA quality. And that's submitted to the NRC staff at the time you enter into the Option 2 process and before categorization is done, along with an explanation of the scope and schedule of what's going to be done.

And that characterization, and as well as passed on to the integrated decision making panel so that they understand what they're dealing with in terms of the PRA quality.

And the things we want to look at are:

NEAL R. GROSS

How well does the PRA address the as-built as operated 1 2 plans; what did the peer review say about the internal 3 events PRA; how were those observations that were classified as significant in 00-02 parlance, that's A 4 5 or B --6 CHAIRMAN APOSTOLAKIS: But this list 7 doesn't say anything about uncertainty. And it talks 8 a lot about sensitivity. 9 Now, as far as I know, the standard 10 computer codes that the industry is using to do their 11 PRAs have capability of propagating uncertainty, the 12 standard behind, you know the failure 13 uncertainty. And I'm surprised that you resort to 14 sensitivity studies all the time. Why? What's wrong 15 with or is it so expensive to do? I mean, it would 16 seem to me that it's kind of routine these days to do 17 that. 18 MR. TRUE: Yes. I don't think -- I quess 19 there are two things about that. Certainly there are 20 tools available for the major PRA codes to allow you 21 to do uncertainty calculations on the parametric uncertainties at least. 22 23 CHAIRMAN APOSTOLAKIS: Yes. 24 The sensitivity analyses that MR. TRUE: 25 we're talking of tend to be more focused on the

WASHINGTON, D.C. 20005-3701

1	modeling and assumptions of the model.
2	CHAIRMAN APOSTOLAKIS: Well, that's not
3	the impression I get when I read NEI 00-04, and we'll
4	come to that. I mean, I would agree with you a 100
5	percent that that's what should be done. But if you
6	read the document, that's not what it says. But this
7	is one of our questions.
8	MR. TRUE: Okay.
9	CHAIRMAN APOSTOLAKIS: So we'll come to
10	that.
11	MR. TRUE: In particular related to the
12	facts and observations in this slide where we mention
13	sensitivity analyses, I believe it's relatively rare
14	to have comments about the uncertainty distribution on
15	individual perimeters that come out of the peer review
16	and have those be an A or B significant in the overall
17	result.
18	CHAIRMAN APOSTOLAKIS: Well, we'll see.
19	We'll see.
20	MR. TRUE: So it's usually we're dealing
21	with you didn't use this seal LOCA model or you made
22	this assumption about room cooling or time for
23	operator actions, or those kind of things.
24	CHAIRMAN APOSTOLAKIS: Well, for those I
25	fully agree that the sensitivity analysis would be

very useful. But, again, I mean when I read the document that's not what it says. So we have to fix that.

MR. TRUE: Okay. Well then --

CHAIRMAN APOSTOLAKIS: Now, I have another question on this.

MR. TRUE: Okay.

CHAIRMAN APOSTOLAKIS: It seems to me, I'm a little bit concerned that if one has a PRA, we're going to spend a lot of time talking about its quality. If one does not have a PRA, then we wave our arms, we do screening analysis and we come up with some results that may be questioned for 10 minutes, and that's it. Is it really over kill here just because you happen to have the study? Then we talk about the quality, have you used the ASME standard, have you used the industry certification process. And then we go to the fire and seismic and say, well, I'll do some screening calculations and here is my categorization. And believe me, it's conservative.

I mean, just because -- in other words, are we penalizing people for doing PRAs because now they have to defend them forever? It should be the other way around. Your life should be much more difficult when you don't have the PRA.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1	MR. TRUE: That's a wonderful question on
2	excellence.
3	CHAIRMAN APOSTOLAKIS: Well, let's go on.
4	It's just that I'm curious just because we have
5	something, we scrutinize it to death and then in
6	another area we say well we're going to do some
7	conservative calculations and they will be good
8	enough.
9	MR. TRUE: Yes.
10	DR. POWERS: If the calculations are
11	demonstrably conservative
12	CHAIRMAN APOSTOLAKIS: Are they in the
13	other areas? I mean, I look
14	DR. POWERS: They demonstrative to be
15	conservative and the PRA is demonstrably realistic,
16	then isn't that the appropriate split of labor?
17	CHAIRMAN APOSTOLAKIS: Yes. But you put
18	to big "ifs" there. Yes, certainly.
19	MR. TRUE: Well, I think the second half,
20	I mean the PRA is intended to be realistic. So that's
21	the
22	CHAIRMAN APOSTOLAKIS: I understand that.
23	MR. TRUE: I think it gets more attention,
24	which is part
25	CHAIRMAN APOSTOLAKIS: I think we should

32 make sure that the quality of the decision making process, you know, and its inputs is more or less uniform in the places where we have a PRA and in the places where we don't. And, again, I'm not convinced that that's the case. Okay, let's put it that way. I'm perfectly willing to be convinced, but I am not And I think again as we discuss our right now. questions later, these issues are going to come up. MR. TRUE: Okay. One other thing about the PRA and the quality of the other analyses. still incumbent upon a licensee to demonstrate that they reflect the as-built/as-operated plant and that

the things that carry over from the internal events PRA that may have been significant in that PRA, which is usually the basis for the other mode and hazard analyses, are properly addressed and identify any sensitivity studies necessary to address other areas of concern. And that's passed on to the IDP as part of their considerations.

CHAIRMAN APOSTOLAKIS: Why such an emphasis on the internal event PRA? wouldn't want the fire PRA to reflect the as-built and as-operated?

MR. TRUE: Yes. No, that's what I was just saying. The last three bullets are the other PRAs.

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

1	And we have basically the same standard for those that
2	we have to reflect the as-built/as-operated plant.
3	That the peer review comments that have been received
4	on the internal events PRA, which is usually used as
5	the input for fire PRA, at least for doing the
6	conditional core damage probability calculations, have
7	been addressed and don't effect the fire PRA, for
8	example. And then look for any PRAs where there's a
9	need for sensitivities to address issues in those PRAs
10	also.
11	CHAIRMAN APOSTOLAKIS: Now, in your
12	MR. TRUE: I think we have the same
13	standard on both. But because and practically
14	speaking the internal events PRA tends to be the
15	center and the focal point or the kernel of all the
16	other PRA analyses come from, we tend to put more
17	words around the internal event study.
18	CHAIRMAN APOSTOLAKIS: Even though we know
19	that the experience over the last 25 years with PRAs
20	has told us that fires and earthquakes usually
21	dominate the risk, right?
22	MR. TRUE: It depends upon the plant, but
23	that certainly wasn't South Texas' experience, but
24	CHAIRMAN APOSTOLAKIS: Well, it certainly
25	does

MR. TRUE: -- other plants. 1 2 CHAIRMAN APOSTOLAKIS: -- but overall I 3 think it's a true statement that they if not dominate, they are among the dominant contributors? 4 5 MR. TRUE: Yes, I would agree with that. Yes. 6 7 This was in case we wanted to talk about this. 8 9 Step 2, which is the actual categorization 10 process and all of the figures that go along with 11 that, we're looking at CDF and LERF. Importance 12 measures are used as a screening tool. We look at 13 both the initiator and the event mitigation. 14 we're looking for those attributes. 15 Back to the question about defense-in-16 depth, what we try to do there is step beyond the PRA 17 itself and provide some additional information to the IDP on the defense-in-depth and the role that the SSC 18 19 plays in providing defense-in-depth. 20 In particular for the RISC-3 SSCs, we have 21 a process that we go through to looking at both core 22 damage and early containment failure prevention and 23 the role of SSC plays in defense-in-depth in that 24 area.

CHAIRMAN APOSTOLAKIS: Again, I'm a little

confused here. It seems to me that if you have a robust PRA and you're using the importance measures from the PRA, the question of defense-in-depth should not arise because that's built into the PRA. That's why the Fussell-Vesely in RAW came out the way it did, because of the defense-in-depth. Defense-in-depth should be an issue when you're now departing from the PRA, when

Defense-in-depth should be an issue when you're now departing from the PRA, when you categorizing SSCs in areas where you don't have a good PRA or you don't have a PRA at all.

Why would I care? I mean, the fact that this pump is part of a one out of three system in the PRA is reflected on the importance measures. So on top of that I want to think about defense-in-depth again, unless I have left something out?

So I think these things should be made clear that, you know, when the panel is deliberating certain things are relevant to certain things and in other cases they're not relevant.

I mean diluting the input here it seems to me. That's why it all comes out the way it does, because there is some different -- like at South Texas they have higher redundance than the average plant. So if I calculate Fussell-Vesely in RAW, I will see that there. Now in other instances where I don't have a

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

2 they have to worry about defense-in-depth. 3 This is simple enough? 4 MR. TRUE: Well, your question is simple 5 enough. I think the answer may be simple enough also, 6 and we kind of skipped through this in the guiding 7 principles. That we started with 1.174 in the 8 principles of risk-informed regulation in where we 9 wanted to go. And some of the things in 1.174 invokes 10 in the defense-in-depth area are there's reasonable 11 balance, diversity or redundancy not introducing 12 common-cause failures. 13 CHAIRMAN APOSTOLAKIS: Yes, I know. 14 MR. TRUE: Those kind of things. And 15 that's what we were trying to address through the core 16 damage. 17 CHAIRMAN APOSTOLAKIS: Yes, but I mean we should be going beyond 1.174 wherever we feel that we 18 19 know enough now. That's already a four year old 20 document, right? 21 MR. TRUE: Okay. 22 CHAIRMAN APOSTOLAKIS: What I'm saying is not necessarily inconsistent with what's in 1.174. 23 24 It's just a further refinement, I think. 25 My point is this question is much more

PRA, then I want to alert the panel to the fact that

1 important in the cases where the panel does not have 2 a PRA they can rely on, or maybe not at all, then when they have a PRA. For the internal events that's very 3 4 good and has gone through the reviews and all that. 5 Because then the importance measures reflect that a degree of defense-in-depth that's in the plant. 6 7 MR. TRUE: Yes. 8 CHAIRMAN APOSTOLAKIS: And I believe that 9 should be part of the training of the panel. 10 should be a training session where they 11 understand what the whole situation is. 12 Steve, do you have anything? 13 DR. ROSEN: No. I think you have it 14 exactly right, George. 1.5 DR. KRESS: Well, Ι think with problem, and that is if I look at redundancy and 16 17 diversity of mitigation systems and bypass, isolation 18 and early hydrogen burn and things having to do with 19 long term containment integrity, those will be in the 20 I don't know what defense-in-depth things will 21 not be in the PRA that you have to alert the panel to. 22 And that's what my problem is. 23 CHAIRMAN APOSTOLAKIS: Well, but --24 DR. KRESS: There probably aren't any. 25 CHAIRMAN APOSTOLAKIS: Well, if there is

1	a PRA, yes, I'm with you. But there are many other
2	situations where they're categorizing things without
3	a PRA or using a screening approach.
4	DR. KRESS: Like fire or seismic?
5	CHAIRMAN APOSTOLAKIS: Yes. Yes. Then
6	they have to worry about this.
7	DR. ROSEN: Or things that aren't modeled
8	in the PRA.
9	DR. KRESS: Yes. But those won't be these
10	things. They
11	DR. ROSEN: They will typically be in
12	RISC-4 anyway.
13	CHAIRMAN APOSTOLAKIS: Right. Right.
14	There is a reason why they're not in the PRA.
15	DR. ROSEN: That's right. Because the
16	analysts couldn't envision a sequence in which that
17	was imperative
18	CHAIRMAN APOSTOLAKIS: Well, it seems to
19	be that point
20	DR. ROSEN: But you have a point with fire
21	and seismic, though.
22	CHAIRMAN APOSTOLAKIS: Yes.
23	MR. HOOK: Because those can be important
24	and they're not a PRA.
25	CHAIRMAN APOSTOLAKIS: I mean clear cut

guidance like that I think would help a lot, not only with the categorization, but moving things along, you know. So next time, for example, we visit 1.174 we'll have the benefit of all this.

By the way, NRC staff is you ever feel the need or urge to jump in, do not hesitate.

Mike?

MR. CHEOK: This is Mike Cheok.

A quick comment of this defense-in-depth. I think you're right that if it's in the PRA, that should be a consideration in your defense-in-depth considerations. But remember that the importance measures now only deal with CDF and LERF and we need to pull in things like long term containment heat removal using the defense-in-depth arguments.

CHAIRMAN APOSTOLAKIS: Well, if you are changing the objectives of the categorization, then of course, you're absolutely right. But that's exactly what I would like to see in black and white; do this in that case, do that in the other case. So what you're doing now is you're going beyond what the importance measures reflect. And then, of course, you're right; you have to worry about it. You are in the category of cases where you don't have a good PRA result, right?

1	DR. KRESS: Or alternatively there's no
2	reason why you couldn't have an importance measure for
3	those things.
4	CHAIRMAN APOSTOLAKIS: For those things,
5	yes. Sure.
6	MR. CHEOK: That's correct. But, you
7	know, right now we have the CDF and LERF matrix as to
8	one step we are looking into.
9	CHAIRMAN APOSTOLAKIS: That's right.
10	MR. CHEOK: Unless we expand those matrix,
11	we have to deal with defense-in-depth.
12	CHAIRMAN APOSTOLAKIS: Well, that's my
13	whole point, that we can say: (1) for CDF and LERF if
14	the PRA's of good quality, then there's no other
15	issues of defense-in-depth. Those are all built into
16	it. Then (2) now if you want to worry about the late
L7	containment failure and so on, then of course the
18	Fussell-Vesely in RAW do not reflect those, as they
L9	are calculated today.
20	DR. KRESS: But they could.
21	CHAIRMAN APOSTOLAKIS: Adrian? Oh, sure.
22	MR. HEYMER: As regard the input into the
23	discussion, we can have it now or we can take it later
24	on when we get into the questions. But it might be
25	worthwhile hearing from some of the pilots.

1 Any CHAIRMAN APOSTOLAKIS: Certainly. 2 time. Yes. 3 MR. HEYMER: That have gone through this 4 process, for them to just briefly describe how they 5 addressed that in specific instances. 6 CHAIRMAN APOSTOLAKIS: Yes, we can pick up 7 these things again when we talk about the question. 8 MR. HEYMER: Okay. Well, we'll wait until 9 then. 10 MR. BURCHILL: This is Bill Burchill from 11 Exelon. 12 You made a comment that I think I'd just 13 like to make we understand your comment. 14 One of the fundamental principles in our 15 approach as an industry to supporting this Option 2 16 initiative is that we would be consistent with the 17 current framework of risk-informed applications that 18 are specified by the regulation. And, you know, 19 whether 1.174 is going to change in the future, it currently provides the direction to evaluate from a 20 21 number of different perspectives. 22 And I think you're absolutely correct that 23 where we have a PRA, we think it provides sufficient 24 information, but on the other hand what we've also 25 done is responded to those guidance from the current

1 regulatory environment that says advise the IDP on 2 whether there's an impact. So when we look at defense-in-depth it 3 doesn't necessarily mean that we're doing something 4 5 separate from the PRA that would necessarily be in conflict with it, but having done the PRA and having 6 7 done the categorization, we say well does that have 8 any impact on defense-in-depth and then we advise the 9 IDP whether or not that's the case. CHAIRMAN APOSTOLAKIS: Yes. I didn't mean 10 11 to imply that you should deviate from 1.174. For 12 heaven's sake, no. But you can certainly refine 13 certain things. And my other point is that the panel 14 15 typically will not consist of experts who understand 16 the PRA and its subtle and then understand the plant, 17 and understand all sorts of things. 18 DR. ROSEN: George, excuse me. I think it At least in the South Texas case and I assume 19 20 that the staff would insist on similar capability in other cases of other licensees, the panel has a risk 21 22 and reliability expert on it. Not every member is a 23 risk and reliability expert. 24 CHAIRMAN APOSTOLAKIS: That's true.

DR. ROSEN: But there is one, and his job

is to keep the panel informed of any implications like the ones we're talking about.

CHAIRMAN APOSTOLAKIS: My point is that the more explicit the guidance to the panel, the better off all of us will be. Okay? And making sure that you discuss the defense-in-depth assessment appropriately, but in certain instances is not as important in others. That means that would be a useful thing rather than saying defense-in-depth is important, you have to look at it in a blanket sort of way.

MR. BURCHILL: Bill Burchill again.

Yes, I think you're absolutely correct. And I think if you have a full compliment, let me put that way, of PRA information that's applicable, then the defense-in-depth becomes a supplementary piece of information, perhaps confirmatory or perhaps just advisory. But as you point out as well, where you do not have the PRA information and perhaps are you only using screening techniques, the defense-in-depth probably becomes a more important part of the mix of information.

MR. CHEOK: George, real quickly I just want to read 2 sentences from 1.174. It says here that it -- I just lost the place.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1	"It has been and continues to be an
2	effective way to account for uncertainties. If
3	comprehensive risk analysis is done, it can be used to
4	help determine the appropriate extent of defense-in-
5	depth to ensure protection of the public health and
6	safety. When a comprehensive risk analysis is not
7	done or cannot be done, traditional defense-in-depth
8	considerations should be used or maintained to account
9	for uncertainties."
10	That's what 1.174 says and I think it
11	agrees with you just said and what Bill just said.
12	CHAIRMAN APOSTOLAKIS: We all agree.
13	DR. FORD: Could I just ask a question
14	about the final bullet? By that do I understand
15	physically what you're considering is long term
16	degradation of concrete and the rebar?
17	MR. TRUE: No.
18	DR. FORD: No.
19	MR. TRUE: We're talking about the long
20	term well, no unearly failures of the containment
21	under severe accident conditions. Failure to remove
22	decay heat, long term over pressure over temperature
23	conditions.
24	DR. FORD: Okay. Because I know that in
25	the plant license renewal area the integrity and

degradation of the concrete of the rebar is under 1 2 consideration, but that's not what you mean in here? 3 MR. TRUE: No. No. 4 DR. FORD: Okay. 5 MR. PARRY: Can I just add a comment, just to clarify that. 6 7 This is Gareth Parry from the staff. 8 What's under consideration here, things 9 like the systems that are used to remove decay heat, 10 like the RHR system, containment sprays, fan coolers 11 but not the structures themselves. I think that's 12 right. 13 MR. TRUE: Correct. Correct. 14 DR. FORD: What about integrity of the 15 containment, the physical integrity? 16 Oyster Creek I know that there we had problems -- I 17 think it was Oyster Creek. We had problems of 18 degradation, however in that case some of the steel. 19 Does that come into this out of all 20 categorization of RISC-3 components? 21 MR. TRUE: I don't see a path that someone 22 could conclude that the containment is RISC-3. 23 containment pressure boundary is RISC-3. So I think we believe that the treatment of the containment will 24 25 continue as is and we're talking about changing the

1 treatment. 2 Okay. DR. FORD: Not going to change 3 that? Same is true of the reactor 4 MR. TRUE: 5 coolant system --6 CHAIRMAN APOSTOLAKIS: Are you saying that 7 these categorization process as a generous statement 8 does not apply to passive components? Is that what --9 I mean, Dr. Ford has asked two or three questions so 10 far and I'm not sure what the answer is. You refer to 11 the ASME case. 12 MR. HEYMER: Where the ASME code cases 13 reflect, which is really focused on piping and vessels and such. 14 15 CHAIRMAN APOSTOLAKIS: Right. 16 If the licensee wishes to MR. HEYMER: 17 involve that code case and use that, then he can 18 incorporate the results from that passive 19 categorization into what he's gotten by the pressure 20 boundary. Otherwise, the pressure boundary would stay 21 as it is today. 22 We do not see things like containment 23 structures being included in that, and as such they 24 would stay exactly as they are today. And I think one 25 of the principles we have is that the component or the

WASHINGTON, D.C. 20005-3701

1	structure stays where it is today unless you can show
2	that it's of low safety significance.
3	DR. ROSEN: But even in that case, Adrian,
4	if the licensee wishes to use a code case, what you're
5	doing is accepting or utilizing some flexibility to
6	change the inspection intervals or testing intervals,
7	but not to remove the components from scope?
8	MR. HEYMER: Well, in this case we would
9	look beyond that. We would take it to the next step.
10	So you
11	DR. ROSEN: You've gone through the code
12	case you're saying?
13	MR. HEYMER: Yes. So if it came down, it
14	wouldn't just be increase in the interval necessarily
15	of the inspection activity.
16	MR. CHEOK: I think the way the staff
17	views this issue is that everything starts off as
18	RISC-1 and it stays in RISC-1 unless you have
19	justification to move it to RISC-3. So if you want to
20	move a passive component from RISC-1 to RISC-3, you
21	would have to use, for example, the ASME code cases to
22	justify moving it to RISC-3.
23	DR. FORD: So if the staff came to you and
24	said the containment vessel on the Seaborn Station and
25	as an informed member of the public, I could say the

rebar is going to corrode. The staff asked you prove to me that the containment has still got its original design integrity; that would be kicked into the current in the IDP process?

MR. HEYMER: Well, no. That to me is a completely different issue associated with the current design and the integrity of the containment as it is today and is not a risk-informed activity. This process doesn't go out and say is the equipment adequate today. We assume it is. What we're doing is going through a categorization process to look at the insides and say if it's 1 today, can we justify making it of low safety significance? It doesn't take into account well is the design with the design assumptions or the corrosion rates, etcetera, are they still valid today. To us that's a different question.

DR. FORD: Okay.

CHAIRMAN APOSTOLAKIS: Shall we go on to the questions now or you have more?

MR. PARRY: I mean, we've discussed the defense-in-depth. You've insisted that the PRA has everything we need in it for looking at core damage issues. And I look at the slide and it seems to have some sort of a balancing between mitigation and prevention in it, kind of what you look for in those

context.

What you also stipulated was that perhaps a defense-in-depth assessment is more required for some issue like fire. And when I look at the slide it does not have anything in it that's familiar to the issues of defense-in-depth when I think of fire.

Now, is that just translation or is there some understanding here that these words deal with the prevention of fire; the detection and suppression of fires and the prevention of damage caused by fires here hidden in these words?

MR. TRUE: No, there's nothing hidden in the words. I think fire is a difficult one when you're searching for defense-in-depth, because as a practical matter we have designed our plants to have a protected train in most cases for fires. So if you have a fire, a large fire, you'll be left with one, exactly one train of mitigation which by definition isn't really defense only. It's a level of defense-in-depth, but you're not going to get more levels of defense-in-depth than one in most plants for most situations.

MR. PARRY: In most plants.

MR. TRUE: Unless you're South Texas and you have three 3 trains and they're all separated and

NEAL R. GROSS

one of the last plants built in the country.

In most plants in the U.S. we have gone to a -- Appendix R has driven us to this single path. And because of the initiating event frequencies we see in fire PRAs, I don't see how a train that's used to mitigate a fire could ever have low safety significance because there's only one train.

And so I don't think we're going to find a lot of additional defense-in-depth in the fire area. It's just my experience from doing fire PRAs.

MR. BURCHILL: Bill Burchill from Exelon.

I guess I'd like to temper that just a little bit. If you talk about the Appendix R bounding fire, you know what we call an exposure fire, what you're saying is correct and the plant is designed specifically to provide a path for its protection. But in fact, the fires that will be more likely to occur in the plant at a higher frequency level are not bounding exposure fires or large control room fires, or something of that nature.

Most fires that have and probably will occur in a plant are of a much less extensive impact. And in those cases certainly the fires are protected through the use of the EOPs. You don't get your extreme safe shutdown procedure. You're working

1 through EOPs. And, in fact, you do look for defense-2 in-depth. You do look for any pathway that can control 3 pressure, reestablish inventory if that's necessary. 4 You know, obviously decay heat removal and so forth. 5 So, I think we have to be very careful not 6 to let our thinking be dominated by the Appendix R 7 design base approach. For that case what Doug is 8 saying is certainly true. But for the more likely 9 situation there are certainly are a number of ways that are available and, in fact, are actually invoked 10 through the use of the EOPs. 11 12 CHAIRMAN APOSTOLAKIS: But I think the general -- I'm sorry. 13 14 MR. BURCHILL: And in fact, that's what a 15 fire PRA represents. I mean, a fire PRA starts by 16 going through what is the realistic response. We had 17 this discussion, I think at an ANS meeting, Dr. Rosen. 18 In fact, the PRAs going to represent all 19 those realistic paths. 20 CHAIRMAN APOSTOLAKIS: But I mean would 21 the door, for example, that's supposed to be closed to 22 prevent fires from spreading from one compartment to 23 another, the smoke and so on, would that be part of the defense-in-depth philosophy? I mean, that you 24 want these doors closed and so on because you are 25

preventing the fire from spreading; and that's not 1 2 going to be in the PRA I don't think. 3 MR. TRUE: Right. Right. CHAIRMAN APOSTOLAKIS: You know, if there 4 5 So is that kind of thinking in part of the quidance to the panel or they will think about it 6 7 naturally because they're experienced people? I don't 8 know how that works. 9 Now, the fire protection engineers, you 10 know, when you speak about defense-in-depth, they will 11 tell you we have measures to prevent fires from 12 occurring. Then given that the fire exists, then we 13 want to mitigate its consequences and so on. I think what we said in the 14 MR. TRUE: 15 fire section was that we felt fire suppression systems 16 were something that would be normally reflected in 17 fire risk analyses, and we could use this process. But that if you were going to go --18 19 CHAIRMAN APOSTOLAKIS: But what we're 20 screaming about this is you don't have that benefit, 21 It's screening analysis that is --22 TRUE: Well, we should talk about fire, because --23 CHAIRMAN APOSTOLAKIS: We will. 24 We will. 25 MR. TRUE: And fire barriers like the door

you mentioned in general it's rare that a fire PRA 2 explicitly addresses those. CHAIRMAN APOSTOLAKIS: 3 Does not? MR. TRUE: And so we said in order to do 4 5 a reclassification -- like as Mike said, the premise 6 is you stay where you are unless you have a case. And 7 so you'd have a case that said I've looked at this 8 barrier and even if it doesn't work, it doesn't 9 increase the risk and therefore it could be moved 10 down. But we don't see that as being a natural 11 fallout from importance measures, that would have to 12 be a focused look at barriers. 13 So we think the process could apply to barriers, but we don't think a practical matter it's 14 15 going to be applied. 16 CHAIRMAN APOSTOLAKIS: Anyway, let's move 17 on because we are spending too much time. Shall we 18 jump into the questions. 19 MR. TRUE: Okay. I want to just jump to 20 one last --21 CHAIRMAN APOSTOLAKIS: One last, okay. 22 MR. TRUE: One last thing on applications. 23 CHAIRMAN APOSTOLAKIS: Good. 24 MR. TRUE: Just so you understand where we 25 are.

Three of the owners groups -- that was the 1 2 last slide -- have pilot -- have undertaken pilot applications of the categorization process 3 in fact, in all cases developed 4 quidance. And, 5 additional guidance that they've used in that process. And they've looked at both safety related 6 7 and non-safety related, tried to get a balance of SSCs removing different boxes. 8 9 The NRC staff has been involved 10 observing the IDP deliberations on that. And we've 11 had a case where we've had a spectrum of 12 information; fire approach is different, 13 And we believe, and we'll talk more approach is. 14 about this when the pilots talk some more, we believe 15 that through that that NEI 00-04 is a comprehensive and robust --16 17 CHAIRMAN APOSTOLAKIS: Well, I wonder how you can draw that conclusion? What exactly does a 18 19 pilot application tell us? 20 I mean, they take a document and they say 21 okay it tells us to categorize certain things in a 22 certain way. We do it and it works. We put them in 23 category 3. I mean, where the pilot tell me that this 24 was not appropriate or -- I mean, how can it question

the document?

1 It could question the ease with which the 2 document can be applied, but unless the panel that 3 evolved it, the panel comes back and says gee, you 4 know, everything you're telling us to do is nonsense, 5 which I don't think is the case. 6 So, I wonder --7 DR. ROSEN: That can't happen because the 8 panel is the process in a lot of respect. 9 CHAIRMAN APOSTOLAKIS: Well, I don't know 10 how I can conclude it's comprehensive and robust. 11 DR. ROSEN: Oh, I agree. I mean, I would 12 be interested. 13 CHAIRMAN APOSTOLAKIS: I just don't know that. 14 15 MR. HEYMER: We started and we developed 16 a draft guideline document. And some of the pilots 17 provided input into that. And then we took that document and we took it into the field and we gave it 18 19 to people and said now can you use this document. 20 And so the real process is to test out the 21 document. And they started to use it and they 22 identified some problems. 23 The IDP actually had some problems in the 24 training process, and that's how we've gone through 25 the lessons learned.

We're not saying that Rev. B as you see it today that was forwarded in June is the document. We need to make some adjustments and in a 4 number of areas. But the fact that the pilots took it and they could understand the document, and that they went through categorization а and identified weaknesses or areas where we needed to improve it, but they still went through it. And actually they came out at the end. And as we went through the pilot process, we've learned from the first and third look, and the second. And I think what we ended up with when you get to Surrey, admitting that we're going to have to refine it some, shows that we do have a reasonable and comprehensive process in place.

It's an evolution. It's to document; did they understand the document, could they use the document.

> Bill, did you want to say anything? MR. TRUE: No. Tom.

MR. HOOK: Having observed the Wolf Creek IDP and participated in the Surrey IDP, as Adrian indicated there were lessons learned in terms of some small word changes to the evaluation criteria in the NEI guide, specifically in section 5.2 in the IDP guidance on addressing defense-in-depth issues for

1

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

candidate RISC-3 components.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Where I believe the Surrey IDP felt much comfortable with the new words and appropriateness to address their concerns from the deterministic perspective from their areas expertise with those words then the Wolf Creek did and probably the Quad Cities did. So I think there was an evolution in the specific words that brought the IDP to feel more comfortable with the categorization process. Not as much with the active, because I think the active didn't need as much revision, but the passive in terms of the draft ASME code case underwent significant revision between the Wolf Creek and the Surrey IDP having reflected the comments from the Wolf Creek IDP where basically it didn't work and they kind of gave up on the passive categorization at Wolf Creek. And Bob Lutz can speak to that more from the Westinghouse perspective.

In terms of your asking the question about well how does the IDP validate the process, I think the IDP validates the process when the members feel like the process works from their perspective, from their expertise and their view of is it acceptable to move this component for which I have some special knowledge of from RISC-1 to RISC-3 or RISC 2 to 4, and

such.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

And at Surrey I think the members felt like they understood the deterministic basis as well as the PRA basis for components being in their categories much better than in the earlier IDPs.

MR. BURCHILL: Bill Burchill from Exelon.

I just wanted to add to that sort of segueying off of your comment about I think you said the IDPs won't revolt. In fact, and I don't want to state this in too exotic terms, the IDPs in fact will revoke if they do not feel the process is correct and addressing the right issues.

The IDP panel members are not a randomly selected group, of course. They're specifically chosen for both their expertise and their experience. And to be quite frank about it, they're protective of what they believe is the integrity of plant and particularly those coming from operations, they're very protective. And so they do not take at just face value what they're presented. They challenge it. In every one of the cases of our pilots it's been quite an experience. In one case it was near revolt and they said your process needs to consider the following things, your process must be bringing me the correct information.

NEAL R. GROSS

So, I think that it's been a real learning 1 2 experience for each of us that's been involved with We've, of course, previously had the similar 3 4 experience with maintenance rule expert panels, but 5 now we're talking about actually changing things in the plant, particularly leading to treatment changes. 6 7 And we are very strongly challenged by these IDPs. 8 DR. ROSEN: That experience is 9

inconsistent with mine on the South Texas panel.

MR. TRUE: I'd expect that.

MR. CHEOK: George, I guess the staff has also been present at these three pilots. And one of the main staff comments was that there needed to be more structure in the NEI 00-04 process and in the IDP documentation as to what was deliberated. And I think I agree with Bill and everybody else who said that there's a lot of deliberations that goes on to be in these IDPs and that they actually go through extra lengths to try to determine that something is low safety-significant.

What the staff's comment was that I think we need to document this kind of process to ensure that it does always happen in the future and that also w.⊝ need to document it in the IDP present deliberations so that we can know what they talked

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

1 about and what the basis for when you something in 2 RISC-3. 3 So a lot of this process that's been 4 talked about is not now in documentation that we can 5 see, but we are pushing for more of this kind of 6 documentation to be present. 7 CHAIRMAN APOSTOLAKIS: Okay. Shall we go 8 to the questions? 9 MR. HEYMER: We provided a handout. We 10 weren't going to put these up on the screen. 11 got a handout. We were going to talk from these and 12 so it would be an interactive process between the 13 industry participants and the Subcommittee here and 14 with the NRC joining in. 15 So rather than put just the question and 16 that bullets up, the real purpose of the bullets is 17 just a summary, but it would be more of a discussion 18 session based on the questions as we go through them. 19 And I think some of them we've already got 20 into in partial manner. And I think going through the 21 exercise we've just done will help us. 22 Question 1: Why are there are four -- we 23 read this as to be why there are four categories 24 instead of three. 25 CHAIRMAN APOSTOLAKIS: That's what

says.

1.4

MR. HEYMER: And, you know, when we started this off this morning the NRC staff, we came in with one proposal, the staff looked at it and said perhaps it would be more practical to come up with a quadrant approach and not have 50.49(b) as we did in Option B to Appendix J, but have a separate rule. So we took a look at the quadrants and we believed it could work.

Now, we've evolved a little from that, but I still think that a quadrant structure is correct. I will note that as we get into the treatment area we think that we're looking at three categories of treatment as regards Appendix B stroke safety related, augment quality and industrial balance of plant type activities. And that balance of plant activities is really a spectrum from items that you might work on as regards to water cooler way up into something that might be actually approaching the augment quality type of activities for something that has significant importance to the plant that may still be low safety-significant.

So I think what we're looking at here is not necessarily a hard line between RISC-3 and 4, but more of a perforated line between 3 and 4. But the

NEAL R. GROSS

T	categorization is still there because we're not
2	changing the design basis. We're still keeping the
3	nomenclature of safety related, and that means
4	something in the regulatory space. So I do think the
5	quadrant structure is practical. It does move
6	forward, but we are looking at I guess if we went
7	through Option 3 and we're successful in everything in
8	Option 3 that we're trying to go to, then perhaps we
9	would just end up with 2 categories. But we see that
10	the categorization is 4 with 3 degrees of treatment
11	and with the third section of treatment being
12	industrial balance of plant treatment being a very
13	much a graded process depending upon where you are as
14	regards to the importance.
15	But if the staff want to jump in there to
16	mention the quadrant process.
17	MR. REED: I don't disagree with anything
18	he said.
19	CHAIRMAN APOSTOLAKIS: Sorry?
20	MR. REED: I don't disagree with anything.
21	This is Tim Reed from the NRC staff. I
22	agree with his characterization.
23	CHAIRMAN APOSTOLAKIS: So Option 3 might
24	combine the two of them, but not Option 2?
25	MR. HEYMER: Right.

DR. ROSEN: That's just because of the way 1 2 we structured Option 2. 3 MR. HEYMER: That's correct. 4 DR. ROSEN: It has nothing to do -- I mean, if you didn't have that, you would say that box 5 6 3 is -- we probably wouldn't have put the components 7 that end up in box 3 in box 3, would not have made 8 them safety related in the beginning if we had this 9 process. 10 After we designed the plant or as we were 11 designing the plant we did the PRA and IDP as part of 12 an integrated design process for the plant that would 13 have ultimately emptied box 3 into box 4. 14 MR. HEYMER: Right. 15 DR. ROSEN: And would have said okay, 16 these things are not risk significant, therefore we're 17 going to be treat them as nonsafety related. 18 I think if you'll look at a MR. HEYMER: 19 new plant, I mean I think you would probably look to 20 two categories, possibly three, but certainly I think 21 you would look at two. Because the fewer number of programs you have the better it is from a long term 22 23 perspective. 24 But, yes, I mean if we were starting off 25 from scratch we probably wouldn't have the box 3

1	category.
2	DR. ROSEN: Well, the fact of the matter
3	is we're starting off from scratch. Because there are
4	some new plants being thought of by such companies as
5	Exelon and Dominion. So I think that if it's
6	revelation to anybody, that revelation might be
7	important in what those entities are doing.
8	CHAIRMAN APOSTOLAKIS: Anything else on
9	this question?
10	MR. BURCHILL: I was just going to
11	comment.
12	From a utility perspective it's actually
13	important to us to have the boxes 3 and 4 because
14	there are continuing regulatory requirements before
15	Option 3 may change them that apply to those RISC-3
16	components. And it's very important for the plant to
17	maintain cognizance of that and assure that they're
18	meeting those requirements.
19	So it really becomes a matter of
20	bookkeeping even if treatment really is the same
21	between the two categories.
22	DR. KRESS: That has to do with
23	functionality requirements?
24	MR. BURCHILL: Yes, in some cases.
25	DR. KRESS: Yes. Personally, I don't see

1 any downside to having 4 boxes. So, you know, it just 2 provides additional information as far I'm 3 concerned. 4 MR. BURCHILL: Yes. And again, it's 5 almost a simple as mundane bookkeeping; the plant 6 being able to keep track of those components that they 7 have to maintain a continuing regulatory compliance. 8 DR. ROSEN: Those components which were 9 born safety related? 10 MR. BURCHILL: Correct. 11 DR. ROSEN: Which we now understand 12 probably shouldn't have been. 13 MR. BURCHILL: Absolutely. 14 DR. ROSEN: But we will continue to 15 maintain their functionality. 16 MR. BURCHILL: Correct. 17 DR. SHACK: Well, I always assumed that 18 the staff have some other -- you know, when we say 19 they're not safety-significant, they're not safety-20 significant in terms of CDF and LERF. And it comes 21 back to these questions that Tom and Mario keep 22 bringing up about sort of frequency consequences and 23 some of the other things. And I look at this attempt 24 to maintain functionality in RISC-3 as trying to keep 25 a handle on those kinds of concerns without bringing

in a new metric.

And so I always assumed that the RISC-3 and the emphasis on the functionality there was really part of a defense-in-depth frequency consequence kind of consideration that wasn't explicitly brought in. And if you said that CDF and LERF were your only considerations, then I think you would end up with a two bin system. But if you brought in explicitly other kinds of measures, you would end up with in fact something like the 4 quadrant box.

And that sort of one my questions that came in here, as I looked through this, is suppose you made the scope the same as the maintenance rule and you brought in Part 100 considerations; the component is used to meet those requirements and make that an explicit part of the consideration. Would you simplify some of these arguments over whether the component has to be functional or not? And, you know, you just automatically boost it up. Would it change the scope all that dramatically?

MR. HEYMER: Tom?

MR. HOOK: For the passive component categorization and the current draft ASME code case, Part 100 is a consideration, just to address that specific issue for pressure boundary components.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

1 MR. HEYMER: Okay. Moving on. Question 2 Bill Burchill will start the response from the 3 industry perspective on this. Bill? 4 MR. BURCHILL: Yes. Actually I'm going to 5 to the next four questions which were 6 generally categorized in your letter as the use of CDF 7 and LERF as the sole criteria. 8 The first question asks whether there's a 9 logical inconsistency between the safety criteria used 10 current licensing activity, specifically 11 concept of frequency versus consequence and the 12 criteria used in Option 2. 13 And we took this quite literally in trying 14 to respond to it. We think that Option 2 15 consistent with other risk-informed applications which 16 we've previously talked about and in that sense addresses more than just CDF and LERF. It does address 17 18 defense-in-depth considerations, preservation 19 safety margin considerations and so forth. 20 But of more to the question the consistency, I think sort of what I would say on 21 22 philosophic plane if you look at our current licensing 23 structure beginning with, I guess, Reg. Guide 1.70 24 Rev. 2 back in the mid-'70s, we articulated that there 25 was a clear distinction between those high frequency

events, relatively high frequency, anticipated operational occurrence events and the limits that we would place on them, you know, which are things like DNBR and critical power ratio. And then the next step down the curve would be those moderate frequency events where we would then impose -- actually it turns out it's similar limits to the AOOs. And then the very low frequency events, normally referred to as design basis events where we go to things like Appendix K and more severe limits.

And our thinking is that in fact what we're doing here is actually continuing the logical extension of that curve that core damage and large early release, neither one of which are associated with any of those first three categories because they disallow that as an end consequence, but now you consider an end consequence that's more severe than the most severe design basis accident consequence but generally of a much lower frequency. You know, some orders of magnitude in cases, but some coming close.

So if you think of the curve of the frequency versus consequence as generally sort of the Farmer line that was articulated almost 30 years ago, that this is just a logical extension of that whole concept. And as such, in fact, adds an enhancement to

our inquiry about the safety of the plant. You know, it says I've got these three that are under design base, they have a graduated set of criteria consistent with the challenge frequency and we're now looking at yet another point on that curve. And we're saying for these events which have a much more extreme end point, you know, generally we would expect to see them in a much lower frequency.

CHAIRMAN APOSTOLAKIS: I'm not sure I follow this argument. Couldn't there be a system or a component that would prevent the minor release but when it comes to serious severe releases, the system is really irrelevant? Would that system come out as being risk significant is CDF is my criterion? I think the thrust of the question is that there may be some SSCs that are really preventing minor releases, Farmer called them "of nuisance value," and these may not be captured. They may not be declared the significant if you look at the severe stuff. That's really the thrust of this.

I mean, there's no question that by going to CDF and LERF you're going beyond design basis and everything you told us is valid. But are we missing some stuff that, you know, may be preventing minor releases that may create an uproar or whatever by

WASHINGTON, D.C. 20005-3701

the

focusing on the severe accidents beyond design basis? 1 2 BURCHILL: I understand. I think 3 there's two parts to the answer. One is that under 4 Option 2 specifically we are maintaining functionality of those pieces of equipment. 5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Well, let me start with things that simply stay in RISC-1. Things that stay in RISC-1 we're not changing anything. So what we're really only talking about is the subset that would be reclassified because of safety-significant into RISC-3. And in those cases we're compelled to maintain the functionality for all of their design basis responses, which would be for these less severe events.

Now, we're going to have a later question that deliberates, of course, whether or not there's an actual impact on that functionality or its reliability with respect to treatment. The evidence generally to date is, I guess, at best inconclusive on that, but it doesn't indicate a strong change in the negative And, in fact, you know probably at best neutral.

So what we believe is that being compelled to maintain that functionality that we're supporting the response to those less severe events and that we're in fact not degrading that.

NEAL R. GROSS

1	DR. KRESS: That presumes that the
2	original classification of those as safety-significant
3	captured their significance with respect to these
4	smaller releases.
5	CHAIRMAN APOSTOLAKIS: Is it possible that
6	some of them were not RISC-1?
7	MR. BURCHILL: Well
8	DR. KRESS: And it's possible that they
9	didn't capture all of those because the process by
10	which they were the criteria used to put them in
11	that category might not have captured all of them.
12	CHAIRMAN APOSTOLAKIS: I mean the old
13	DR. KRESS: We got a new way to do it now,
14	but
15	CHAIRMAN APOSTOLAKIS: I understand. But
16	were they safety related in the old scheme?
17	DR. KRESS: Oh, yes. That's the reason
18	they're in that category.
19	CHAIRMAN APOSTOLAKIS: They were safety
20	related. Yes. All right.
21	MR. BURCHILL: Yes. Right. I mean if
22	they're safety related
23	DR. KRESS: They were safety related. Now
24	that presumes the old process for determining they
25	were safety related caught all these frequency

consequence event components; that might be at the low frequency nuisance level. I'm not sure they did. proof of the pudding in that is if you had a PRA that looked at all those things and actually calculated a frequency consequence and did a RAW with respect to components on these lower frequency consequence events. Had a RAW on the F-V. And to me that would be a proof of the pudding, and I'm not sure it's captured this way because it has a presumption in it that they were captured originally. DR. ROSEN: Let me ask a question designed to get very tangible about this. For example, what did the PRA independent panel at Surrey do with things in the waste gas processing system? MR. HOOK: They worked in the scope of the pilot where the Surrey IDP --MR. BURCHILL: Well, they were at Quad, the standby gas treatment system was one of the systems chosen. And, in fact, through the measures that were presented to the panel from the process of their significance determination, it was recommended that the system be reclassified into RISC-3. And the IDP did not accept that. The IDP in fact -- you know, I said about revolt. They rejected that information

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

1	and said we will not reclassify this.
2	DR. ROSEN: Here the IDP is standing for
3	defense-in-depth.
4	MR. BURCHILL: Yes.
5	DR. ROSEN: And just using their intuition
6	in saying
7	MR. BURCHILL: Right.
8	DR. ROSEN: there isn't that much to be
9	gained from doing this and potentially something to be
10	lost, and we'd just rather not do it, so don't.
11	MR. BURCHILL: Precisely.
12	DR. ROSEN: And that's a familiar pattern
13	from experience with IDPs. Just because the process
14	allows it doesn't mean that the expert panel has to go
15	along. And so I'm glad to hear that response.
16	DR. KRESS: Let me rephrase my concern.
17	We have a category here called nonsafety related but
18	safety-significant. You have a category because you
19	did a PRA that said hey, we someone got this component
20	overlooked in the old process and that we really
21	should have been safety in there.
22	Now, what I was saying is if but that
23	was with respect to CDF or LERF. Now, if you extended
24	that concept to some low level frequency concept, I
25	was saying is it's possible we missed those, we might

1	have missed some other things. And the only way we
2	find it out is do the PRA. That was the nature of my
3	comment.
4	CHAIRMAN APOSTOLAKIS: So you're really
5	changing the argument. Billy was saying
6	DR. KRESS: Just turn it around.
7	CHAIRMAN APOSTOLAKIS: that to go from
8	1 to 3 you have a functionality requirements and so
9	on.
10	DR. KRESS: Yes, exactly.
11	CHAIRMAN APOSTOLAKIS: But Tom is really
12	saying how about from 4 to 2.
13	MR. BURCHILL: That's an interesting
14	point. In fact, I want to address both the 1 to 3 and
15	the 4 to 2.
16	CHAIRMAN APOSTOLAKIS: Okay.
17	MR. BURCHILL: Because you could have, for
18	example, a component. In fact, the example Doug put
19	on his slide about the containment valves. You could
20	have you know, the vent valves. That's normally
21	under design base intended to close. Okay. And what
22	we've got is a situation that for the PRA we want it
23	to open. We want it to vent.
24	So whether or not that would be a
25	candidate for reclassification from 1 to 3, I'm not
1	1

1 But we certainly would now identify a new sure. 2 functionality, you know, because of this inquiry that would have a set of attributes associated with it 3 4 which in fact may change the treatment of that 5 component; if nothing else to cause us to monitor its 6 condition and capability for this new attribute. 7 think -- I quess I don't 8 something that degrades anything that's presently in 9 place. I think actually what we're presented is an 10 opportunity to identify new functionalities and 11 attributes that we really want to spend some time on, 12 you know, that we want to pay some attention to. 13 DR. KRESS: Yes. I don't think it degrades 14 anything presently in place either. I think there's 15 a potential for missing things that the current 16 process missed in the first place. 17 MR. BURCHILL: Well, actually now understand completely what you're saying. 18 19 DR. KRESS: Yes. 20 MR. BURCHILL: Yes. And we're going to have to think about that. 21 I don't think any of us 22 would stand here today and say we will quarantee this 23 process, we'll pick up those things that we might have 24 forgotten before. I don't think there's any -- we 25 would not -- yes, understand.

1	DR. KRESS: Yes. And that is the basis of
2	my comment.
3	DR. ROSEN: But there is guidance at NEI
4	00-04 that says if something like that shows up
5	MR. BURCHILL: Yes.
6	DR. ROSEN: that becomes an opportunity
7	for the plant to exercise its 50.59 process.
8	MR. BURCHILL: Yes.
9	DR. ROSEN: And to make it safety related
10	to the extent possible and to recognize an error. I
11	mean, that's what the corrective action systems do
12	everyday.
13	DR. KRESS: Yes, but my point was that I
14	don't see in the process how you find those thing.
15	DR. ROSEN: Well, he's right. It's not the
16	process that does it, although there's a lot of the
17	process puts a lot of light and scrutiny on
18	components. And in that process you're naturally
19	going to find a cockroach if there is one.
20	DR. KRESS: It may very well, and I'm not
21	sure of that. It's not explicit.
22	DR. ROSEN: You're right.
23	CHAIRMAN APOSTOLAKIS: Okay.
24	MR. BURCHILL: Okay. The third question
25	had to do with somewhat of a variation I think of this

concept of the frequency versus consequence. 1 2 addresses explicitly the provision of layers of protection which are part of the defense-in-depth. 3 4 And that these pieces are generally classified as 5 important to safety. 6 The implication of the question is that 7 we're going to change something that's going to either 8 change that level of defense-in-depth or eliminate it. 9 And our answer to that is that compliance with Part 10 100, you know, as the example in the question is is 11 not impacted by Option 2. In other words, we're still 12 compelled of course to comply with that regulation. 13 Neither are there layers of protection explicitly impacted by Option 2. We don't anticipate 14 15 in fact that equipment is going to be removed from the 16 The only thing that we understand would be changed would be the treatment requirements, but we 17 18 must maintain functionality. 19 So there's not an expectation that we're 20 actually changing these levels. 21 DR. KRESS: There could be a potential for 22 changing the balance between CDF and LERF? You might 23 change CDF some and not LERF or vice versa? And 24 wouldn't that be a change to the defense-in-depth? 25 MR. TRUE: It's possible that CDF

1	theoretically could change more than LERF, but we are
2	controlling that amount of change to be a very small
3	change.
4	MR. BURCHILL: In both cases.
5	MR. TRUE: In both cases. So, yes, as a
6	matter of
7	DR. KRESS: You're saying you're keeping
8	the balance within an appropriate range by keeping it
9	small?
10	MR. TRUE: In some appropriate range.
11	MR. BURCHILL: The reason I was a little
12	stumped on your question is I really wasn't thinking
13	of CDF and LERF as separate perimeters being an
14	illustration of defense-in-depth.
15	CHAIRMAN APOSTOLAKIS: But they are.
16	MR. BURCHILL: Yes, it's interesting.
17	CHAIRMAN APOSTOLAKIS: At the high level.
18	MR. BURCHILL: Yes. Yes.
19	DR. SHACK: So the argument in maintaining
20	functionality is not the same; although you have the
21	functionality if it works, the reliability could
22	potentially be degraded?
23	MR. BURCHILL: Yes.
24	DR. KRESS: That's why a RAW tells you.
25	CHAIRMAN APOSTOLAKIS: Well, that's what
- 11	

1	the whole issue is here, right?
2	MR. BURCHILL: Okay.
3	DR. SHACK: To come back and say that
4	you're maintaining functionality just doesn't really
5	address the question in a sense either. We're
6	changing the requirements. Now whether they have a
7	significant impact is a different that's a
8	different question.
9	MR. BURCHILL: But that in fact
10	DR. SHACK: Which, of course, is the
11	relevant question.
12	CHAIRMAN APOSTOLAKIS: Was not even a
13	question.
L4	MR. BURCHILL: Yes, it was a comment.
L5	CHAIRMAN APOSTOLAKIS: Just an argument
L6	supporting the other question.
L7	DR. KRESS: Yes, you're right.
18	CHAIRMAN APOSTOLAKIS: Which were number
.9	2 and number 5, I believe. 2 and 5 have question
20	marks at the end. Three and 4 really are preludes to
21	the questions.
22	Anyway
3	MR. BURCHILL: Let me just use the
4	opportunity with question 4, however, even though it's
5	not posed as question
1.1	

CHAIRMAN APOSTOLAKIS: Yes. Yes.

MR. BURCHILL: -- to clarify that we are not addressing within this Option 2 arena the spent fuel pool and the fuel handling systems. It says rad waste systems. In fact, we are doing some of that, but it's principally the spent fuel pool and fuel handling are not explicitly under the scope of this.

We've talked about this functionality item and defense-in-depth, so unless there's a question on 4, we'll go on to 5.

MR. PARRY: Well, yes. You conclude the response to 4 by saying there's no conclusive evidence that a "'category-one quality requirements' actually provide improved SSC performance." I mean, I think that's true. I guess I would ask is there conclusive evidence that they don't provide improved SSC performance?

MR. BURCHILL: Well, I mentioned previously that I think our position is clearly there is not conclusive evidence. However, probably the most extensive body of evidence that we're aware that's actually attempted to provide this comparison was submitted on the South Texas docket in their exemption request. And I'm failing right now to remember the exact number of components, but it was in

the 20,000 range, I think. I may have that figure incorrect. But it was a large number that were looked at with comparison between those that had been maintained under a safety related regime and those that had been maintained under a commercial practices regime. And that document pretty clearly shows there's no statistical bias one way or the other.

Now, there's been argument about whether the conditions that were imposed were sufficient to test the case and so forth. But at least the evidence we're aware does not indicate a degradation in a systemic bias way.

Okay. Number 5 is a difficult one. It says: How does the ensure of SSCs that are deemed risk significant not essential for addressing acts of terrorism and sabotage? How does that get addressed?

We're looking at the potential for radiological release under the LERF consideration. But we do not under this program explicitly address acts of comission or sabotage or terrorism. We consider those are specifically addressed in a structured way under the security programs and we don't see that anything that we are doing here would actually change that. There's no linkage across to how the security program addresses preparation for

that type of an impact on the plant.

The programs, as I say, are not within the scope of Option 2. The one place which you may be aware that the PRA does get applied, we do assist occasionally in the security program in identifying what are called target sets of equipment. You know, those that would present the plant with disabling effect and therefore might be the focus of a sabotage or terrorism activity. But there's nothing about what we're doing under Option 2 that would change that activity or dilute the information that's being presented in support of the security program.

To be frank with you, I think what we could come up with as an answer on this one, because it's not considered under this, Tom, did you have a --

MR. HOOK: Yes. I just wanted to make one point. That in the target sets for plants there are nonsafety related components in the target set. So it's not a presumption that something's credited for sabotage and terrorism is a safety related component. So that dispels the concern about moving something from RISC-1 to RISC-3 as having an impact in terms of the expectation of its quality requirements for mitigating terrorism and sabotage events.

MR. BURCHILL: Right.

NEAL R. GROSS

1 CHAIRMAN APOSTOLAKIS: Well, maybe this is 2 a good time to take a short break. 3 So we will recess until 10:15. 4 (Whereupon, at 10:10 a.m. a recess until 5 10:2 a.m.) 6 CHAIRMAN APOSTOLAKIS: So we are now on 7 question 6. So whose going to respond to that? 8 We discussed as we went **HEYMER:** 9 through sort of an overview of NEI 00-04 the PRA 10 quality and we had some discussion there. 11 thought that it would be worthwhile as we're in this 12 question and we've covered some of these issues, that 13 we would ask the pilot plants to speak to how they've 14 dealt with this issue as they've gone through Option 15 2. And so, Tom? 16 MR. BURCHILL: Yes. Actually I think it's 17 a little bit broader. 18 This is Bill Burchill with Exelon. 19 A little broader than just pilot plants. 20 I'm going to really try to speak to this from a 21 broader utility perspective. 22 There's a lot of focus in the PRA quality 23 area that's been placed on the peer review process and 24 the certification of PRAs as the measure of quality or 25 perhaps the ASME standard or other standards that

under development as the majors to be applied. And I want to step back from that a little bit and talk about really how do you get quality in a PRA. Those two tools are certainly measures that are applied when a PRA exists and somebody wants to come in and evaluate it or the utility itself wants to evaluate it. But there's a much bigger picture on what produces PRA quality, and I'm going to try to speak to that and then Tom Hook is going to provide some other specific examples.

I think in today's environment where we are using PRA extensively for risk-informed application and daily, in fact, hourly perhaps in A4 support under the maintenance rule, that the first thing that one has to have to ensure quality is a well structured PRA program.

And what I mean by that is PRA, we've joked about this over the past few years. PRA has come out of the closet. You know, it's now a -- you know, we don't even call it PRA in at least Exelon anymore. We call it risk management. And it's a function that is right along side design engineering, system engineering, the maintenance function, operations function. It's a recognized function and it's governed by processes and procedures just as

NEAL R. GROSS

other functions in the operation of the plant.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

So a well structured program, which I think one will find in all utilities today, is the first starting point.

That process has to have internal process controls. Certainly as recently as even four or five years ago if you went to a utility and looked at the degree to which the way one goes about doing the preparation of a PRA or its documentation, you might find a less satisfactory condition than you would like. Today I would tell you that when you go out to utilities they either already have in place or are rapidly developing very highly structured procedures and quidelines for they everything do, and particularly those areas that already are continuing use like the maintenance rule A4, those are all highly structured; the interface between the PRA function or the risk management function and the operations group and the work planning and work control or work management group is very well defined.

I think the third hallmark is you have to have a highly component PRA team. You cannot do what we're doing today with PRAs with amateurs. The people that are on the PRA team on the risk management group, they have to demonstrate their capability. And I know

that in Exelon and I believe this is becoming the practice, these people are certified just like other engineering disciplines. We have, in fact, seven different certification guides that each one of our risk management engineers must demonstrate their competence. You know, it's like a qual. process. So I think that leads to PRA quality.

The fourth is what I will call the documentation area. The improvements that have been made, certainly post IDP and very strongly driven by the certification process have forced utilities to really seriously think about the degree and extent and quality and traceability and retrievability of the documentation that goes along with their PRA. And I'm not talking just about what's written in a paper, but you know what decisions were made in developing of entries, fault trees, you know, approaches to human reliability analysis, whatever. Those are documented, those are retrievable.

You mentioned earlier, Dr. Apostolakis, that several of the PRA codes can provide the uncertainty analysis. Well, likewise they can provide documentation. There's automated tools for ensuring that those thought processes that are used to develop a PRA are captured.

We all I believe have a process of requiring ourselves to do periodic PRA updates. We have varying cycles on that, but the ASME standard, as you know, also compels that a periodic determination of the adequacy of the PRA to meet the representation of the as-built/as-operated plant is required.

And we also do unscheduled updates. If we have any modification in our plants, every modification in fact is evaluated for risk impact from two perspectives. is whether One not the modification itself changes the risk of the plant and if so, that we recognize what the impact is. But also whether as a result of that modification the PRA itself must be changed so that for its other applications, you know, for example again A4, that that PRA adequately represents the plant.

So, we will have unscheduled updates to represent some specific either design change or procedure change. We will also then periodically go back and check the whole PRA and literally go in and check everyone of the 11 elements.

Now, as far as the risk management engineer himself and how does he assure that the tool that he's using or that he's improving is adequate, technique one is something I'11 just call

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

reasonableness checks. I mean, there's a wild wealth of information today about PRAs. I mean, we're not functioning with one or two studies. You know, every utility has, and we're talking specifically full power internal events but we could be talking the other risk sources where those exist at different utilities as far as their quantification tools.

There's a lot of peer checking that can take place by just the individual risk management engineer. There's a lot of documentation of how other plants of similar design, similar vintage, similar equipment, how they have been assessed with respect to their risk profile. And so the first point in a reasonableness check would be, obviously, to go out and see how does the result you've generated compare with what others have found.

We do a series of acceptance reviews that can range from a second risk management engineer sometimes who, depending upon the nature of the development, is totally independent from the development process or to even bring in an outside party and review our PRAs. This is even before we would go to a certification team.

I don't want to represent to you that we do that in each and every change, but depending upon

NEAL R. GROSS

the magnitude of the change if we had a significant update to a PRA, it's more than likely we would bring in another party to look at our work and see whether or not that was adequate.

Another point is, and this is certainly true at all utilities today, we all have significant management oversight of the application of our risk management tools. Again, PRA has come out of the closet. We are no longer a little study group off to the side where, you know, it's a study, it's nice, we look at it and it produces pretty pictures with pie charts and we put it on the shelf and don't pay too much attention to it anymore. Ιt is now used everyday. It influences work planning. It influences the operation of the plant and management pays attention to those things. Management wants to know that those things that are influencing that plant's operation are sufficient.

Now we'll come finally at the end of my list to the PRA peer review and certification process, and the use of standards.

I think what you can see that I'm trying to develop is that those things when they're applied will only be successful in showing that the PRA is adequate if all these other attributes have been met.

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

1 In Exelon we have ten sites, literally 17 2 PRAs for 17 operating unit, and we've had them all 3 through certification. I can tell you it's a fairly grueling experience. And I can't imagine that those 4 5 would have been successful in not only measuring the 6 PRA, but in developing a favorable impression of their 7 capabilities if we hadn't done all of these preceding 8 activities that I've described. 9 What shall I say? I'm not trying to just 10 be rah-rah about it. This is a very serious business. 11 It's an integral part of the plant's operation today, 12 and it's taken quite seriously and, therefore, it is 13 now integrated into the main fabric of the overall 14 engineering operation. 15 I can tell you personally that my MBO -we don't call it that -- for the past 2 years, 16 actually 4, but particularly for the past 2 has had a 17 18 very strong point in it about bringing the risk 19 management activity into the mainstream 20 engineering department and the overall 21 organizations activities. 22 I'm going to turn it over then to Tom Hook 23 who can give some more specific examples. 24 MR. HOOK: I just wanted to talk about 25 Surrey and North Anna and Dominion's PRA quality

attributes that we think makes the PRA suitable for use in an Option 2 type application.

Now. first of all. plant that а participates in license changes through Reg. Guide 1.174 already has to address the quality attributes in the Req. Guide in terms of the design meeting the -of the models being consistent with the plant design, the quality of the PRA staff, the peer review having been performed. So most plants having submitted Req. Guide 1.174 license changes already meet the quality attributes of that reg. guide. And Dominion has a living PRA program to ensure that it can continue to support Reg. Guide 1.174 type submittals at anytime.

The second attribute that Bill touched on that I think is very important for ensuring quality for my experience having worked in expert panels for the maintenance rule of two different utilities, is that there is a questioning attitude during the categorization process that occurs for the maintenance role. And many of the modeling problems that occur or inconsistencies with the plant design are uncovered during the maintenance rule review process, and that was very helpful at North Anna and Surrey in upgrading the quality of the PRA model.

Surrey and North Anna also were involved

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

in the risk-informed ISI and performed full scope 1 2 class 1, 2, 3 ISI expert panel process and looked at 3 a large scope of components independently in another 4 expert panel and obtained a significant amount of comments and feedback, and PRA quality improvements as 5 6 a result of the exchange. 7 Then through the NEI certification process PRA review there were additional comments that come 8 9 back from outside observers through --10 CHAIRMAN APOSTOLAKIS: These comments, 11 Tom, I mean, you're using a failure rate, for example, is that a distribution that you are using typically or 12 13 a point value and is anyone questioning whether that 14 value's reasonable? I mean, how does that work? 15 MR. HOOK: Those types of questions 16 typically do not come up unless there's -- it's point 17 estimates. in general. And only -- the expert panel 18 focuses more on the dependencies in the model and the 19 accident sequence analysis than on failure rates 20 unless the failure rates look totally inconsistent 21 with expectations. 22 CHAIRMAN APOSTOLAKIS: But, I mean, don't even know how these expectations are formulated when you talk about 10 to the minus 3, 4, 5. it's not something that we have some intuition about

23

24

that the failure rate should be this. I mean, we are looking at all these studies for a number years and then we say, well, gee, I expect it to be in the 10 to the minus 4 region.

mean, we keep talking about failure rates and point estimates and so on. And I don't know where they come from and whether anybody questions them, or you know, why not use a distribution and is there a population of distributions out there that are reasonabler. And it's not just the failure rates. I mean, human error rates. And then the dependencies between human actions and so on. There are so many places where a factor of 2 here, a factor of 1 or a half there, you know, pretty soon we're talking about serious factors. And I don't know that anyone really looks at these things in a critical way.

Now, for some reason I'm under the impression the independent panel will not do this, even though they have a PRA expert on them. And it bothers me. I don't understand. I mean, and then we propagate those point estimates, we don't know what we're getting out of it. I'm pretty sure these things work fairly well, most of the time. What I'm complaining about is that I haven't seen a systematic

analysis or study that shows that they do actually work.

I don't know doubt that what you're proposing most of the time will give reasonable results. But in terms of building and maintaining public confidence, it seems to me that somebody ought to look at this thing and say yes it doesn't matter; that if you use the standard point estimates that people use, you are going to get reasonable Fussell-Veselys and RAWs and, you know, that in combination with the expert panel questions will lead to reasonable results. But I haven't seen that, and I don't know.

I mean, somebody says, yes, I'm going to use 5 10 to the minus 3 and another guy says no, I'll use 10 to the minus 4. What's the basis for that and what do I get out if a complex system like a PRA? You know, we know from the theory that inputs that are points estimates, so you don't know what you get out. If they are mean values, that is you know.

And then we declare them as being mean values without any basis, in my view. Why should the number be a mean value just because we say so? And that bothers me.

Again, I don't think it's something that

NEAL R. GROSS

will really turn everything you are doing upside down.

No. I know it won't. What really drives these things is model uncertainty. But why don't we take care of the stuff we know how to take care of so we don't have this feeling that what we're doing is okay? I mean the reactor safety study 30 years ago did do that.

MR. BURCHILL: I was just going to clarify that I agree with you. I don't think that the IDP is going to delve into this. It's not their mission nor, frankly, would they have the time or expertise other than their particular member from the risk management group. Certification teams do.

quite challenging on the data sources that you use; whether or not they are recognized in peer review data sources, are they up to date, do they account for -- and I'm talking about generic sources now -- and then I believe that it's fair to say that they also challenge if you do not have plant specific data considered, if you've not upstated your data source, why have you not. And they will challenge has there been any known trend. The first thing they'll challenge is you do you know the trend in behavior of your components with respect to their reliability. and then they'll challenge whether or not if there has

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

been anything that would indicate deviation from your prior, so to speak. Have you taken it into account?

CHAIRMAN APOSTOLAKIS: But, Bill, that my concern. Do people do this on a routine basis? I mean, when we pick up a PRA and somebody has used it in Option 2, they have done a categorization and they use point values, what assurance do we have that these point values are plant specific and that they are indeed mean values? Do we have an assurance there? I mean, are they under any obligation to show us how they did that?

I remember some of the IDP, you know, some were very good. They used the standard methods to update and so on, as you know. But others, I remember one said oh for events for which we felt we didn't have significant plant specific information, we used generic sources only. For other the others we just used the plant specific data. And you scratch your head and say, first of all, how did they decide that they didn't have significant plant specific information. And then why this arbitrariness? Ι mean, we know how to handle these things.

And I think if we did that in this document, then a lot of the concerns about the sensitivity analysis would go away. And, in fact,

NEAL R. GROSS

1	what you told us earlier, Doug, is the way to do it.
2	Do a sensitivity analysis on major model
3	uncertainties, not playing with a point decimal
4	lambda. Who cares?
5	You're spending money on the pilot
6	studies. I mean, would it be really an extraordinary
7	expense to add a short study of several months showing
8	to us that these things are handled well or they're
9	relevant, or it doesn't matter? I don't understand
10	that.
11	MR. TRUE: To me it's somewhat of a semi-
12	infinite problem.
13	CHAIRMAN APOSTOLAKIS: In it not infinite,
14	no.
15	MR. TRUE: Because the situation that
16	exists in most plant specific PRAs is that a large of
17	portion of data is taken from generic sources and the
18	mean value from that generic source is used as a point
19	estimate in the calculation.
20	And then for dominate by some definition
21	or important by some definition, important components
22	plant specific data is collected and then used to
23	update that generic information to reflect more plant
24	specific evidence.
25	The peer review process will look at all

1 pieces of that and say is the generic source you 2 started with a reasonable generic source --3 CHAIRMAN APOSTOLAKIS: Well, if they did 4 what you just described. I'm not sure they always do 5 Do they really take the mean value of the generic distribution as a point value? 6 7 I think the peer review team MR. TRUE: would have a hard time if you didn't do that. I think 8 9 you would get criticized for that in your peer review. 10 There may be --11 CHAIRMAN APOSTOLAKIS: And the issue may 12 not be so much the hardware, how about the human error 13 rate? 14 Well, the human errors are, MR. TRUE: 15 obviously, one of the most difficult portions of the 16 PRA to even compute and assign a probability to, much 17 less have confidence that we have a true mean value of 18 that parameter. In most cases --19 CHAIRMAN APOSTOLAKIS: Well, let me let 20 you know where I'm coming from. The Fussell-Vesely in 21 RAW are uncertain, aren't they? I mean, if the 22 Lambda - -23 MR. TRUE: Yes. 24 CHAIRMAN APOSTOLAKIS: Is there a simple analysis someplace, some study that shows that the 25

1	categorization is not effected by these uncertainties
2	the way we're doing it now or was it a figure in the
3	old paper by Cheok and Parry and Sherry that showed
4	the some evidence that indeed for a lot of the
5	components it doesn't matter unless the uncertainty is
6	very, very large. But wouldn't the more systematic
7	study show? I mean, there is a paper in the
8	conference in '96 in PSA where a couple guys from
9	Maryland did a similar thing.
10	You know, document that it doesn't matter,
11	that the uncertainty's not something I should worry
12	about rather than saying use point estimates and do
13	it, and then the expert panel really will take care of
14	it.
15	I think it probably doesn't matter,
16	actually. But I would like to see that it doesn't.
17	MR. TRUE: I think one of the problems
18	CHAIRMAN APOSTOLAKIS: Just once.
19	MR. TRUE: I think such a study might have
20	some value and give us some more confidence. But the
21	importance measures are really screening tools to try
22	and bring in the components and
23	CHAIRMAN APOSTOLAKIS: Yes, but screening
24	tools are supposed to be conservative. How do you
25	know they are?

1	MR. TRUE: Well, how do we know that 2 and
2	.005 are the right thresholds?
3	CHAIRMAN APOSTOLAKIS: Well, that was
4	another question that would be raised. Yes, don't
5	assume we know.
6	DR. ROSEN: You can't go much lower than
7	those numbers. I mean in terms of setting thresholds.
8	Those are almost where we are before we started this
9	exercise. I've characterized them as extraordinarily
10	timid. You know, how low can you go. You could go to
11	a one.
12	CHAIRMAN APOSTOLAKIS: 1.8.
13	DR. ROSEN: Yes, you could go to 1.8, you
14	could go to 1.0. But we're talking about individual
15	components that have a RAW of 2, this is
16	CHAIRMAN APOSTOLAKIS: I just don't
17	understand this reluctance to actually demonstrate
18	once and for all that what we're doing makes sense
19	instead of having to take it as an article of faith.
20	That's all I'm saying. I need one cross mark. We're
21	not talking about a million dollar study here. It's
22	some experience guys like you can do it very quickly.
23	MR. TRUE: I think that the
24	CHAIRMAN APOSTOLAKIS: How about that?
25	MR. TRUE: I'd be happy to do a million

dollar study. No.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

CHAIRMAN APOSTOLAKIS: And then we play with the sensitivities and, say, take all the failure rates, put them in the 95th percentile. Hey, come on, Come on. This is not a sensitivity study worth its name. A sensitivity study should look at model uncertainties and say, you now, we have some uncertainty there, we really don't know how to handle But, look, if we do this and this and that and play some sensitivity games, we get this warm feeling that, yes, we are not off.

MR. TRUE: We'll get to the sensitivity studies in another question. Yeah. In some year we will.

I think we may learn something from such a study, but as Steve said, these thresholds are relatively tight already to begin with. And they're going to be screening in a very large fraction of the components that are modeled in the PRA as safety-significant. It's not like we've set bounds very far out and we're worried about already missing things.

And then on top of that when we do the sensitivity studies we'll talk about in a little while, we're even bringing more components over those tight thresholds into the screening process. And I

1	think if anything, we are probably being conservative
2	in bringing in all the different
3	CHAIRMAN APOSTOLAKIS: But you say we're
4	probably being conservative. I don't know that.
5	MR. TRUE: Well, I don't know how to prove
6	that we are
7	CHAIRMAN APOSTOLAKIS: Well, you could.
8	MR. TRUE: or that we are being
9	realistic or conservative in this.
10	DR. KRESS: It has to be done on a plant
11	specific basis.
12	MR. TRUE: Because it's really specifics
13	of the plants and more so to the modeling assumptions
14	and things that go into the model than the parameter
15	estimates.
16	CHAIRMAN APOSTOLAKIS: That's why one does
17	studies like that, to show that the process is
18	conservative or at least reasonable results. The fact
19	that it may be difficult to prove it 100 percent of
20	the time doesn't mean that you shouldn't try.
21	MR. TRUE: I guess I don't know if I did
22	a study like that what the acceptance criteria would
23	be for the result. Is it that nothing changes? Is it
24	that
25	CHAIRMAN APOSTOLAKIS: I don't know, for

1	<pre>example, if I actually propagate the uncertainties to</pre>
2	Fussell-Vesely how much probability will be above the
3	.005 or not. I don't know that. I suspect most of
4	the probability will be above for the components you
5	are declaring as RISC-1. I don't know how much. You
6	know, I haven't done it myself. I don't know. And
7	RAW, the same thing. I mean these things are
8	uncertain.
9	DR. KRESS: But the problem is a RAW of 2
10	means something for one plant in terms of its effect
11	on CDF and something entirely different for another
12	plant.
L3	CHAIRMAN APOSTOLAKIS: That's another
L4	problem, yes.
15	DR. KRESS: And
L6	MR. TRUE: Relative importance measure
L7	are
.8	CHAIRMAN APOSTOLAKIS: Yes, they're
.9	relative.
0 0	MR. TRUE: They're around the base value.
21	And so a plant with a low CDF and a RAW of 2 has a
22	much smaller absolute impact on risk than a plat with
23	a higher CDF would have.
4	DR. KRESS: Yes, and I find that to be a
:5	problem. You know, that's penalizing the good plants.

WASHINGTON, D.C. 20005-3701

1	MR. TRUE: Well, I think that it reflects
2	a desire to stay within the basic framework you have
3	DR. KRESS: You know, it's just like 1.174
4	in a sense, but that's penalizing the good plants in
5	my mind, and it's treating them unfairly. You know,
6	I think I'm saying that the thresholds ought to be
7	plant specific. They ought to have something to do
8	with their effect on CDF. You ought to incorporate
9	the uncertainties because you need to have some the
10	uncertainties will be different for different plants
11	and you need to have a consistency in the confidence
12	level that you want to meet these thresholds.
L3	And, you know, it's just not coherent to
L4	say we'll use 2, and that's it for an example.
L5	CHAIRMAN APOSTOLAKIS: For example
L6	DR. ROSEN: You're requesting a revision
L7	to 1.174.
18	DR. KRESS: Well, I've been suggesting
.9	that for a long time.
20	CHAIRMAN APOSTOLAKIS: Well, let me if
21	you do a study like the one I mentioned, one of the
22	things that you may want to investigate is defining a
23	new RAW, RAW STAR, which is the ratio of the numerator
24	as we do it now, you know, increasing actually it's
25	a denominator increasing the unavailability to 1

1	and carculating the new CDF, but the reference value
2	now will be perhaps 10 to the minus 4. The goal, now
3	the base CDF. And see what happens. Then you are
4	moving more to a more absolute measure.
5	DR. KRESS: Yes, that would incorporate my
6	problem then. Yes.
7	CHAIRMAN APOSTOLAKIS: See, studies
8	when I say studies, I don't mean just propagate
9	uncertainty. I mean if you start investigating the
10	whole analytical basis of the methodology, and then
11	you could come up with questions like that. Would
12	that be reasonable? I'm not saying it will be, but
13	here is a possibility that would answer this question.
14	DR. KRESS: That would answer my question.
15	CHAIRMAN APOSTOLAKIS: Why use relative
16	values for all the plants when, in fact, again we have
17	a paper from distinguished members of the staff here
18	that say that you should not be using these things, as
19	I recall.
20	MR. PARRY: Can I chip in here, since
21	we've been referred to? This is Gareth Parry again.
22	CHAIRMAN APOSTOLAKIS: Oh, you heard
23	distinguished member and you felt
24	MR. PARRY: No, I heard mention of a
25	paper.
- 1	

1 Remember that these -- and what's Doug or Bill said -- that these criteria for RAW for Fussell-2 Vesely are in fact only screens. 3 4 DR. KRESS: Yes. 5 The ultimate test, and you'll MR. PARRY: see it in NEI 00-04, is the absolute value of delta 6 7 CDF and delta LERF. 8 Now, yes, you could change the RAW and 9 Fussell-Vesely thresholds on a plant specific basis, 10 and actually if you read Appendix A of Reg. Guide 11 1.174 you'll see we suggest it. But in a way, does it 12 matter that much if in the end you're going to do this 13 final test on delta CDF and delta LERF? It's a step to the final categorization --14 15 DR. KRESS: That just confirms that the 16 choices you made didn't do it. 17 MR. PARRY: Yes. 18 DR. KRESS: But you might have been able 19 to put a lot more things in different categories. 20 MR. PARRY: Oh, you might have been able 21 to put a lot more, yes. 22 CHAIRMAN APOSTOLAKIS: But the thing that 23 bothers me, Gareth, is that we are saying or we're 24 asking ourselves does it matter that much too many 25 Where do you draw the line? When does it

1	begin to matter?
2	It doesn't matter that we don't have a
3	structure IDP process whereas SDP did. It doesn't
4	matter that perhaps the factor by which we increase
5	the failure rates is 2 to 5 rather than 10, as SDP
6	did. It doesn't matter that we don't do an
7	uncertainty analysis. Nothing seems to matter.
8	MR. PARRY: Actually
9	CHAIRMAN APOSTOLAKIS: I don't know when
10	we'll have to worry about the things mattering
11	anymore.
12	MR. PARRY: Right. I don't think that's
13	true. And I think when we get to
14	CHAIRMAN APOSTOLAKIS: Oh, come on.
15	MR. PARRY: And when we get to discussing
16	these issues later on, I think you'll see that they do
17	matter.
18	CHAIRMAN APOSTOLAKIS: Every single one
19	that I mentioned is true, isn't it? They're proposing
20	2 to 5 now, not 10.
21	MR. HEYMER: I really
22	MR. PARRY: Well, they're proposing that.
23	MR. HEYMER: struggle with the word we
24	do not have a structured IDP process.
25	CHAIRMAN APOSTOLAKIS: Well, I don't see

1	it in the document.
2	MR. HEYMER: And we recognize that, among
3	other things that the pilot plants identified, is we
4	must give it more structure.
5	CHAIRMAN APOSTOLAKIS: Oh, okay. Well, if
6	you're talking about something that has been improved
7	and changed, that's a different story.
8	DR. ROSEN: Well, that comes to one of the
9	base questions. You guys are going to have to come
10	back, is that right?
11	MR. HEYMER: Yes. This is not the final
12	product. We've got to
13	DR. ROSEN: You agree it's not your final
14	product.
15	MR. HEYMER: Right.
16	DR. ROSEN: It's a work in progress.
17	MR. HEYMER: It's a work in progress. It
18	was put out there for the pilots to take and test and
19	we recognize that in some areas, like in the IDP
20	guidance, it needs to be strengthened. And we're
21	going to do that. We've got some comments from the
22	staff to incorporate. We've got error insights from
23	the IDP and the process. And then we've got the
24	staff's comments to incorporate. And then we'll be
25	forwarding that back for sort of Rev. C.

1	DR. ROSEN: Well, maybe you ought to also
2	look at what the staff is planning to do with the
3	regulations in 50.69. Because there's no Appendix T
4	anymore and yet B refers to an Appendix T.
5	MR. HEYMER: Right. Well, Rev. B was
6	written in May last year when Appendix T was
7	breathing. And now it's now. So, I mean, you know
8	there's certain things that we need to adjust.
9	We are at an interim stage.
10	CHAIRMAN APOSTOLAKIS: Right. But I get
11	the impression that both the staff and you feel that
12	a lot of things don't matter, but I feel they do. Or
13	at least I'm asking no, I'll take that back.
14	What I'm saying is just demonstrate that
15	they don't matter. Please take the time to
16	demonstrate they don't matter.
17	MR. HEYMER: Or have a basis for the w to
18	5 as opposed to
19	CHAIRMAN APOSTOLAKIS: Yes.
20	DR. ROSEN: And to be fair, George, I
21	think we have to give the staff it's chance to tell us
22	what they think about this document. We haven't done
23	that yet.
24	CHAIRMAN APOSTOLAKIS: No, they are
25	supposed to jump in whenever they disagree with the

1	industry is saying.
2	DR. ROSEN: Oh, they are? Okay.
3	CHAIRMAN APOSTOLAKIS: That's what they
4	told me, right?
5	MR. REED: We haven't got to the specific
6	item yet.
7	CHAIRMAN APOSTOLAKIS: Yes. They're not
8	going to have a separate presentation. Just jumping
9	in. Silence means concurrence.
10	DR. ROSEN: No. I think what Tim Reed
11	said was, Tim said they hadn't gotten to the specific
12	issues yet.
13	MR. REED: Well, some of the specific
14	issues are concerned with the IDP, we're not to that
15	yet. We're not to the particular question yet, and
16	then we'll jump in.
17	MR. MOIENI: George, this is one of the
18	reasons
19	CHAIRMAN APOSTOLAKIS: You have to speak
20	to the microphone.
21	MR. MOIENI: Oh, sorry.
22	CHAIRMAN APOSTOLAKIS: That way you have
23	volume and identify yourself.
24	MR. MOIENI: I don't know how to change
25	the volume. I don't know yet.

1 CHAIRMAN APOSTOLAKIS: You don't know who 2 you are? 3 MR. MOIENI: This is Parvis Moieni. 4 CHAIRMAN APOSTOLAKIS: 5 MR. MOIENI: I think I have a response to 6 at least the criteria, where we draw the line. 7 Because we did the risk-informed IST a couple of years 8 ago, the criteria for Fussell-Vesely was .005 or 9 And when we did the exercise and identified the low safety significance, pumps and valves, to 10 While testing 11 basically increase the interval. 12 interval we realized with that line we could not meet 13 the criteria in 1.174 on the delta CDF and LERF. 14 one of the options was not to do anything or basically 15 to stay with whatever we did in terms of having low safety significance, or go back and revisit the 16 17 screening. 18 So to make a long story short, we reduced 19 it to .001 in order to meet the criteria for the delta 20 CDF and later LERF. So even though the code case in 21 ASME said .005, we used .001. 22 So this is a response to your question 23 that we really, even back then, we didn't know that 24 this came from the Bible and said this, this is .005. 25 So we had to change it and redo the categorization,

redo the Fussell-Vesely and RAWs and some of the low 1 2 safety significance went back to --3 CHAIRMAN APOSTOLAKIS: Well, that's the 4 kind of thing that I would like to see, that's a 5 sensitivity analysis that I would like to see in the 6 study that I'm proposing. You know, how sensitive are 7 these things? 8 And now when you tell me you reduce it by 9 a factor of 5, right? 10 MR. MOIENI: Yes. 11 CHAIRMAN APOSTOLAKIS: From .4. That 12 brings up again the issue of uncertainty in the 13 importance measures. Does that go completely outside 14 the distribution of the Fussell-Vesely. I don't know. 15 I've never seen any study like that. 16 I'm sure you guys are doing things when 17 things don't work out the way they're written in the 18 documents. But why would it be, you know, 19 difficult to do a study that looks at all these things 20 as says, look, there are certain conclusions that we can draw and certain approximations that are valid 21 most of the time, and let's go ahead and use them. 22 23 I mean, when the reactor has proposed approximations like the prompt jump on approximation 24 25 and all that stuff, they actually documented that they

1	were approximations. Why can't we do the same thing
2	in PRA? And I'm sure in other sciences like material
3	sciences they do similar things.
4	DR. KRESS: No, that's exact.
5	CHAIRMAN APOSTOLAKIS: Anyway, I think you
6	got the thrust of the comment here.
7	DR. ROSEN: Could I ask a question on a
8	slightly different subject here, and that is that
9	there is something in 00-04 that leads me to the
10	conclusion that if the independent panel decided that
11	they wanted something to be in not safety-significant,
12	that they couldn't just do it, put it in not safety-
13	significant no matter what the PRA said?
14	It seems the independent panel can
15	override the PRA results. There's no specific
16	expressed prohibition against that that I see.
17	MR. TRUE: It can only move it up. It
18	can't the IDP cannot move down.
19	DR. ROSEN: Can you point to where that
20	says that in here?
21	DR. SHACK: It doesn't say that.
22	DR. ROSEN: No.
23	DR. SHACK: It says it can move it down.
24	CHAIRMAN APOSTOLAKIS: Yeah, in fact, that
25	was one of my questions. I saw it somewhere. I don't

WASHINGTON, D.C. 20005-3701

1	remember where now. But I remember SDP said that
2	DR. SHACK: Right. SDP
3	CHAIRMAN APOSTOLAKIS: the panel can
4	never bring it down. But in your documents I think
5	they can do it.
6	MR. TRUE: I think they can only do that
7	if there
8	CHAIRMAN APOSTOLAKIS: Now, where did I
9	see that.
10	MR. TRUE: is a set of circumstances.
11	DR. SHACK: Yes, they have to justify it,
12	but they can do it.
13	MR. TRUE: This flow chart is intended to
14	reflect
15	CHAIRMAN APOSTOLAKIS: Ah. On page 6 of
16	the letter to Mr. Pietrangelo by the staff, question
17	7 says there is a need to provide guidance about what
18	authority the IDP has for making a determination that
19	an SSC is low safety-significant when the PRA
20	indicates the SSC is safety-significant. So I'm sure
21	the staff had some basis for writing this.
22	MR. TRUE: What this flow chart shows
23	DR. ROSEN: Perhaps could be focused a
24	little bit.
25	DR. SHACK: It's on page 29 it's the "if"

1	statement.
2	CHAIRMAN APOSTOLAKIS: Okay.
3	DR. SHACK: If the IDP determines that
4	this in many cases special treatment will have low or
5	no impact on such SSCCs, which meet the criteria, if
6	the IDP terms this is the case, it may decide to
7	classify the SSC as low safety-significant.
8	MR. TRUE: Sorry. What page is that?
9	DR. SHACK: It's page 29. It's the second
10	paragraph from the bottom.
11	MR. TRUE: 29 and 30 are not
12	DR. SHACK: I think what's it's saying is
13	that if it's meeting only because you've done such a
14	conservative analysis that you've thrown it way up,
15	they can then sort of argue it back down.
16	MR. TRUE: Well, this particular paragraph
17	has to do with SSCs that strictly got in on the basis
18	of high Fussell-Vesely and high failure probabilities.
19	DR. SHACK: Right.
20	MR. TRUE: Because what happens is, the
21	thing we were concerned about with that particular
22	paragraph was that often times you will have a base
23	CDF and there'll be a particular type of scenario that
24	is relatively important. And the PRA analyst will add
25	a recovery action of some kind which may invoke the

1 us

б

use of a system, import kind of a screening value on that HEP and thereby bringing in the SSC as important.

An example might be refilling the RWST for a steam generator tube rupture or lining fire water for injection of certain cases.

It's given a conservative high HEP or high failure probability, but it happens to address more than the half of percent of the total CDF. And it brings the sequence down in the process by -- that recovery, it brings the sequence down in the mix still above a half percent of the contribution. But it's really kind of a screening approach to how important that thing is. And we didn't think it was fair to make those things get the same level of significance if they were already treated conservatively with their failure probability as something else that's being modeled in a way and structured in the model.

Really only focused on that particular set of high failure probability and recovery action type things. It was something that was raised actually as part of the BWR pilot not because it applied directly to the systems they looked at, but because they identified this could be a problem in future applications.

So, that statement only applies to that

NEAL R. GROSS

1	narrow set of circumstances.
2	Now, if we go to the flow chart that we
3	used for the IDP, basically what we asked the IDP to
4	do is to make sure that we've got the right functions
5	both to and core damage included. This kind of
6	talks to the way Tom was referring to in the IDP,
7	understanding how we've reflected the SSC. Then we go
8	over all the information on the basis for
9	categorization; the importance measures, the defense-
10	in-depth assessment, different hazards, how we
11	addressed all of those. And then their decision is is
12	the SSC reflected appropriately? That's really the
13	decision they get to make.
14	And if they think it's
15	DR. KRESS: Well, does that mean to say is
16	the SSE categorized appropriately?
17	MR. TRUE: No. Is the SSC is reflected
18	appropriately in the inputs to the categorization
19	process? Have we got
20	DR. KRESS: Oh, you got all the things
21	that bear on that SSC?
22	MR. TRUE: Yes. Right.
23	DR. KRESS: Okay.
24	MR. TRUE: And if the view it reflected
25	appropriately, then basically if it's identified as

risk significant, it stays risk significant and all they're doing is confirming that we got the right attributes and that they understand the attributes.

Τf it's found to be low safety significant, then they're asked to look at the risk information in more detail. They asked to look at -and the basis behind why the thing was found to be low safety-significant. They'll look at defense-in-depth and safety margins. And then they're asked to make a judgment about should it really stay RISC-3, but they're given the flexibility to say no, I don't think it should be RISC-3, it should go back up to RISC-1.

DR. SHACK: My problem with your viewgraph is it doesn't seem to me to reflect the South Texas experiences where the IDP actually classified most of the components, you know.

This sort of focuses on what they're doing when they get the PRA input and the PRA has sort of done some preliminary classification. There seems to be very little guidance for how they're to deal with the components that aren't in the PRA in this current version compared to the much more structured process I thought we got from STP, where they immediately realized that they were going to be doing a lot of the categorization for things that weren't explicitly in

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

1	the PRA. And this flow chart really, you know, you're
2	thinking about things that are in the PRA when you're
3	looking at this chart, I think.
4	MR. BURCHILL: I think the upper part of
5	that chart is not at all restricted to PRA
6	information. That is, in fact, all information that
7	is gathered for the whole population of SSCs that are
8	being considered.
9	MR. TRUE: In fact, we think that the five
10	questions that STP asked are embodied in the flow
11	charts and things that we use in the categorization
12	process.
13	DR. SHACK: Then why not put them
14	explicitly in is sort of my question?
15	MR. TRUE: Well, I think they are. We're
16	going to get we'll get to that.
17	CHAIRMAN APOSTOLAKIS: Now let me see
18	where we are here, because
19	DR. ROSEN: Well, let him answer the
20	question; why not put it in explicitly?
21	MR. TRUE: I think it is. These are the
22	five questions. And the first question has to do with
23	is it an initiating event. In the flow chart for
24	consideration of events related to internal events, we
25	have a question that says can the failure of this

1	component cause an initiating event. Okay. What we
2	call a
3	DR. ROSEN: Where?
4	MR. TRUE: a complicated initiating
5	event.
6	CHAIRMAN APOSTOLAKIS: I didn't see it in
7	there.
8	MR. BURCHILL: I think it's 244. 244
9	page 27 on the right side of that flow chart.
10	Actually, it's at the top of the flow chart, the
11	diamond to the left and it's on the right side of the
12	flow chart relative to the complicated initiating
13	events.
14	MR. TRUE: Now, we did qualify it a little
15	bit more than South Texas did and not say all
16	initiating events. But we asked if it wa a
17	complicated initiating events and those which had an
18	importance greater .005.
L9	DR. ROSEN: How did they know that up
20	front when they're at that stage?
21	MR. TRUE: The categorizers that are
22	providing information to the IDP will know that.
3	DR. ROSEN: Know that? The categorizers
24	will know that at that stage?
25	DR. SHACK: But see, that again means

we're dealing with components that are in the PRA. 1 2 CHAIRMAN APOSTOLAKIS: The PRA, yes. 3 MR. TRUE: Well, if it's not in the PRA --4 well, it's either explicitly or implicitly in the PRA. 5 Implicitly includes the fact that the component's 6 failure could have effect on something modeled in the 7 PRA. 8 I mean, balance plant piece of equipment that could cause a loss of turbine trip, we only have 9 10 an event that's a turbine trip event. That doesn't 11 have all the possible components. But those 12 components are implicitly in the PRA because they're 13 part of the turbine trip initiating event. a component has a function that's 14 15 totally independent of -- could create a challenge to the plant or mitigating it, then it's not going to be 16 17 in the PRA and asking that question will it cause an 18 initiating event because it has nothing to do with it. 19 DR. SHACK: Well, I just have the feeling 20 that phrasing the question this way versus the South 21 Texas way gives a very different focus on what the 22 panel's looking at. 23 CHAIRMAN APOSTOLAKIS: Yes. But you said 24 I thought earlier, Adrian, that Rev. C will provide 25 some more structure, is that true?

1	MR. HEYMER: Well, Rev. C will pick up
2	some of the comments and the comment that Dr. Shack
3	mentioned about well if it's not modeled in the PRA,
4	is there guidance. And one of the feedback, we
5	certainly I think we had and correct me if I'm
6	wrong, Jason, from the Wolf Creek and I think from the
7	Quad Cities was specifically in that area that we need
8	to add something a little bit more explicit in the
9	guideline, what to do with components that aren't
10	modeled in the PRA as regards to guidance for
11	CHAIRMAN APOSTOLAKIS: So you wouldn't do
12	something like
13	MR. TRUE: There will be some more.
14	Particularly if they have this notion of implicit
15	DR. ROSEN: And you're telling me that
16	there's protection against the IDP overriding the PRA
17	results and built into the structure. But I would be
18	more comfortable if in the wording of this thing it
19	made that absolutely clear and even referred to the
20	diagrams to say how that result is obtained by
21	correctly flowing through the diagram in the process.
22	MR. TRUE: Okay. I think that's a fair
23	comment.
24	MR. BURCHILL: I don't think Tom finished.
25	MR. HOOK: I just had a couple more points

	123
1	on PRA quality.
2	CHAIRMAN APOSTOLAKIS: Let me say that 1
3	think I'm going to lose at least one member at 12:00.
4	We have really addressed several of these questions in
5	the last 15 minutes. Maybe we can address the
6	questions that we have touched yet, like the fire. I
7	mean, we touched it earlier, but there were specific
8	questions how conservative it is and so on. And
9	anything else where you gentlemen disagree with what
10	the thrust of the question was? Because otherwise I
11	don't see how we can wrap this up in a reasonable
12	amount of time.
13	And the other thing is since you are
14	revising this, I wonder does the staff want us to
15	write a letter this time? Would you like to see a
16	letter from us? So we have to decide that ourselves
17	without input from an expert panel.
18	MR. REED: We're going to have to give
19	that some thought.
20	CHAIRMAN APOSTOLAKIS: Sorry?
21	MR. REED: We're going to have to give
22	that some thought.
23	CHAIRMAN APOSTOLAKIS: Give it some

So, if it's okay with you, I'd like to

24

25

thought, yes.

1 destroy your presentation and jump to things that --2 I mean -- you can handle it. 3 MR. REED: Okav. 4 CHAIRMAN APOSTOLAKIS: Okay. So now, 5 Doug? 6 MR. TRUE: Yes. 7 CHAIRMAN APOSTOLAKIS: Shall we go to --8 think we disagree on the sensitivity 9 analysis and uncertain. I mean, all I'm saying is I'd 10 like to see a study that confirms that what you're 11 proposing is indeed reasonable, you know, instead of 12 doing these sensitivities and arquing that fifth and 13 95th percentile -- I mean, gee wiz. 14 TRUE: Maybe I should put this a 15 little bit more directly. In my mind the purpose of 16 the sensitivity studies and the raising and lowering 17 of values across the board is a way to exercise the 18 model to see if there are opportunities because of 19 changes in evidence or information that SSCs are going 20 to break one of those thresholds. 21 CHAIRMAN APOSTOLAKIS: But it seems to me 22 that what you said earlier this morning is really 23 where the proper role of sensitivity studies is. there is a model uncertainty, I would be happy to see 24

those things. But see them on failure rates, I mean

when we can propagate that uncertainly in a travail 1 2 manner, I mean I don't know that that makes any sense. 3 MR. TRUE: Right. Maybe we should --4 MR. HEYMER: And Bob -- Bob Lutz from 5 Westinghouse. In the AP600 didn't we look uncertainty and sensitivity and if we go to what 6 7 follows question nine? 8 MR. LUTZ: This is Bob Lutz from 9 Westinghouse. 10 I had prepared with the help of one of my 11 colleagues back at Westinghouse sort of a summary of 12 what went on on the AP600 new plant application a 13 couple of years ago where we did do a full uncertainty 14 analysis in that submittal as part of the 15 documentation for the design certification. And we also did a number of sensitivity analyses. 16 17 tried to summarize on one slide. 18 We did the uncertainty analysis to try to 19 look at the CDF and LERF and make sure that we did not 20 have a large variation in CDF and LERF between the 21 mean and the 5th and the 95th percentile values. And 22 what we found is obviously specific to the AP600 23 design, but what we found is that between the mean and 24 the 95th and the mean and the 5th percentile values,

that we didn't see more than about a factor of 3

variation in the overall core damage frequency or LERF numbers.

We also did a number of sensitivity analyses, much more than what is being proposed here in the Option 2 framework that's in NEI 00-04. And, again, this is all documented back in the licensing analyses. But we didn't see any SSCs coming from a negligible contribution to LERF or CDF becoming a dominant contributor when we did these sensitivity studies.

In other words, nothing that had a RAW value or an F-V value close to 1.0 changed to a significant RAW or F-V value when we did the sensitivity analyses. Now, that's what's documented and it's -- within what we did, we didn't document it in any of the licensing analyses, but within our how house back when we were going through this.

We also looked at RAWs and F-Vs at the 5th percentile and 95th percentile level. And, again, found the same thing; that nothing that had an RAW value, for example, near 1.0. In the mean case when we went and looked at the 5th or the 95th percentile case, nothing jumped up. So we had some confidence on that application that nothing that was in the grass or down in the background using the mean value would jump

1	up when we did sensitivity or uncertainty analyses.
2	And that's I think probably one of the
3	extensive comparisons that we do have to date of
4	sensitivities and full uncertainty analysis. I
5	brought this along just for what it's worth.
6	And, again, the plant design's a little
7	bit different, but it does show that in this one case
8	that there was no significant differences.
9	CHAIRMAN APOSTOLAKIS: Well, that's good
10	to know. But that was not in the report, and that's
11	part of what I have in mind as there is this paper
12	in the proceedings of the PSA conference '96, which
13	you are probably familiar with already.
14	MR. TRUE: Quad City meeting?
15	CHAIRMAN APOSTOLAKIS: Yes.
16	"Consideration of Probabilistic Uncertainty and Risk
17	Based Importance Ranking." And the distributions here
18	are Fussell-Vesely and RAW, and all that. I mean,
19	something along these lines would be helpful, you
20	know. This was done by graduate students. So maybe
21	you want to know which one it is, or you want a copy
22	now? We can give you a copy.
23	MR. TRUE: A copy would be great.
24	CHAIRMAN APOSTOLAKIS: Okay. We'll make
25	copies and hand them out.

1	MR. TRUE: Probably just the authors'
2	names and I can pull it out of the proceedings.
3	CHAIRMAN APOSTOLAKIS: Modares and
4	Agerwal.
5	MR. TRUE: I can't find that.
6	CHAIRMAN APOSTOLAKIS: It's PSA '96, page
7	230.
8	MR. TRUE: Even better.
9	CHAIRMAN APOSTOLAKIS: Volume 1.
10	MR. TRUE: Okay.
11	CHAIRMAN APOSTOLAKIS: And other things.
12	I mean, as I say, that paper by the distinguished
13	members from the NRC staff in reliability engineering,
14	which you probably have, would probably be a good one
15	to look at. You have that? "Use of Importance
16	Measures in Risk-Informed Regulatory Applications"?
17	MR. TRUE: Yes. Yes.
18	CHAIRMAN APOSTOLAKIS: You have it and you
19	promptly ignored it, right?
20	MR. TRUE: I didn't think any of us
21	ignored it.
22	DR. SHACK: I mean the one that shows the
23	point estimates are very close to the mean.
24	CHAIRMAN APOSTOLAKIS: Yes. And also
25	talks about the advisability of using the thresholds

1	as they are. Yes.
2	DR. ROSEN: So now where are we, George?
3	To the NRC staff?
4	CHAIRMAN APOSTOLAKIS: Well, let's talk
5	about external events, because that's really something
6	that I think bothers us. And we had a question or a
7	couple of questions, at least, on
8	MR. TRUE: I have to say I didn't get the
9	same impression from reading the questions as I've
10	gotten here today. So, take me to the question that
11	you think
12	CHAIRMAN APOSTOLAKIS: Well, question 16
13	and 17.
14	MR. TRUE: Okay. Sixteen, I missed
15	understood what you were asking about. I thought you
16	were asking in 16 about places where we had PRAs
17	available, how do we handle them quantitatively. And
18	the answer was we looked at them individually and then
19	we compute these integral importance measures using
20	this equation. That's just basically weighting it
21	based on the CDF contribution of each hazard.
22	And then the sensitivity study we've
23	talked about looks at that.
24	So there must have been something more to
25	this question than I read from it.

1	CHAIRMAN APOSTOLAKIS: Well, go on to 17.
2	MR. TRUE: Okay. So then 17 question is
3	focused on fire versus fire PRA.
4	CHAIRMAN APOSTOLAKIS: So let's look at
5	these two figures now. 3.1-2. You don't have a
6	transparency, do you?
7	MR. TRUE: Yes, we do.
8	CHAIRMAN APOSTOLAKIS: Oh, great. Let's
9	put it up because that's important.
10	MR. TRUE: 3.1-1 and 3.1-2. Okay.
11	CHAIRMAN APOSTOLAKIS: Okay. Good.
12	MR. TRUE: This figure is effectively the
13	same as the internal events figure with the exception
14	that I loped off the initiating event question because
15	individual components aren't really contributors to
16	initiating events in the same way the fires as they
17	are for other internal events.
18	So basically the questions are is the RAW
19	greater than 2 or Fussell-Vesely greater than .05. If
20	it is, can it have been safety significant
21	CHAIRMAN APOSTOLAKIS: Now let me
22	understand this. When you say calculate draw in
23	Fussell-Vesely for components addressed in 5 PRAs
24	MR. TRUE: Yes.
25	CHAIRMAN APOSTOLAKIS: are you doing it

1	now with respect to the contribution to core damage
2	frequency from the fire
3	MR. TRUE: From the fire.
4	CHAIRMAN APOSTOLAKIS: Not for the whole
5	thing?
6	MR. TRUE: From the fire and then at the
7	end we come back and take that important measure
8	CHAIRMAN APOSTOLAKIS: And you weight?
9	MR. TRUE: And weight it and compute
10	overall.
11	CHAIRMAN APOSTOLAKIS: Now, again, I mean
12	that it sounds reasonable, but why is that
13	something we want to do? I mean, the whole idea of
1.4	the importance measures is to look at the whole PRA as
15	one entity and say this is the ranking. Right now we
16	are breaking it up and say no we're going to do a
17	separate one for fires, earthquakes, internal events
18	and then somehow put them together.
19	MR. TRUE: Right.
20	CHAIRMAN APOSTOLAKIS: I mean that's more
21	defense-in-depth it seems to me. So it's okay, but
22	MR. TRUE: It's more defense-in-depth,
23	it's more conservative because we're breaking it apart
24	and looking at individual pieces. But at the end we
25	bring it back together and when we pass the

information to the IDP, we give them both contexts.

And basically what we said is if something is important from an internal events perspective when it's isolated by itself, it's important.

In my opinion we have a lot of confidence, a lot of experience with importance measures and internal events PRA. If we found that the importance was high for another hazard source, then we give the IDP that value plus the aggregate, which is the -- or integral, which is the combination importance measure. And if that fire or fire, for example, was a small contributor to the total CDF, then we allow it to be kind of diluted. But if it's a large contributor, it's still going to be a significant importance measure at the end, and we think that it deserves that weight.

But if we combine them altogether and you have a plant, for example, like Quad Cities that has low internal events CDF and moderate fire CDF, then nothing relating to internal events is ever important because it's always swapped out by fire. And the only things that are important are the fire mitigation systems. And we didn't think that that was appropriate because the basis on which you do fire PRA is totally different than the basis on which we do the

2 3 4

internal events. And the uncertainties are different, the input assumptions are different, and they're just different beasts we felt deserved being separated apart.

Within internal events we made an allowance for the fact that if you were dominated by some unique hazard like internal flooding, we said you should pull that out and look at everything absent that so that you don't swamp out the plant responses and the defense-in-depth that's integrated in your ability to respond to traditional initiating events by this big lump that's a particular vulnerability to an internal flooding or some unique hazard.

MR. BURCHILL: Let me add to that. As you know, Quad Cities is one of my major challenges 4 years ago when I came to ComEd. And the fire PRA, which is a overstatement, of course, that existed at the time showed a hideously high core damage frequency. And when we examined it, even casually, we found that it was extremely poorly structured.

CHAIRMAN APOSTOLAKIS: But now let me come back to what you and Doug were saying earlier this morning about all these reviews and these engineers who are reviewing the risk management programs and so on, and that these -- we have high quality. How come

1	in that case
2	MR. BURCHILL: It was a terrible product-
3	
4	CHAIRMAN APOSTOLAKIS: You mean the
5	process was terrible as terrible?
6	MR. BURCHILL: The process that developed
7	it was a terrible process.
8	CHAIRMAN APOSTOLAKIS: So it was not what
9	you described here?
10	MR. BURCHILL: It is not what I described
11	this morning. It was not put in place since I've been
12	there.
13	DR. ROSEN: When did you say that was?
14	MR. TRUE: It was the IPEEE?
15	MR. BURCHILL: The IPEEE for Quad Cities
16	was developed in '96/'95. '95/'96 time frame. One of
17	my first challenges when I arrived on the scene in
18	January of '98 was to go look at this beast and find
19	out what was it telling us. And, you know, as I say,
20	even a casual examination showed me that it was very
21	poor. And I will in no way even try to rationalize
22	for you how it got prepared in the way that it was.
23	Now, when we went about to totally redoing
24	that fire PRA, we did exert the types of controls that
25	I described to you. But nevertheless, even with that

there were certain things that we did and did not do.

The major thing, of course, because fire is a highly spatially dependent hazard, is you have to know a great deal about all of your cable routings in order to know exactly what gets impacted by a particular spatially defined fire. And you have to know then what you can take credit for. You have to know both what the fire will impact so the fire modeling comes into effect, and you have to know where those cables are that are important to other pieces of equipment's operation, which aren't even in that spatial area. I mean, that's the whole challenge with fire PRA.

So we spent -- you know, I don't want to put this in numerical terms. But we spent a lot of money to go chase cables. But we only spent a certain amount of money. I mean, I won't say to you that I know where every individual cable chase in that plant. So in certain cases where we had a fire in a compartment, you know, if we knew where the critical pieces of equipment were that had cables through or where the cables were for critical pieces through that compartment, then we could explicitly model it.

If we didn't, then we just -- if we knew it entered that compartment but we didn't know

NEAL R. GROSS

1 precisely where it ran -and frankly, 2 impractical to go track that down, we just assumed 3 that we lost that piece of equipment. I mean, this is 4 standard practice. 5 So, the fire PRA in my opinion at least 6 suffers in comparison to the internal events PRA from 7 two considerations. One is that the ignition 8 frequencies for the first are nowhere nearly as 9 sufficiently defined as our internal events initiating 10 event frequencies. And in cases of absence of 11 knowledge, we believe that we biased them in a high 12 direction; in other words, a conservative direction. 13 DR. ROSEN: But not all plants had that problem of lack of knowledge of the configuration? 14 15 MR. BURCHILL: No, I understand that. 16 DR. ROSEN: Some plants knew precisely 17 where the cables are. 18 MR. BURCHILL: Some plants do. 19 And then the second part is that point; that the adequacy of your fire PRA to show a CDF 20 21 that's comparable to your internal events absolutely 22 depends on your intimate knowledge of those cable 23 routings. 24 So it's two things. It's the ignition 25 frequencies themselves and then the adequacy of the

WASHINGTON, D.C. 20005-3701

cable routing knowledge so that you can do the fire modeling.

Now, absent that I would submit to you that if you have a -- and you'll challenge me on this -- but a reasonable representation of the plant, although still somewhat conservative, you can still gain a great deal of information about what pieces of equipment are really important for mitigating the fire. And so now on relative basis I can look in my fire PRA and I can say, you know, what are the importance measures associated with equipment. And that will tell me how important the equipment is on a relative basis for responding to fire. But I wouldn't pretend it to be directly comparable to the same importance majors coming out of the internal events PRA. You see what I'm saying?

And that's, I think, another reason for separating this. Because you can gain information out that fire PRA that's helpful to understand the importance of equipment. And as Doug said, it could go either way. You could either lose that information or it could swamp the internal events if you lumped them altogether, because they're not on the same playing field. And I would submit there's very few PRAs in which they are on the same playing field.

NEAL R. GROSS

б

1.0

1	CHAIRMAN APOSTOLAKIS: Which essentially
2	comes down to how uncertain you are about the fire PRA
3	results really. And it's one way of
4	MR. BURCHILL: And how you dealt with
5	that.
6	CHAIRMAN APOSTOLAKIS: It's one way of
7	handling.
8	So let's answer the question that was
9	raised.
10	MR. CHEOK: Actually, let me supplement
11	what Bill and Doug just said.
12	By separating the initiators we can gain
13	insights we cannot gain whereby lumping them. In
14	essence this kind of maybe relates to question 5 on
15	sabotage.
16	What happens when we have an event that
17	maybe could make a fire event more important, by
18	having this separate pieces of importance measures,
19	you can now deal with question 5 a little better
20	maybe.
21	CHAIRMAN APOSTOLAKIS: Well, the only
22	thing that worries me is that I mean, this is
23	reasonable. I don't recall in 1.174 having anything
24	like this unless you tell me to go read Appendix X.
25	MR. CHEOK: I think if you read Appendix

1 || A --

CHAIRMAN APOSTOLAKIS: Oh, God.

MR. CHEOK: We do say that you need to treat the importance measures cumulatively and separately because each will give you a different insights.

CHAIRMAN APOSTOLAKIS: Could you point me to the page. I'd like to see that. And also it's not just a matter of importance measures. I mean, I think in general when you do risk-informed applications, shall we start doing this in a consistent systematic way and say now you have to separate fires from internal events and do certain things? Let's not what the basic approach says, right? I don't think -- I mean, if you look at the figures in 1.174 --

MR. TRUE: It's total.

CHAIRMAN APOSTOLAKIS: It's total. It doesn't say, you know, consider things separately. It may be buried in Appendix A, something --

MR. CHEOK: But remember we are saying that importance measures are not your decision making tool. You see a delta change that is, the importance measures are things that you bring into the IDP for them to deliberate on.

CHAIRMAN APOSTOLAKIS: Right. Right.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

MR. CHEOK: These are insights you bring in to the IDP. And I think we mentioned it this morning in terms of defense-in-depth. You know, a RAW value basically tells you SSCs that are in single, double or maybe triple event cut sets, so you're talking about things that are maybe sensitive to defense-in-depth in terms of levels of protection.

Fussell-Vesely would tell you whether an SSC appears in many different cut sets which tells you that, you know, it's there to mitigate a lot of different functions.

CHAIRMAN APOSTOLAKIS: My point was that if you look at the basic diagrams that are in the main body of 1.174, there is no distinction between parts of PRA that are done poorly or very conservatively versus other parts that are not done that way. There is one global delta CDF that you have to consider. And now what I'm saying is that, you know, this sounds reasonable to me. Maybe that idea of treating certain things differently from others should be studied more carefully and maybe change the basic approach. Because I don't know what delta CDF means. Now if we do it for fires or for something else in light of what Bill just told us.

Anyway, that's an idea. Let's go back to

NEAL R. GROSS

1 the question here. Where is the corresponding, you 2 know, that diamond you have there are all greater than 3 2? 4 MR. TRUE: Right. 5 CHAIRMAN APOSTOLAKIS: If I go to the next 6 figure --7 MR. TRUE: Okay. Let's go and we have one 8 there, too. Okay. What we did here is -- well, let 9 me back up. 10 In our five analysis we start with a fire scenario and you look for factors which can allow you 11 12 to screen that fire scenario out. And screening it 13 out means that its frequency gets below one times 10 14 15 So you say I'm going to have a fire in this area, it 16 causes this much damage, what are the things that are 17 left and what are the systems that could suppress or 18 terminate that scenario. And once you've gotten that 19 scenario below 10-6 you stop. You don't continue to 20 recover it to try and refine into a true CDF. 21 just screen it below 10-6 and say I don't have to 22 worry about it anymore. It's not a vulnerability in 23 my plant. That's what fire was really intended for is 24 to identify vulnerabilities.

And so when you're all done you end up

NEAL R. GROSS

Τ	with screened scenarios and unscreened scenarios.
2	Unscreened scenarios are those that you could never
3	get below 10 ⁻⁶ even though you incorporated all the
4	success paths and information that you had available.
5	And so what we said was that for a
6	component that participates in an unscreened scenario,
7	it's used to mitigate an unscreened scenario, so
8	it's part of a scenario, it's built into my 6, it's
9	automatically safety-significant. I don't care if
10	it's
11	CHAIRMAN APOSTOLAKIS: It's a candidate?
12	MR. TRUE: It's a candidate. Well, it's
13	safety-significant and then whether it's safety
14	related or not makes it a candidate of RISC-1 and
15	RISC-2, and that's passed on to the IDP to make the
16	final decision about.
17	DR. ROSEN: And even the IDP and all its
18	glory can't change that?
19	MR. BURCHILL: That's right.
20	MR. TRUE: Right.
21	CHAIRMAN APOSTOLAKIS: So let me
22	understand
23	MR. BURCHILL: And it can't ever get to
24	RISC-3?
25	CHAIRMAN APOSTOLAKIS: It can never get to

1 || RISC-3?

2

MR. TRUE: Right.

3

MR. BURCHILL: Right.

what about all those ones that you squeezed below the

could actually be large. And so what we said there

was that if it doesn't participate in one of those

we're saying is it didn't really have anything to do

with fire risk. But if it does participate and it was

part of the reason you were able to screen it below,

then we ask if you didn't credit that, would you bring

that scenario back above the threshold and make it an

kind of a look at it to say if I don't credit that as

a I come out of this box and move back into this other

box over here, where we said everything was important,

so we're taking all the things that participated in

the unscreened and all of those that helped to screen

out scenarios and putting those back in.

come back down and, again, are RISC-1 or 2.

scenarios, then we're going to make it low.

There could be a bunch of them and the risk

MR. TRUE: Okay. So then we're left with

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

MR. PARRY: Can you walk me through George's door?

So it's sort of like a risk achievement

NEAL R. GROSS

unscreened scenario.

1	MR. TRUE: The barrier, I think what I
2	said about barriers was that you would have to have a
3	fire PRA I think what the guidance is you have to
4	have a fire PRA that was focused on looking at that
5	barrier which would take you back to the other figure
6	and we wouldn't be using this figure. And I think you
7	would use the same process and basically say
8	MR. PARRY: Most people don't have a fire
9	PRA that looks on barriers.
10	MR. TRUE: Right.
11	MR. PARRY: Okay. So what do they do with
12	barriers?
13	MR. TRUE: They are not allowed to they
14	don't have a compelling case to move it from safety
15	related, a/k/a RISC-1 to RISC-3. So it remains RISC-
16	1. Or it remains under whatever program it's in. It
17	may actually be in an augmented program, in which case
18	it starts in RISC-2 and stays in RISC-2.
19	MR. PARRY: So we've got what? A thousand
20	fire barrier penetration seals that are always going
21	to be in a high risk category, RSC category?
22	MR. TRUE: Safety-significant category?
23	MR. PARRY: Yes.
24	MR. TRUE: Yes. Without having done an
25	analysis to show that they are, they remain in the

safety-significant category. 1 2 MR. CHEOK: Unless you can show that they 3 are not important in screening out of the sequences in 4 your fire screening analyses. In other words, if you 5 had used the barrier to justify fire independence, you 6 have to maintain the current programs unless you can 7 show that even if you remove the programs, 8 screening does not matter. 9 I think the staff also has one more 10 question with respect to this figure, and it's a 11 little more subtle than just the typical barriers when 12 you do screening. When you go to the PRA leg of this 13 figure a lot of people would define fire damage 14 states. And when you define fire damages states, you 15 take credit for things like fire suppression systems, 16 sprinklers, response from the fire department, 17 wherever. MR. TRUE: 18 Right. 19 And that gets to be put into MR. CHEOK: 20 your split fractions in your fire damage stated entries. 21 22 MR. TRUE: Right. 23 MR. CHEOK: That things don't normally get 24 propagated to the final cut sets because in your final 25 cut sets you come in with a single event where you say

it's damaged stage 3 -- where you have, you know, a

large fire that is suppressed in 3 minutes. So in

essence when you have -- when you take credit for

suppression systems, that seldom gets propagated to

the importance measures, and the staff has a question

for NEI on that.

MR. TRUE: I'm not familiar with your question, because I frankly haven't taken the time to go through all your questions on top of these 23. But what I'll say about that is that I believe we can use the same -- I agree with you that it's uncommon to see those show up in traditional importance measures, but I believe that we can use the same basic importance measure concepts, RAW 2, Fussell-Vesely and .05 for those systems. It just would take a separate calculation to look at what the benefit you're getting out of those systems is.

MR. CHEOK: I think this is something we need to discuss more. Because we define a lot of our runs over our fire property runs by using certain parameters like suppression systems and I'm not sure if that actually gets propagated all the way to theorem can get easily propagated to the importance measures. But that's something we need to discuss more.

1	MR. TRUE: Okay. It's probably a place
2	like where we need more maybe we could use more
3	guidance than the guidance document.
4	CHAIRMAN APOSTOLAKIS: And all this
5	assumes, of course, that whoever did the 5 kept track
6	of the screen scenarios, right? If they have not,
7	they cannot apply this. Do they keep that
8	information?
9	MR. TRUE: Yes. Yes, as part of the
10	5 processes.
11	CHAIRMAN APOSTOLAKIS: How about if you do
12	the HCLPF in what do they call that, in seismic?
13	MR. TRUE: Okay.
14	CHAIRMAN APOSTOLAKIS: It's the same idea?
15	MR. TRUE: It's the same basic concept in
16	that what we're saying is that the seismic margins
17	approach was intended to make sure we didn't have any
18	vulnerabilities to seismic risk. And in that process
19	you were required to have two safe shutdown paths that
20	you had 1 is the PRA one which looks like every
21	other PRA one.
22	Basically what we said there was that if
23	you have identified that component as being part of
24	your safe shutdown paths in your safe shutdown
25	analysis for seismic margins, it is if it supports

т	the sale shutdown path, then it is salety-significant.
2	If it's not something that's important to
3	one of your safe shutdown paths, then it's not and it
4	goes to a
5	CHAIRMAN APOSTOLAKIS: And if you do all
6	this, you cannot really develop the integral what
7	you call the integral form of importance measures
8	because you don't have a CDF, right?
9	MR. TRUE: Right. And you that
10	aggregate calculation and the sensitivity study at the
11	end will vary by a factor of 2 to 5. Obviously
12	doesn't get factored back in here.
13	CHAIRMAN APOSTOLAKIS: So how does that
14	work now?
15	MR. TRUE: But the
16	CHAIRMAN APOSTOLAKIS: In other words what
17	you just said is, if I understand correctly, that we
18	cannot really calculate delta CDF?
19	MR. TRUE: For the seismic contribution.
20	CHAIRMAN APOSTOLAKIS: Oh. So we don't
21	know whether we meet 1.174, do we? Especially given
22	the fact that these things are among the significant
23	contributors a lot of the time.
24	MR. TRUE: But all of these what we're
25	all of these that are credited are going to remain
1	

treated. So it's the ones that aren't on the success
path that are possibly be moved to RISC-3 or 4. If
they make it through all the other screens and those
aren't what we need in order to assure that our
seismic risk is low.
So the ones that were included to make
sure our seismic risks are low, stay safety-
significant.
CHAIRMAN APOSTOLAKIS: Right.
MR. TRUE: So it's the ones that are not
part of that that are kind of marginal helpers in the
seismic risk area, you may want to look at it.
CHAIRMAN APOSTOLAKIS: Yes.
MR. TRUE: Those are the ones that
potentially might change by a factor of 2 to 5.
CHAIRMAN APOSTOLAKIS: Right. And that we
don't know the impact.
MR. TRUE: And those are the random
failure rates anyway of the components that we're
changing by a factor of 2 to 5. So, yes, we're
missing a small slice of the delta CDF, but we felt
like because we were taking everything on that path,
that
CHAIRMAN APOSTOLAKIS: That's an
interesting point you just made. In these analyses,

1	for example, in the seismic analysis we had the
2	ragility curves, right? When you do you 2 to 5
3	calculation, you don't touch those, do you? Because
4	they're not
5	MR. TRUE: We were going to change just
6	the random unreliability
7	CHAIRMAN APOSTOLAKIS: Only the random?
8	Oh. Okay. Interesting.
9	Okay. Anything else on the questions?
10	MR. TRUE: We had a lot of discussion
11	about this, is it conservative, is it not
12	conservative?
13	CHAIRMAN APOSTOLAKIS: No. I think the
14	way you describe it is conservative, that's my
15	impression. The way you describe it here.
16	MR. TRUE:
17	DR. SHACK: Well, we tried. It was
18	actually our intent. Good.
19	DR. SHACK: Well, I'm not sure in this
20	one, though, if you had a relatively large seismic
21	contribution, that you could be sure that the delta
22	CDF with the other paths were small. You know, it
23	becomes it's one of these thing where the yes,
24	you've gotten the largest one and you've made it
25	manageable, but it's not clear to me that the delta

CDF associated with the others is necessarily small. 1 2 It's just -- it's not dominate. 3 You know, in the 5 at least you've got a 4 You know, a have a quantitative criterion for 5 what you've screened out. 6 MR. TRUE: Yes. 7 DR. SHACK: In this one all you know is 8 that, you know, it's less than the two that you've 9 picked. 10 MR. TRUE: Yes. Ι think that my impression, and I'm not the seismic expert for sure. 11 12 My impression is that if you're able to meet the 13 HCLPFs in the seismic margins approach, that you can 14 have reasonable confidence that your total CDF from 15 seismic is going to be on the order of 10⁻⁵. And so -16 - and that's for the things that are treated. 17 Now, you may be actually above 10⁻⁵ if 18 your HCLPFs didn't meet the earthquake, but we've 19 already got all those components that didn't meet the HCLPF because they're a part of our safe shutdown path 20 21 for making it safety-significant. 22 So we're talking about some change to a 23 fraction of the 10⁻⁵ kind of a value, which gave me some confidence that we're still kind of in that same 24 25 ball park.

1	DR. SHACK: Yes. But if delta CDF is
2	I mean, you know, it's a small contribution to the
3	total CDF, but when you're looking at the deltas that
4	you're interested in, is not you know, we're not
5	looking at 10 to the 4th anymore. You know, if you're
6	going to demonstrate that the delta CDF is small
7	MR. TRUE: It's between 10 ⁻⁶ or less
8	than 10^{-5} and, hopefully, less than 10^{-6} . Yes. But
9	it's not all that
10	CHAIRMAN APOSTOLAKIS: Shall we move on?
11	Now, in the common-cause failure area
12	MR. TRUE: Yes.
13	CHAIRMAN APOSTOLAKIS: on question 20,
14	which and 21 is blank. Oh. Okay.
15	MR. TRUE: We didn't understand that.
16	CHAIRMAN APOSTOLAKIS: Why should no,
17	I thought your
18	MR. TRUE: We didn't understand 21.
19	CHAIRMAN APOSTOLAKIS: Well, it's related
20	to the comment I'm about to make.
21	MR. TRUE: Okay.
22	CHAIRMAN APOSTOLAKIS: I think the
23	implication in 20 or what you're doing in here is that
24	the common-cause failure term is a separate event
25	because in RAW and Fussell-Vesely can be calculated.

1	In other words, I have a PRA, I have
2	MR. TRUE: What you said is statement of
3	the facts, right?
4	CHAIRMAN APOSTOLAKIS: Yes.
5	MR. TRUE: That's true.
6	CHAIRMAN APOSTOLAKIS: And the thrust of
7	these questions is that it really isn't, but if this
8	component A fails, it effects that fact effects a
9	number of terms. I mean, when I calculate RAW and I
10	set that component down, it should effect a term that
11	has only random failures, it should effect the term
12	has common-cause failures, because that component is
13	down now.
14	MR. TRUE: Okay. Yes, but the
15	CHAIRMAN APOSTOLAKIS: So we're not going
16	to take the common-cause failure term as a separate
17	entity, as if it were a separate component in other
18	words?
19	MR. TRUE: Okay.
20	CHAIRMAN APOSTOLAKIS: So yes, go
21	ahead.
22	MR. TRUE: Let's take it one at a time.
23	Fussell-Vesely is effectively setting the
24	failure rate to zero, right?
25	CHAIRMAN APOSTOLAKIS: Yes.

MR. TRUE: So that takes the common-cause
term to zero. So Fussell-Vesely I think we
hopefully we can agree that the approach of
considering all of those together addresses that.
CHAIRMAN APOSTOLAKIS: Considering what?
MR. TRUE: We take the sum of all t he
Fussell-Veselys and assign that to be the Fussell-
Vesely importance of the component.
CHAIRMAN APOSTOLAKIS: And that's bounding
or what is it?
MR. TRUE: Well, I believe it's bounding.
MR. PARRY: It is, because they're
independent failure modes of the component.
CHAIRMAN APOSTOLAKIS: Mutually exclusive.
They're mutually exclusive.
MR. PARRY: That's right. But that's
right.
MR. TRUE: Yes.
MR. PARRY: So the cut sets are mutually
MR. PARRY: So the cut sets are mutually exclusive. So
-
exclusive. So
exclusive. So MR. TRUE: Unless by some chance you had
exclusive. So MR. TRUE: Unless by some chance you had MR. PARRY: Well, there may some

1	different phase.
2	CHAIRMAN APOSTOLAKIS: So in essence what
3	you're
4	MR. PARRY: And you would get a different
5	sequence.
6	I think it's true that it's the right way
7	to do it.
8	MR. TRUE: Yes. It's the right to do it.
9	It's certainly not
10	CHAIRMAN APOSTOLAKIS: But you are talking
11	about the Fussell-Vesely of a single component now
12	that has 3 failure modes, right?
13	MR. TRUE: Right.
14	CHAIRMAN APOSTOLAKIS: You are not
15	addressing the question of how to handle the common-
16	cause term also?
17	MR. TRUE: I'm trying to do that.
18	CHAIRMAN APOSTOLAKIS: Okay.
19	MR. TRUE: So there's a figure the
20	answer to question 22, what we probably should work
21	from and then we'll get and you had a question
22	about that table. Get the table out of the report and
23	corrected an alignment problem that we had in the
24	report, which I apologize for.
25	So basically what we did was we said okay,

1	in a PRA a component has various failure modes.
2	Independent failure modes and common-cause failure
3	modes. What we want to do in the area of Fussell-
4	Vesely is we're going to compute a component in
5	Fussell-Vesely importance, and for doing that we're
6	going to take the sum of the individual component
7	failure mode Fussell-Vesely importances. So these
8	Fussell-Vesely importances sum to this .00952 value.
9	CHAIRMAN APOSTOLAKIS: So this is the sum
10	of all these four numbers.
11	MR. TRUE: The sum of those numbers, yes.
12	Because the decimal points align, it's not obvious
13	that that's the case, but that's what it is.
14	DR. ROSEN: We'll trust you.
15	CHAIRMAN APOSTOLAKIS: Well, but wait a
16	minute now. Let me the failure to open versus
17	failure to remain
18	MR. BURCHILL: Right. It's not physically
19	possible that those both occur unless they're time
20	dependent failure situations in a scenario. But at
21	least we have that's why we think it's conservative
22	because we've actually added what may be in fact
23	mutually exclusive failure modes.
24	MR. TRUE: You can't fail or remain open
25	shouldn't be able to fail or remain open and fail to

WASHINGTON, D.C. 20005-3701

1	remain closed in the same at the same time.
2	DR. ROSEN: Well, if you get caught in the
3	middle.
4	MR. TRUE: Well, you could, yes. Although
5	that usually would be categorized as one failure or
6	the other.
7	CHAIRMAN APOSTOLAKIS: But the common-
8	cause failure again represents now what kind of
9	failure? To open or to remain closed?
10	MR. TRUE: To open. To open. We don't
11	usually have a common-cause term for failed to remain
12	closed.
13	DR. ROSEN: Closed.
14	CHAIRMAN APOSTOLAKIS: And you have a
15	oh, there was a number there. So the .004 is
16	MR. TRUE: Is it's importance. That
17	actually happens to be the most important of the
18	Fussell-Vesely importances.
19	CHAIRMAN APOSTOLAKIS: So this Fussell-
20	Vesely now is calculated by assuming by treating
21	the common cause term as an independent separate term,
22	is that what that means?
23	If I go to the PRA and I set that common-
24	cause term equal to what, zero?
25	MR. TRUE: This term? Yes.

1	CHAIRMAN APOSTOLAKIS: Then it will get
2	.004?
3	MR. TRUE: It will reduce the total by
4	.004
5	CHAIRMAN APOSTOLAKIS: Okay. And as if
6	nothing else happened?
7	MR. TRUE: Yes. There's a basic event in
8	the model that says common-cause failure of these two
9	valves.
10	CHAIRMAN APOSTOLAKIS: Right.
11	MR. TRUE: And I computed that with an
12	alpha factor model or a beta factor model, or whatever
13	model. But I have a basic event that says common-
14	cause failure, this .004 reflects the Fussell-Vesely
15	importance of that basic event.
16	CHAIRMAN APOSTOLAKIS: Although in
17	reality, I mean if you use the alpha factor or the
18	beta I mean the multiple Greek letter method, 1 and
19	4 really have the failure rate of valve A times beta
20	and gamma?
21	MR. TRUE: Right. Right. Right. I agree.
22	CHAIRMAN APOSTOLAKIS: So they're really
23	not independent basic events. I mean, you know,
24	lambda appears in both?
25	MR. TRUE: Right. But if we're going to

1	zero, I think they all go to zero at the same time.
2	CHAIRMAN APOSTOLAKIS: They all go to zero
3	at the same time. But that's not how you calculated
4	the Fussell-Vesely. You set one versus equal to zero
5	and then the other. You don't put them down at the
6	same time.
7	MR. PARRY: George, maybe excuse me.
8	The way you calculate them, they're not independent.
9	But they represent independent failure modes of that
10	component because the valve A fails to open is what's
11	classified as the independent failure to open. Event
12	4 is that subset of those failure causes of valve A
13	that would also fail all the others.
14	CHAIRMAN APOSTOLAKIS: Right.
15	MR. PARRY: So they are, in fact,
16	independent events from the point of view of physics.
17	It's just that when you calculate it by taking the
18	lambda for 1 and multiplying by a few betas or alphas.
19	CHAIRMAN APOSTOLAKIS: But if you do that,
20	I mean the importance of lambda is different. It also
21	effects two terms.
22	MR. PARRY: Well, that's yes, but
23	that's why they're adding them. They're not looking
24	at the
25	CHAIRMAN APOSTOLAKIS: Can they

1	demonstrate that if you add them, you get the correct
2	result
3	MR. PARRY: They're not looking at the
4	importance of lambda. They're looking at the
5	importance of the component.
6	CHAIRMAN APOSTOLAKIS: Right. And that's
7	not something that's obvious to me. He just says that
8	we are doing it this way without any justification. I
9	have to sit down and figure it out myself if it's
10	correct, and I don't like that.
11	MR. TRUE: You don't like that you had to
12	figure it out?
13	CHAIRMAN APOSTOLAKIS: Yes. Because them
14	I have to do the same for RAW. I have to understand
15	every line you have here. And, you know, why should
16	the user have to do this? Can you just explain why
17	these things are reasonable? Somewhere.
18	MR. TRUE: Okay.
19	CHAIRMAN APOSTOLAKIS: Okay.
20	MR. TRUE: We can explain that, why
21	they're reasonable.
22	CHAIRMAN APOSTOLAKIS: Good.
23	MR. TRUE: The next one may be somewhat
24	more contentious because I don't think the staff
25	agrees with this completely.

MR. PARRY: You are right.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

MR. TRUE: Okay. We've resolved the fact of how we calculate the component importance for Fussell-Vesely, right? That's clear what we're doing?

CHAIRMAN APOSTOLAKIS: Well, I understand what you're doing. It's just that it's not clear to me that it's reasonable what you're doing. But I understand what you're doing. Now let's go to RAW.

MR. TRUE: Okay. Let's go to RAW.

CHAIRMAN APOSTOLAKIS: But you said you can supply proof that it's reasonable. So, you know, I'll wait to see it.

MR. TRUE: Okay. For RAW in the PRA we have in the same individual basic events, and we can compute a RAW for each of those individual basic And we in our categorization process have said that we will not include the common-cause -- the RAW of the common-cause term as part of computation of the total component importance from a RAW perspective and unless -- unless the conditional probability of the additional components failing that's used in alpha factor method is less than .005. And the reason for that is that if it's greater than .005, which in most cases it is -- it's usually around between .01 and .1, then the Fussell-Vesely is

1	going to be bounding anyway. Because the only way to
2	get a RAW of 2 with a Fussell-Vesely lower than .005
3	is if the failure rate or the event that you're
4	setting to true has a value that's smaller than .005.
5	CHAIRMAN APOSTOLAKIS: Doug, and you
6	expect the reader to figure that out? Why don't you
7	supply some arguments that this is
8	MR. TRUE: There's a footnote that
9	describes it.
10	CHAIRMAN APOSTOLAKIS: There's a footnote
11	which I never understood.
12	MR. TRUE: Okay.
13	MR. PARRY: I have got to say I don't
14	really understand the footnote either. Because I
15	think it refers to the conditional common-cause
16	failure probability, which is the product of the
L7	alphas.
L8	MR. TRUE: Right. It does.
L9	MR. PARRY: Yes. Whereas, in fact by
20	using the same argument that you used to sum the
21	Fussell-Veselys you can turn it around and say that
22	you also have to consider each of these basic events
23	when you're considering RAW. Because remember what
24	these separate events are is they're separate failure
5	modes, if you like, of the component. Therefore, why

1	would the common-cause failure the common-cause
2	failure mode is a very strange one in that it also
3	impacts other components. But it still fails
4	component A, and therefore it's equivalent. So I
5	think you should consider it.
6	CHAIRMAN APOSTOLAKIS: Isn't the problem
7	stemming from the fact that item 4 is treated as a
8	separate entity from 1 and 2? I mean, if you say the
9	common-cause failure forget failure rates.
10	The term is QA times data.
11	MR. PARRY: Yes.
12	CHAIRMAN APOSTOLAKIS: Then I'll go
13	everywhere in my PRA, I'm looking for the RAW of A.
14	And wherever I have Q of A I'll set it equal to one.
15	MR. PARRY: You could do that
16	CHAIRMAN APOSTOLAKIS: Clearly, I could.
17	I mean, that's what I must do.
18	MR. PARRY: No, no, no.
19	CHAIRMAN APOSTOLAKIS: There's a
20	difference between must and could.
21	MR. PARRY: No, not necessarily.
22	CHAIRMAN APOSTOLAKIS: Not necessarily.
23	MR. PARRY: Right. Because what you're
24	assuming is that the impact of whatever change you're
25	doing is only effecting the random failure

Т	probability. It could equally effect the coupling
2	factor between the components A, B and C.
3	CHAIRMAN APOSTOLAKIS: It could. It
4	could.
5	MR. PARRY: And by doing what you suggest,
6	but you're only focusing on
7	CHAIRMAN APOSTOLAKIS: But it's a step in
8	the right direction.
9	MR. PARRY: It's a step in the right
10	direction.
11	CHAIRMAN APOSTOLAKIS: Because the
12	component is down.
13	MR. PARRY: It's a step in the right
14	direction.
15	CHAIRMAN APOSTOLAKIS: Yes.
16	MR. PARRY: But there is no right answer
17	to this because RAW is itself a very
18	CHAIRMAN APOSTOLAKIS: Oh, but there is a
19	wrong answer.
20	MR. PARRY: Yes, and I think this is the
21	wrong answer.
22	DR. ROSEN: This is the wrong answer and
23	a
24	MR. PARRY: But there's no right answer in
25	the sense that RAW is such a strange extreme
	!

	165
1	importance measure.
2	CHAIRMAN APOSTOLAKIS: I want to know what
3	happens to the CDF if this component is down. Now, in
4	the community's wisdom the common-cause failure is
5	represented by 2 times beta times gamma, times delta.
6	Well, if I have accepted, then I have to go and set Q
7	equal to zero, to 1 there. Now, whether beta, gamma,
8	delta will also go up is another question. But I
9	think I would go back to the comment that, you know,
10	how much can they go up. Because they're already
11	pretty high. It's the Q that really brings everything
12	down by I mean, beta is 10 percent, gamma is close
13	to one. I mean, how much are you going to change it.
14	Change it a little bit if you want, but it's the Q
15	really that brings everything down.
16	MR. PARRY: Well, the
17	CHAIRMAN APOSTOLAKIS: And it seems to me
18	that's the way it should be done.
19	MR. PARRY: It depends what you're
20	thinking you're doing, I think. It's
21	MR. TRUE: Let me take a brief stab at
22	defending what we did.
23	CHAIRMAN APOSTOLAKIS: I think you should.

that documents all these things.

And I think that comes back to my request for a study

24

1	MR. TRUE: Okay. I think that several
2	things I think we can agree on several things.
3	Common-cause RAW is an extreme term. It's
4	saying that all the components in that group fail 100
5	percent of the time for 100 percent of the year and
6	DR. ROSEN: Now calculate CDF on that
7	basis.
8	CHAIRMAN APOSTOLAKIS: Wait a minute.
9	MR. TRUE: And calculate CDF.
10	CHAIRMAN APOSTOLAKIS: Where does it say
11	that? It doesn't say that.
12	MR. PARRY: Where does it say that?
13	CHAIRMAN APOSTOLAKIS: The way you
14	calculate its importance says that, and that's what
15	I'm objecting to.
16	MR. TRUE: No. It's the RAW term for
17	common-cause event in a PRA
18	CHAIRMAN APOSTOLAKIS: And that's what I'm
19	saying.
20	MR. TRUE: You set it to one
21	CHAIRMAN APOSTOLAKIS: You could never
22	calculate the RAW of the common-cause event, that's my
23	point. Because it doesn't make sense. It's not a
24	basic event.
25	MR. TRUE: Okav

1	CHAIRMAN APOSTOLAKIS: We call it basic
2	event, but isn't.
3	MR. PARRY: But it is a basic event.
4	MR. TRUE: So you agree with me, you're
5	running you agree. You're agreeing that's
6	CHAIRMAN APOSTOLAKIS: I what I'm
7	saying is that
8	MR. TRUE: You happen to agree with that.
9	CHAIRMAN APOSTOLAKIS: What I'm saying is
10	that, yes, the codes do treat it as a separate basic
11	event, but in fact it is a coupled event with the
12	other things. And if you look at the multiple Greek
13	letter method, for example, then it's obvious that Q
14	is everywhere. And you are really calculating the RAW
15	of A. So you're setting A equal to I mean, QA
16	equal to one for failure of the unavailability going
17	to one and then you should go to all the terms in the
18	PRA that have that QA and set it equal to one.
19	MR. PARRY: That's an artifact of the way
20	you calculate
21	CHAIRMAN APOSTOLAKIS: A what?
22	MR. PARRY: That's an artifact of the way
23	you're calculating the common-cause failure
24	CHAIRMAN APOSTOLAKIS: But that's what
25	you're doing. I mean, you can't do it this way here

and later on say no I'm not going to do that anymore.

MR. PARRY: You got to go back to what the definition of the events is. And the event -- the first event is the random failure of component A. The fourth event is the failure of component A in conjunction with other components. But it's still a failure mode of component A. That's the way those events are defined in NUREG 47 and its subsequent progeny. But it's an artifact of the way that we calculate the probabilities of those events that you calculate anyway to use lambda.

CHAIRMAN APOSTOLAKIS: I'm surprised you have to pay for the multiple Greek letter model.

And the other thing that really I think is upsetting right now is that we are doing this analysis here in real time, talking to each other, and the question is why hasn't the Office of Research investigated these things and settled them once and for all? Is it so difficult? Why? Would it take a million dollar study to do these things? No. Why do I have to come here and at 12:00 listen to Gareth tell me that it's an artifact and it doesn't matter, and this and that, and then Doug give something else?

I mean, if we are to have --

MR. PARRY: I didn't have the math,

NEAL R. GROSS

George.

CHAIRMAN APOSTOLAKIS: I know you didn't, but I want to put words in your mouth.

If we -- I mean one of the goals of the agency is to have -- to build and maintain public confidence, right? I don't think we're doing that by doing things like that and arguing the last moment, yes, it makes sense, it doesn't make sense. It seems to me we should have a piece of work somewhere that documents that these things make sense, they are conservative or they're not conservative, and this, and this and that.

MR. PARRY: Well, actually, we do have a comment into NEI on this particular point. So that does --

CHAIRMAN APOSTOLAKIS: Well, this committee has issued reports that are more than 2 years old commenting on the problems with importance measures. I'm not sure anybody read them. The study should have been done already to settle the issue of importance measures and how you calculate them.

MR. CHEOK: George, there's no one from the Office of Research here, but I guess I'll speak for them a little bit.

They do have a limited study on importance

NEAL R. GROSS

1	measures, and Louis Chu here from BNL is helping them
2	do it.
3	And I think in terms of common-cause
4	failures, I believe that the results show that there
5	were four additional SSCs that would become important
6	if you had included the RAW common-cause failure.
7	CHAIRMAN APOSTOLAKIS: So we should wait
8	then until we see the study from Brookhaven before we
9	say anything about this?
10	Are you addressing these questions, Dr.
11	Chu? Come up here to the microphone.
12	DR. CHU: Okay. This is Louis Chu,
13	Brookhaven Lab.
14	I think I work on some calculation
15	using the Sequoyah SPAR model.
16	In terms of calculating the RAW
17	considering the CCF, we I did I think exactly the
18	way George described it. That is, in the SPAR model
19	you calculate a common-cause failure probability in
20	terms of the alpha factors times the Q value. So
21	there's an expression for it.
22	And it happens that the SPAR model has the
23	capability of, you know, you fail the component it
24	will recalculate this common-cause failure
25	probability. As a result, I believe this is the right

way, the accurate way of accounting for common-cause 1 2 failure when you calculate a RAW value. 3 CHAIRMAN APOSTOLAKIS: So you're saving 4 not to consider the term as a separate entity and 5 calculate its RAW, but calculate the RAW of Q, which appears in two different places? 6 7 DR. CHU: Yes. We -- we --8 CHAIRMAN APOSTOLAKIS: For the component? 9 Even though Gareth says it's an artifact, which I 10 agree. Because--11 MR. PARRY: And, actually, we disagree 12 with Louis -- at least I disagree with Louis' point of 13 view, too. Well, thank you 14 CHAIRMAN APOSTOLAKIS: 15 very much. I mean, that proves my point. We don't 16 have a definitive study that tells us how these 17 things --18 MR. PARRY: I don't think the study is 19 going to help you. But we know we can do it several 20 ways, but you've got to get back to thinking what are 21 you trying to do with evaluating the importance 22 And if you're trying to get the absolute measure. 23 importance of component A, then you have to look at all its failure modes. That's --24

MR. TRUE: But it is only a portion of the

1	common-cause
2	MR. PARRY: Well, yes, but it doesn't
3	matter. If that common-cause fails A, it's a
4	different failure mode of A.
5	MR. TRUE: Then then
6	CHAIRMAN APOSTOLAKIS: But it does fail A.
7	MR. PARRY: Yes.
8	MR. TRUE: Then I think we need to
9	reconsider the use of the criteria 2 for that kind of
10	a failure mode. Because it's something that's totally
11	different. We're taking a whole group of equipment
12	and failing it and saying that exists for 100 percent
13	of the year at least
14	MR. PARRY: It's only different in degree,
15	Doug.
16	MR. TRUE: for a component that's
17	certainly out of service
18	MR. PARRY: It's only different in degree.
19	You're doing that with all the individual failure
20	modes. So what's the difference there? That's also
21	an extreme measure of the importance.
22	CHAIRMAN APOSTOLAKIS: Well, we cannot
23	resolve
24	MR. PARRY: No, no. Things don't happen
25	for the whole year, which is what you're saying the

Ŧ	common-cause failure is.
2	CHAIRMAN APOSTOLAKIS: Obviously we cannot
3	resolve that issue now.
4	MR. PARRY: Right.
5	CHAIRMAN APOSTOLAKIS: And I don't know
6	how we can resolve it if you guys insist that nobody
7	should look into it and document it someplace. But a
8	study will not help me; I really don't understand
9	that. I really don't.
10	I mean, I would like to see something that
11	documents what Louis just said, what Gareth claims and
12	so on and draw some conclusions. Why is this issue
13	different from anything else that we study and say,
14	you know, this is this way and this is not that way.
15	I don't understand that we have to do it in real time
16	here arguing that it doesn't mean this, and then Doug
17	says we should reconsider the threshold. Well, gee,
18	you know so I'm not sure we can reach a conclusion
19	right now.
20	MR. PARRY: No, but I think you heard that
21	from Mike and from Louis that there is a there is
22	someone looking into this.
23	CHAIRMAN APOSTOLAKIS: Okay. So
24	MR. PARRY: So I think at the end of that
25	we will come up with some position.

1	DR. SHACK: And it makes a difference of
2	4 components?
3	CHAIRMAN APOSTOLAKIS: Yes.
4	MR. PARRY: In a particular example.
5	DR. KRESS: That hardly seems worth, does
6	it?
7	DR. SHACK: Four 4 components?
8	DR. ROSEN: What do you mean by 4
9	components? Four components in the whole analysis or
10	what does is this reference to 4 components?
11	MR. CHEOK: I think this is four
12	additional components in one plant model.
13	MR. TRUE: But is there only two common-
14	cause groups? Is that all that it brings in?
15	MR. CHEOK: I don't know the details.
16	CHAIRMAN APOSTOLAKIS: I don't know, guys.
17	We are wasting our time now.
18	And the other thing is that I hope this
19	study will not just say we did it for Sequoyah and
20	this is what we found. I mean, there may be some
21	logic behind all this and go back to the definitions;
22	what does RAW mean, is it meaningful to really claim
23	that when a component is down, everything goes down?
24	You know, that kind of thing. It is not just that we
25	provide is numerically for this plant and we got these

1	numbers. I mean, that's useful insight, too, but it
2	seems to me the definitions here and I think that's
3	where Gareth was going you know, what does it mean
4	that I have a common-cause failure of 2 valves?
5	Right? What does it mean that one valve fails as a
6	subset? You know, that kind of argument would go a
7	long way to convincing me, at least, that we know what
8	we're doing.
9	MR. TRUE: Okay.
10	CHAIRMAN APOSTOLAKIS: Okay?
11	MR. TRUE: Okay.
12	CHAIRMAN APOSTOLAKIS: All right. Now, I
13	don't have any more questions.
14	DR. ROSEN: Is it lunchtime or are we
15	done?
16	CHAIRMAN APOSTOLAKIS: I don't have
17	anymore questions or comments unless my colleagues
18	around the table Peter? Steve?
19	DR. ROSEN: Are we going to hear the NRC
20	staff?
21	CHAIRMAN APOSTOLAKIS: Well, the NRC
22	spoke.
23	DR. SHACK: The ultimate pièce de
24	resistance of all this is how we calculate delta CDF.
25	CHAIRMAN APOSTOLAKIS: The two to 5.

1	DR. SHACK: The 2 to 5.
2	CHAIRMAN APOSTOLAKIS: Yes, the 2 to 5.
3	DR. SHACK: You know, it's like question
4	15
5	MR. TRUE: Right. That's about the only
6	CHAIRMAN APOSTOLAKIS: Let's discuss that
7	one for a few minutes.
8	MR. TRUE: Okay. I guess the issue here
9	it's actually 14 and 15 are related to this.
10	It is true that South Texas, they do a
11	calculation where the value's increased all the way to
12	a factor of 10. They also did lower values. We don't
13	know if they actually did 5, but I know they did 2 and
14	some other intermediate value.
15	I think that the core of the issues here
16	is that 10 is just as arbitrary as 5. Twenty is just
17	as arbitrary as 10.
18	CHAIRMAN APOSTOLAKIS: But you didn't pick
19	20.
20	MR. TRUE: Right.
21	CHAIRMAN APOSTOLAKIS: Is that by chance.
22	MR. TRUE: We believe that the evidence
23	that we have seen well, we haven't seen evidence
24	that it will change by a factor of 10. That the
25	evidence that was presented by South Texas in their

1	submittal actually said it probably isn't going to
2	change a lot. And there is some
3	CHAIRMAN APOSTOLAKIS: What is it that's
4	changing? The mean value of the distribution?
5	MR. TRUE: The mean value. Yes. The mean.
6	CHAIRMAN APOSTOLAKIS: The mean value?
7	MR. TRUE: Yes.
8	CHAIRMAN APOSTOLAKIS: Not the
9	MR. TRUE: I would say the point estimate
10	value wasn't changing because they didn't I'm not
11	sure they actually computed a mean. But the point
12	estimate they compared didn't change significantly
13	between the two groups. I don't remember whether they
14	computed
15	CHAIRMAN APOSTOLAKIS: Is that the Idaho
16	study that
17	MR. TRUE: No. This is
18	MR. TRUE: We're talking in South Texas.
19	CHAIRMAN APOSTOLAKIS: Well, was
20	MR. TRUE: Now, there are there are
21	DR. KRESS: It was based on that.
22	CHAIRMAN APOSTOLAKIS: I thought that
23	there was an Idaho study, wasn't it?
24	DR. KRESS: Yes, I think so.
25	CHAIRMAN APOSTOLAKIS: It was not a South
J	

1 | Texas study?

1.4

1.5

MR. TRUE: It was South Texas. There may be some work from Idaho, but I haven't seen that.

So we start off with a dearth of evidence. But the evidence that we have says it don't look like it changes a lot. Then there's a pretty big change.

DR. SHACK: Two to 5 is a small change.

MR. TRUE: Two to 5 is more reflective of what we've seen. And given that the evidence shows there's not a lot of change, we said well if there's not -- the evidence says there's not a lot of change, maybe we should just be operating within the same distribution and moving our value we're using from the mean out towards a more 95th percentile kind of value.

And, as you know, the nature of the lognormal distribution is that the mean doesn't get more than about a factor of 4 away from the 95th percentile. And, in fact, as the uncertainties get larger, once you get above about a range factor of about 20, the mean starts approaching the 95th percentile and can even pass the 95th percentile.

So the graph on the next slide between 14 and 15 shows the simple property of the lognormal distribution that the range factors we typically deal with on these kind of parameters are down in the low

NEAL R. GROSS

1	310, 30 kind of a range. But the ratio of the 95th
2	percentile to the mean in that range is below a factor
3	of 5 and above a factor of 2.
4	So we said if we're going to do it and we
5	don't have evidence that the mean does shift or the
6	point estimate factors where it does shift, what we
7	don't believe will happen. We believe individual ones
8	may go up by a factor of 2 or 5 maybe at times. But
9	we'll take them all at the same time and see what the
10	delta risk is.
11	It's only a sensitivity study. And here's
12	a point that Steve made earlier, it's not intended to
13	say this is how bad it's going to get, this is where
14	it's going to go. It's just to say that if this
L5	happened, as a sensitivity what would the implication
L6	be on changing the CDF.
L7	And that's the basis for the 2 to 5.
18	DR. KRESS: Well, the fallacy in that
L9	argument is staying within the same
20	CHAIRMAN APOSTOLAKIS: Yes.
21	DR. KRESS: There's nothing that I know of
22	to say.
23	MR. PARRY: Well, everything's changing.
24	It has to change some.
25	CHAIRMAN APOSTOLAKIS: It's a matter again

of going back and understanding what the distribution 1 2 represents. Is a plant-to-plant variability that the 3 reactor safety study talked about? And what if you're one of the plants that is on the tail already? Right? 4 5 Or does it mean something else? You know, these are 6 the kinds of things that I think we need a little more 7 careful investigation. 8 Does the whole distribution change or not 9 doesn't change, or --10 MR. PARRY: I think also it's setting a 11 dangerous precedent in some ways that that uncertainty 12 distribution is purely a reflection of what we know 13 about the parameters for the state of the plants as they exist at the moment. If we then start using that 14 15 as an excuse for changing it; when we change the state 16 of plants, then Ι think that's 17 intellectually dishonest, let's put it that way. 18 CHAIRMAN APOSTOLAKIS: And you say 2 to 5. 19 Now the problem is what if I do it for 3 and it 20 doesn't pass the criterion, then I go down to 2 and it does, then what do I do? You say --21 22 TRUE: Yes, I think in the end I 23 believe we're going to end up picking an A number 24 based on treatment. But we have yet to define what 25 treatment we're going to do.

1	CHAIRMAN APOSTOLAKIS: Can you document									
2	that somewhere.									
3	MR. TRUE: If a change in treatment is									
4	nominal, we think that the change in reliability would									
5	be nominal.									
6	CHAIRMAN APOSTOLAKIS: Okay.									
7	MR. TRUE: If it's more significant, then									
8	it might be more significant.									
9	DR. ROSEN: Can I ask a few questions?									
10	CHAIRMAN APOSTOLAKIS: Yes.									
11	DR. ROSEN: I just wanted to clarify with									
12	Adrian that what you're going to do with this is come									
13	back with another draft of it? And that's going to									
14	take out all the treatment stuff as well as be									
15	responsive to what you know of the Commission's of									
16	the staff's intent with regard to 50.69?									
17	MR. HEYMER: We will take a look at their									
18	comments, factor those in. We will take a look at the									
19	lessons learned we've documented from the pilots, and									
20	there's still one more pilot to go. And once we've									
21	done that, we'll take an attempt to redraft it. We'll									
22	meet with the task force to review it. And then we'll									
23	submit it as Rev. C.									
24	DR. ROSEN: Could you answer my question									
25	about the treatment?									

1	MR. HEYMER: The treatment the
2	guideline based on some decisions that were made in
3	January will focus just on treatment. Just on
4	categorization.
5	DR. ROSEN: And all the treatments on it
6	will be
7	MR. HEYMER: The treatment it's our intent
8	to call that out and put that into a specific industry
9	guideline that will not be endorsed by the NRC.
10	DR. ROSEN: Okay. Thank you.
11	MR. HEYMER: And industry guide.
12	DR. ROSEN: Now I have another question,
13	which is really goes to our agenda, which is that I
14	came to hear what the NRC to hear what the industry
15	said in response to our questions for sure, and you've
16	done an credible job doing that. But I also came to
17	hear what the staff thought of NEI 00-04.
18	Can somebody from the staff respond to
19	that, Mr. Chairman?
20	MR. CHEOK: Can I real quickly mention
21	about the 2 to 5 factor 2. The staff has asked I
22	guess NEI to justify the fact that 2 to 5, NEI has
23	submitted to us data from STP. The staff has not
24	looked at this data yet and I guess we eventually may
25	do that. But I guess treatment also gets factored

25 |

1	into this factor 2 to 5.
2	What happens if you pick a factor of 5
3	even? Does that mean when treatment is IST, does that
4	mean you cannot increase the test intervals from 3
5	months to more than 15 months because the 5 bounds you
6	to your lambda T by 2 factor? So we need to pull
7	treatment into this discussion when we talk about
8	factors of 2 to 5.
9	DR. ROSEN: Now you answered the question
10	about this particular point. But I was more generally
11	asking the question overall; what is the staff view
12	about Rev. B of NEI 00-04? Do you have any comments
13	on it beyond that?
14	MR. REED: Steve, I can say a few words.
15	DR. ROSEN: Yes, go ahead.
16	MR. REED: I'm just going to focus on one
17	slide. It's going to reiterate a lot of what was said
18	to start off the meeting that Adrian mentioned at the
19	very beginning of the meeting.
20	It starts with a little bit of history,
21	but I think it's important to keep remembering this.
22	Because I think often times we lose the context and we
23	lose the bigger picture.
24	We've been doing this since back in '99
25	when we came out with SECY 99.256 with ANPR. That's

1 what started this whole thing really rolling. 2 since then NEI has been developing the document. 3 we are now on the third round of comments that I 4 believe you all have a copy of, which was sent to NEI 5 several weeks ago. And those comments reflect both our review of draft Revision B as well as all the 6 7 pilot activities that have been observed to date being 8 collected. 9 The reason I think that we didn't hear a 10 strong opinion a whole lot on these specific issues is 11 the fact that we are largely in agreement. Now, you 12 look at the comments and, of course, there's a pretty 13 long list of comments. But to me, anyway, looking at 14 the entire Option 2 picture and categorization, I 15 don't think we're far off. We have some big issues in 16 other areas, but in the categorization area I think 17 all of these can be technically solved. I may be a 18 little too optimistic here, so that's why I'm saying--19 DR. ROSEN: What do you mean big issues in 20 other areas? What other areas are there besides 21 treatment? 22 MR. REED: Yes, exactly. 23 DR. ROSEN: Are you ready to talk to that? I thought you opted out of treatment? 24 25 MR. REED: Well, no, I'm talking about in

1 terms of in the rule. For example, I'll give you an 2 of whether 50.55(a), a special treatment 3 requirement, whether those requirements should be 4 placed on RISC-3 SSCs or removed from RISC-3 SSCs. 5 That's a very big issue. In fact, we met yesterday with NEI and 6 7 ASME on that particular issue to try to understand, 8 you know, gather more information to help us make a 9 decision on whether that should be one of the list of 10 the special treatment requirements that should be --11 you know, the requirements that should be removed from 12 RISC-3. As you know, South Texas was exempted from 13 pieces of 55.55(a). 14 15 DR. ROSEN: Yes. 16 REED: For Option 2 we've been 17 considering in this particular instance all the way 18 from 55.55(a) requirement staying on RISC-3 to the 19 pieces being removed in a similar fashion to South 20 Texas, or the entire regulation being removed from 21 RISC-3. So, it's a very big issue. In fact, I think 22 it's the biggest issue. 23 I would really be puzzled if DR. ROSEN: 24 you deviated from what you did at South Texas. 25 mean, it seems to me it was agonizing in the staff

when we came to a conclusion. Why would you want to 1 2 recognize that? You don't have to answer that. 3 MR. REED: Well, it's been very agonizing for us, I can certainly agree with you on that. And 4 5 there are other issues. 6 I know this Committee and this meeting 7 today was focusing on the concerns and issues on the 8 categorization process, and so that's what we were 9 focused on here today. And --10 DR. ROSEN: But I would echo your comment 11 about 50.55(a). I mean, 50.55. I am concerned that 12 we are doing something -- that we would do something 13 different and that -- and I said why earlier on, was 14 that this is about scope. It's always been about 15 scope; that which is within the special treatment 16 requirements and that which is not. And so if you 17 start using code cases, you're not really talking 18 about scope anymore. You're really talking about 19 iterating with the fine detail. And I think that's 20 the essence of my trouble of going with an approach 21 that relies on code cases rather than dealing with it 22 directly in this building. 23 MR. REED: To continue then, as I think 24 you probably gathered then from -- we were trying to 25 meet on a few of the technical issues where I think it

1	was very clear that, you know, for example on CCF and
2	RAW, that there were some disagreements. But, by in
3	large, we weren't trying to do a lot because, in fact,
4	we are I think in fairly good agreement on the
5	categorization process and, you know, understanding
6	that ACRS may have some concerns separate from that.
7	But, you know, I just pull out what I
8	think we would consider the three biggest issues. And
9	I think all these are solvable.
10	The issue of long term containment
11	integrity and its consideration within defense-in-
12	depth. The issue of the IDP guide, that's where I
13	think where we agree with the ACRS. I think it's also
14	been a feedback from the pilot activities. And I
15	think NEI recognizes in fact that there needs to be a
16	little bit more structure and guidance to the IDP.
17	DR. ROSEN: Can I stop you right there?
18	MR. REED: Sure.
19	DR. ROSEN: In my view what came out of
20	the experience at South Texas was the absolute
21	importance of the IDP. We really didn't anticipate
22	that at first at South Texas. It wasn't clear to us
23	when we started that that was how it was going to
24	shake out. But it became clear very soon.
25	And so the things that were done to

select, to train and qualify the members of the expert 1 panel, the IDP, and its working group became very 2 3 And the structure that they worked in important. 4 because it was going to be so difficult, we could see. 5 The answers were not just going to come out of the end 6 of a computer. 7 The issues of structure and scrutability 8 became even more important. Documentation, clarity. 9 Even continuity of membership of the members; didn't 10 want to have people scuffling in and out of the thing. 11 And that the guideline is absolutely almost silent on 12 those issues, which to me turn out to be some of the 13 important issues, the soft issues, if I may call them 14 those. 15 So, I would encourage both the staff and 16 NEI to pay more attention to what we found to be some 17 of the more important dimensions of this process. 18 MR. REED: I think all the parties agree 19 that there needs to be some work done there, and it's 20 already been mentioned this is a interim product. And so we'll see how it evolves to the next Rev. 21 22 it will. 23 And, of course, the last item there, this 24 is a big issue, it's a lot of what was talked about 25 today. In fact, Mr. Burchill talked quite a bit about

PRA quality. But that's a very important aspect of, you know, is your PRA is a sufficient quality really to support this categorization process? And, you know, staff has -- work has been underway for quite some time reviewing the peer certification process. And we recognize that that's something that will have been done. Now the question is what's necessary for licensees to implement Option 2, what do they need to provide to the staff as a submittal for us to take a look at so we can conclude that, yes, what you've got there in place is good enough to implement this to Option 2.

And it just really turns into a review guidance for the staff in reviewing a submittal to support this. And we actively are working on that, you know, right now.

So, you know, a very quick overview. What I'm really trying to point out is we're pretty far down the road here. We're on the third round of comments. We're not too far off in categorization. We have some big issues. From the staff's perspective I think we can solve. We're hearing, you know, some issues of course from the Committee.

In fact, George, I think we would like if possible to get a letter from the Committee. I think

it would help us do our job better. Because we need if possible to get these concerns documented to help us when we get to the proposed rule stage to help address this when we bring the proposed rule to the Committee.

So, if possible, I think we would appreciate a letter. I understand there's a lot of

So, if possible, I think we would appreciate a letter. I understand there's a lot of views bouncing around, that's going to be a difficult thing for you to do. But --

DR. ROSEN: If we agreed to that, you'd get a letter on Rev. B of NEI 00-04. You need a process letter? Because we know they're going to change it?

MR. REED: Yes, but it helps us -- some of these concerns are pretty broad based and I think it would help us, I believe, to try to have them addressed as we go forward. That's -- in other words, to be better prepared and hopefully get the proposed rule package to this Committee. That's my thinking going forward. But, you know, again, what we were focused on was the issues and concerns from the letter from the ACRS, and we were charming in as we went along. And that was the main focus. This is really to give you a view of where we stand.

And, of course, you have our letters, our

NEAL R. GROSS

22

23

24

25

specific comments on NEI 00-04.

CHAIRMAN APOSTOLAKIS: Any other comments from the members?

DR. ROSEN: Well, I have one more, George.

CHAIRMAN APOSTOLAKIS: Yes. Go ahead.

DR. ROSEN: On this last point, the relationship of NEI 00-02. It was my understanding that that relationship was nil, and that is -- and let me give you my version of it and I will stand corrected if you can help me, or if Adrian can help.

00-02 describes the PRA certification It is part of -- it is referenced in the ASME standard. The standard stands tightly linked with the PRA certification process. And 00-04 invokes the standard, which it hence evokes 00-02. Those are not separable things. We insist on good quality PRAs to support this process would be required. And. therefore, need to meet the standard, the ASME standard which -- or if you prefer a shorthand, you need to meet 00-02 but I think it's a more complete thing and it's certainly scrutable to the public, which may or may not have access to 00-02, to say that you need to meet the ASME standard which incorporate the certification process which is explained in 00-02, although it stood alone before that. I mean, it was

1 part of another process.

So, I don't think -- to me the relationship is not unknown. I'd be interested in your views.

MR. PARRY: Yes, I think the relationship is not unknown in general, but I think the question is what can the staff make out of what the reports say about -- what submittal that come in using NEI 00-04 said concerning the definition of quality, if you like, that came out of NEI 00-02. And I think the staff has some concerns about that, largely because what we have to do as the staff, I think, is to be convinced that the risk input to the IDP is adequately supported by the licensee's PRA. Okay.

Now, for us to do that I think we have to understand precisely what has gone into NEI 00-02 and how the grading process has gone on. And there are some things that I think that we feel a little nervous about.

For example, and our understanding is that NEI 00-02 requires the documentation of facts and observations when a grade 3 is not awarded to a particular element. I may have this slightly wrong, but that's at least what we read into it. But there are equally important issues that are related to the

assumptions that the analysts have made. I'm going to give you a good example, like the HRA method, for example. Human reliability analysis method. They may meet the criteria that are in the ASME standard and the other requirements, I should say, and in NEI 00-02, but those are flexible enough that they would allow a licensee to use any one of a number of different methods which could give you very different estimates of human error probabilities.

Option 2 on that particular issue because one of the requirements is for the licensee to do sensitivity studies on human error probability values, for example, which would make us feel more comfortable that they haven't obscured SSCs because of using very conservative HEPs or they haven't pushed some SSCs to be unimportant because of using very optimistic HEPs.

But nevertheless, there are issues like that that we're sorting through that I think that we have to have more confidence about to accept the results of a categorization using NEI 00-04 coupled with NEI 00-02. And that's the guidance that Tim talked about that we're putting forward as to which of these areas do we need to look at.

And just to give you one of the reasons I

NEAL R. GROSS

1	think why this occurs, is that the sub-tier criteria
2	on which the grading is performed in NEI 00-02 we
3	don't feel that they clearly define what goes into the
4	grades, and in particular what goes into grade 3. So
5	knowing something that has grade 3 doesn't tell us
6	what was done.
7	CHAIRMAN APOSTOLAKIS: Adrian?
8	MR. HEYMER: Yes. You had a number of
9	questions on the certification process, and we didn't
10	really get to those today. We covered the PRA quality
11	ones in some depth. And I think before we can sort of
12	look to some response from this Subcommittee or the
13	full committee, is I think we need to explain where we
14	are with regards to certification process and Option
15	2, and respond to some of those questions.
16	If we want to start discussing those now,
17	we'll introduce
18	CHAIRMAN APOSTOLAKIS: Well, that brings
19	up another issue. We will have a presentation at the
20	full Committee meeting, right? An hour and a half?
21	Are you planning to come, NEI?
22	MR. HEYMER: We're planning to be there,
23	yes.
24	CHAIRMAN APOSTOLAKIS: Well, maybe, you
25	know you can focus on major issues and not take every

1	question that we have asked in detail and address them
2	then.
3	MR. HEYMER: We can focus on the major
4	issues, but I think we also need to emphasize that
5	this document will change. You'll probably see, I
6	wouldn't say substantial changes, but there will be
7	changes in certain areas like the IDP guidance, and
8	there were some specific reasons why we went down that
9	approach.
10	CHAIRMAN APOSTOLAKIS: Yes.
11	MR. HEYMER: And what I understand the
12	staff needs some help in input is regards to drafting
13	the notice of proposed rulemaking, it is a notice of
14	proposed rulemaking. It is not the final rule.
15	CHAIRMAN APOSTOLAKIS: Yes.
16	MR. HEYMER: And we still have a long way
17	to go. There are some substantial issues on the table
18	not associated with categorization.
19	DR. ROSEN: I would only comment, now that
20	I've listened to the staff and Adrian, NEI, that I'm
21	a little bit uncomfortable with the idea, mainly from
22	what you said, Gareth, that the staff is worried about
23	or is uncomfortable with some tier guidance in the NEI
24	00-02 in the certification process.
25	It seems to me that that process is now

embedded in the standard and the proper place to have
voiced those concerns and had them addressed was in
the consensus process. And to now be worried about
that at this stage smacks a little bit of wanting to
change the outcome of the consensus process. I may be
wrong about all that, but think about that comment in
the light of what you said.

MR. PARRY: Yes, I'd like to respond to that. I don't think that the fundamental process of a peer review is reflected both in the standard. And, obviously, the peer process is NEI 00-02. However, NEI 00-02 has not been changed to reflect the consensus process that was done in the standards. So that is a different issue.

And I think it's actually no secret that we have been concerned about the sub-tier criterion in NEI 00-02. We've made this point over the last 3 or 4 years. So I think this is nothing new. This is just a continuing situation. But I think that, you know, the standards is something -- is another animal and that's in terms of the requirements. They're clearer, I think, than the sub-tier criteria of NEI 00-02.

DR. ROSEN: So what you're saying is that NEI needs to conform 00-02 to the standard?

NEAL R. GROSS REPORTERS AND TRANSCRIBER

1	MR. CHEOK: Actually, I think both NEI and
2	the staff recognize that there are some differences
3	between 00-02 and the standard. And as a result of
4	that, I think NEI has asked the staff to look at 00-02
5	with respect to Option 2. And I guess to provide
6	comments as to the adequacy of 00-0s with respect to
7	Option 2.
8	DR. ROSEN: Well, it doesn't make any
9	sense to me to have another set of how you do things
10	different from the standard. I think both NEI and the
11	staff understand that it'll have to come together on
12	the issue of peer certification ultimately.
13	CHAIRMAN APOSTOLAKIS: Okay.
14	MR. BURCHILL: Can I make a comment?
15	CHAIRMAN APOSTOLAKIS: Yes, sure.
16	MR. BURCHILL: I want to just clarify
17	something that Gareth said, and then I also wanted to
18	make a comment on the relationship between the
19	standard and 00-02.
20	In the NEI 00-04 there is an outline of
21	the submittal an applicant would make relative to this
22	categorization process. And in it it's stated that
23	the applicant should have a high level summary of the
24	results of the peer review including any PRA elements
25	that are graded below 3 in the standard elsewhere

or the quideline rather elsewhere says that 1 2 expected that a grade 3 is the nominal grade measure of capability of the PRA for this application. But it 3 also says that the disposition of all peer review fact 4 5 and observations classified as A or B would be 6 reported. And there's a clear distinction between 7 8 the grading scheme under the peer review process and 9 the fact and observation sheets which their level of 10 significance relative to the capability of the PRA is 11 measured in this A, B, C category. And everything in 12 the A/B category, whether it is associated with an 13 element that was graded, you know, 1, 2, 3 or 4, it 14 doesn't matter. All of those are to be reported and 15 how they were dispositioned. So, I just wanted to clarify that there's 16 17 two different dimensions to how that's actually done. 18 And that's required by the quideline to be included. 19 Relative to the ASME standard and the peer 20 review process, I think it is -- help me on this. I think it's section 6 of the standard that refers to 21 22 the peer review process. I think --23 MR. PARRY: Yes, I think that's right. I think section 6 24 MR. BURCHILL: Yes. 25 refers to the peer review process. And at least in

1	the last draft that I've seen, I think which is 14(b)
2	I believe, it's very clear that there's a very tight
3	linkage between the standard and the peer review
4	process. And, in fact, having just gone through it
5	myself personally in order to look to adapt that
6	element of the standard to the one that we're working
7	on for low power and shutdown in ANS, you know, what
8	I found is that it very tightly ties the peer review
9	process into determination of compliance with the
10	standard.
11	And, in fact, the owners groups jointly
12	have underway with the BWR owners group in the lead
13	presently, a very detailed comparison between the sub-
14	element criteria in the peer review process and what
15	the standard calls out. And I think by the time that
16	we're in a position to apply this under Option 2 that
17	will have become in widespread use in the industry for
18	demonstrating through the peer review process how the
19	PRA compares to the standard.
20	MR. PARRY: Can I just add to that?
21	MR. BURCHILL: Yes.
22	MR. PARRY: I think where the comparison
23	has to be made, Bill, if that would be compatible is
24	at the sub-tier criteria level.
25	MR. BURCHILL: Right.

1	MR. PARRY: And at the supporting level
2	requirements of the standard. When that comparison is
3	made, then I think they will be more
4	MR. BURCHILL: That is what we're doing.
5	MR. PARRY: Okay. Good.
6	DR. ROSEN: Good. That's very helpful.
7	And I think that that linkage between those things is
8	what was intended when we set out on this process.
9	CHAIRMAN APOSTOLAKIS: Okay. So is it
10	clear now what the presentation at the full Committee
11	meeting is going to be? The presentation will be by
12	you or you and NEI, or just NEI?
13	MR. HEYMER: Well, I think there's been
14	some confusion over the full Committee meeting,
15	George. What actual date is that?
16	CHAIRMAN APOSTOLAKIS: March
17	MR. MARKLEY: Let me get the agenda real
18	quickly. Yes.
19	MR. PARRY: The 7th, I think.
20	MR. MARKLEY: I think the 7th, but I can't
21	tell you the time off the top of my head.
22	CHAIRMAN APOSTOLAKIS: It's March the 7th
23	at 10:15 in the morning.
24	MR. HEYMER: We need to caucus amongst
25	ourselves to make sure that we can get the right

1	people here for that.								
2	CHAIRMAN APOSTOLAKIS: Okay. So it's								
3	primarily the staff then if they come.								
4	MR. REED: And to make sure I understand,								
5	this is going to focus on NEI 00-04 and the staff's								
6	issues with 00-04 now?								
7	CHAIRMAN APOSTOLAKIS: Well, it says								
8	proposed NEI 00-04.								
9	MR. REED: Okay. In other words, not								
10	focusing on ACRS questions and concerns about on what								
11	our issues are?								
12	CHAIRMAN APOSTOLAKIS: The whole report,								
13	yes.								
14	MR. REED: Okay.								
15	CHAIRMAN APOSTOLAKIS: Okay. I take it								
16	there are no more comments from my colleagues or								
17	questions?								
18	Well, I thank the gentlemen from the								
19	industry for taking the time to come and talk to the								
20	Subcommittee, and staff members.								
21	DR. ROSEN: Before we adjourn								
22	CHAIRMAN APOSTOLAKIS: Yes?								
23	DR. ROSEN: We should discuss amongst								
24	ourselves, not that it's secret but just with the								
25	ACRS, the desire to write a report at this stage. I								

1	think the staff has asked for that.
2	CHAIRMAN APOSTOLAKIS: Yes, the staff has
3	asked for a letter, yes.
4	DR. ROSEN: A letter. And the question I
5	have is
6	CHAIRMAN APOSTOLAKIS: Well, let's go
7	around the table and see how people feel about it.
8	Who wants to start? Peter?
9	DR. FORD: I've still got a concern about
10	a time dependent
11	CHAIRMAN APOSTOLAKIS: No, but should we
12	write a letter?
13	DR. FORD: My consideration is no.
14	CHAIRMAN APOSTOLAKIS: No.
15	DR. ROSEN: My consideration is no also,
16	because I think it's a work in progress. There are so
17	many questions that I have about this that I would
18	like to see the final draft. I think if we wrote a
19	Larkins Graham that said something like we think there
20	hadn't been the right direction, we're glad to see
21	that the staff and NEI at least from the staff's point
22	of view we believe have general agreement, that it's
23	likely to be a success path; that's fine. But I don't
24	think we're ready to write a letter to the Commission
25	on it.

CHAIRMAN APOSTOLAKIS: Bill?

	DR.	SHACK:	I	sort	of	agree	that	we
shouldn't	write	a work	in	progre	ess.	You	know,	if
we're goin	g to h	ave fund	dame	ntal p	robl	ems wi	th thi	ngs
like using fixed values for Fussell-Vesely, you know,								
and the staff seems to be heading down that road, then								
you know,	maybe	we do	nee	ed to	writ	e a l	letter	if
there's a	consens	sus that	tha	t sort	of d	letail	is a s	how
stopper.	I just	don't]	know	•				

I think we'll need some discussion among ourselves to kind of -- you know, if we looked at the staff questions on 00-04 and we've looked at our questions on 00-04 -- you know, suppose they did resolve all their concerns? Would that resolve all our concerns? I don't think all of Mario's concerns will be addressed. But then, I'm not -- you know, he's standing in front of a train here.

CHAIRMAN APOSTOLAKIS: Now when you say we discuss, today or at the full Committee?

DR. SHACK: Somehow in an informal caucus. You know, as to whether -- what issues are still open for us.

CHAIRMAN APOSTOLAKIS: With all the members?

DR. SHACK: I think with all the members.

NEAL R. GROSS

You know, it seems to me, for example, a lot of my 1 2 concerns with the IDP sound as though, you know, 3 that's in such a state of flux. CHAIRMAN APOSTOLAKIS: It is in a state of 4 flux. 5 6 That, you know, I don't see DR. SHACK: 7 there's any point in saying anything about that. You know, the treatment of uncertainties and the use of 8 9 fixed Fussell-Vesely values, you know, that I'm not 10 sure is going to be addressed in any changes that I sort of foresee coming from -- and, you know, if we 11 12 feel that's a show stopper, then --13 CHAIRMAN APOSTOLAKIS: Okay. DR. SHACK: -- we should fire off on that. 14 15 But, you know, my inclination is that my big questions were on the IDP, and that seems to be in such a state 16 17 of flux that I don't see any real point in writing a letter at this moment. 18 19 CHAIRMAN APOSTOLAKIS: Dana? 20 MR. PARRY: It seems that you pointed out 21 a variety of areas where you thought there needed to 22 be some developmental refinement of the technical 23 foundations of the methods. And it seems to me that it would be useful to document those needs within a 24 25 letter that says basically this process is going on

pretty well. And that what the staff and NEI are doing is a pretty good thing. That the technical foundations may need to be shored up and in these areas we think that it would be useful to shore them up and lay them out and whatnot, so that they're in front of people and people can act on them.

CHAIRMAN APOSTOLAKIS: So the way I understand what Dana proposed is, you know, write something that recognizes that things are in a state of flex and a lot of the concerns we raised are being addressed. But here are 1, 2, 3, 4, however many there are issues where we feel we have to express our views now for the benefit of both NEI and the staff as they work on this revision? I think that's what you said?

MR. PARRY: Yes.

CHAIRMAN APOSTOLAKIS: There are certain things we feel we should document at this stage. And we don't have to, you know, be exhaustive and say well we have a worry about the IDP, but that's being addressed.

DR. ROSEN: Well, I think that's the point that I would -- I mean, I could agree with Dana's suggestion, except that I wouldn't want a letter that we wrote now to be viewed by anybody as being

NEAL R. GROSS

1	Inclusive or exhaustive.						
2	CHAIRMAN APOSTOLAKIS: No.						
3	DR. ROSEN: Because there's lots of things						
4	that we talked about.						
5	CHAIRMAN APOSTOLAKIS: And we can say						
6	that, yes.						
7	DR. ROSEN: Including the IDP, etcetera						
8	that we there's no point going into a detailed						
9	discussion of it at this point until we see what they						
10	come back with.						
11	MR. PARRY: I wouldn't want it to be						
12	viewed as exhaustive. Similarly, I wouldn't want						
13	people to look at the areas where technical						
14	foundations need to be shored up to say and you						
15	can't do anything without shoring these. I didn't						
16	hear anything that was so fundamental that in the						
17	area of technical foundations that without its						
18	resolution we were hamstrung. I saw it a matter of						
19	persuasion, a matter of convincing that the						
20	approximate solutions were correct. I didn't see it -						
21	- I didn't hear any of them that said and this is						
22	likely to be a fatal flaw in these approaches.						
23	CHAIRMAN APOSTOLAKIS: That's true. I						
24	guess an element that at least I tried to bring up						
25	here is the element of rigor and public confidence.						

1	Okay. And a lot of the responses have been, yes, but							
2	this doesn't matter or, you know, this is okay. We							
3	tried it in one place and it worked. And I want to see							
4	a little bit more there. And I believe there is a							
5	disagreement or at least an initial disagreement or							
6	not willingness to go along by both the staff and the							
7	industry. And that's something that I would like to							
8	document.							
9	MR. PARRY: Well, there is an element of							
10	public confidence that's going to have be confronted							
11	sooner or later, and it's the question of if you are							
12	a heart surgeon, do you want a grade C student. I							
13	mean, if you're a heart patient do you want a grade C							
14	student doing the heart surgery on you? And, you							
15	know, it is							
16	DR. ROSEN: I think the analogy is not							
17	entirely apt.							
18	CHAIRMAN APOSTOLAKIS: I wouldn't want to							
19	challenge the analogy right now. But you were in the							
20	middle of something.							
21	Okay. I would suggest							
22	MR. PARRY: I don't want to stand in front							
23	of a freight train.							
24	CHAIRMAN APOSTOLAKIS: I would suggest							

1	sure he will send it to everyone here with his
2	views as to what should be in the letter. I think
3	he's working under the assumption that there will be
4	a letter, but you know, we can always talk to him.
5	And I would urge you to do the same. In fact, it is
6	Steve and I who are working on this. So if you can
7	send both of us some points that are along the lines
8	of what we just said; that it will not be an all
9	inclusive letter. It will not address everything. It
10	will acknowledge up front that this is work in
11	progress, but here are a few things that we feel we
12	ought to document at this stage knowing full well that
13	the staff and the industry are still working on this
14	document.
15	So, please send those to us. And then
16	Steve and I will think about drafting something,
17	perhaps.
18	DR. ROSEN: To bring to the full
19	Committee?
20	CHAIRMAN APOSTOLAKIS: Of course, to bring
21	to the full Committee. Okay?
22	And, again, I thank everyone for coming
23	here and spending time with us.
24	And this meeting of the Subcommittee is
25	adjourned.

								209
1			(Whereupon,	at 12:52	p.m.	the	Subcommit	tee
2	was	adjourne	ed.)					
3								
4								
5								
6								
7								
8								
9								
10								
11								
12								
13								
14								
15								
16								
17								
18								
19								
20								
21								
22								
23								
24								
25								

CERTIFICATE

This is to certify that the attached proceedings before the United States Nuclear Regulatory Commission in the matter of:

Name of Proceeding: ACRS Reliability and

Probabalistic Risk Assessment

Subcommittee

Docket Number:

(Not Applicable)

Location:

Rockville, Maryland

were held as herein appears, and that this is the original transcript thereof for the file of the United States Nuclear Regulatory Commission taken by me and, thereafter reduced to typewriting by me or under the direction of the court reporting company, and that the transcript is a true and accurate record of the foregoing proceedings.

Pippa Antonio Official Reporter Neal R. Gross & Co., Inc.

D 0000